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Abstract 
Artemisinin is the parent compound for the latest generation of anti-malarial drugs. In many 
cases of severe or drug-resistant malaria, the artemisinins are the only effective means of 
treatment for this common and life-threatening parasitic infection. However, the current 
supply of artemisinin is unstable, and is predicted to fall far short of demand in the coming 
years. As artemisinin can currently not be economically synthesised, the only source of the 
compound is the Chinese herb Artemisia annua L. 
 
With the ultimate objective of stabilising the global supply of artemisinin, a Consortium of 
academics, agronomics and business partners was established. The Consortium, with funding 
from Defra and the Horticultural Development Company under the name of  Project LINK 
0822, was to examine the feasibility of establishing an “artemisinin supply chain” – from crop 
in the field to pure, active pharmaceutical ingredient – based entirely within the UK. 
 
The work presented in this thesis formed part of this Consortium’s research – namely, the 
establishment and validation of rapid, accurate and economical means of quality control of 
both raw herbal material and purified ingredient. To that end, methods were developed 
allowing both field-based, triaging quantification and more accurate, high-throughput 
laboratory-based quantification of sample material. Improved means of artemisinin 
purification – in particular the removal of the inactive metabolite deoxyartemisinin, which co-
elutes and co-crystallises with artemisinin - were also developed. 
 
In addition, the potential pharmacological value of other compounds besides artemisinin was 
explored – namely, chrysosplenetin. This latter is a methoxylated flavonoid that accumulates 
with artemisinin in the plant, and has been shown, in this study, to have potential in the 
treatment of cancer. 
 
Finally, the feasibility of self-medication with Artemisia annua L. - in the form of herbal teas 
and over-the-counter preparations of the plant – was examined, and the amount of 
artemisinin, deoxyartemisinin and chrysosplenetin in such preparations was examined. 
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During the four years in which the LINK project ran, the Consortium members worked together 
to ultimately develop new lines of Artemisia annua L, that not only flourished in the UK 
climate, but also consistently yielded high (> 2.2 % w/DW) levels of artemisinin – almost a 
twofold increase from that at the beginning of the project. These new lines, together with the 
improved analytical techniques and means of artemisinin purification, demonstrate clearly 
that an artemisinin supply chain can indeed be based within the UK, thus contributing to a 
stable, year-on-year supply of artemisinin.  
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Prologue – background to this research project 
The results presented within this thesis were obtained during four years of collaboration 
between De Montfort University’s Natural Products Research (NPR) laboratory, and a 
consortium of academic, industrial and business partners. Together, the consortium set the 
objective of establishing, as a proof of principle, that -  
 
1. The Chinese herb Artemisia annua L. – currently the only source of the antimalarial 
compound artemisinin – could be grown on a large scale in the UK climate; 
2. Conventional plant breeding techniques could be used to create new, high artemisinin-
yielding varieties of Artemisia annua L. that would thrive in the UK; 
3. The active pharmaceutical ingredient (API), artemisinin, could be extracted from the 
crop and purified to International Pharmacopoeia standards (not less than 97 % and not 
more than the equivalent of 102 % of C15H22O5 ; melting range, 151 – 154 °C) at 
reasonable cost. 
 
In short, the objective of the consortium was to demonstrate that the UK could host the entire 
artemisinin supply chain, from field to laboratory, with the end-product of the chain being 
commercial amounts of pure artemisinin ready for sale to the pharmaceutical industry. The UK 
was considered an especially suitable host for Artemisia annua L. because the plant is a short-
day species: that is, a short day length, such as that found in tropical regions, triggers flowering 
in the plant. As it has been demonstrated that artemisinin levels progressively increase 
throughout the vegetative period of growth, and then drop sharply upon flowering (Weathers 
et al., 2006), it was hypothesised that growing the crop under long-day conditions, such as 
those found in a UK summer, would prolong the vegetative stage, and thus increase the final 
yields of artemisinin in the crop. 
 
Part of NPR’s role in this supply chain was to develop rapid, accurate and inexpensive means of 
quality control for samples produced throughout the supply chain. The major role of such 
quality control was to monitor fluctuations in artemisinin levels in growing crops, in order to 
ascertain optimal crop harvest dates. In addition, it was important to be able to monitor the 
response of plant artemisinin levels to standard agricultural products; herbicides and growth 
regulators, for example. 
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 Crop samples came in two forms: fresh leaf sampled at the site of growth (where the 
analytical objective is rapid, easy-to-use, semi-quantification of artemisinin levels) or dried leaf 
material assayed in the laboratory (in which more precise quantification is desirable). Dried 
leaf samples typically represented sampling of an entire crop on a given date or following a 
given treatment, and such sample sizes were typically greater than 500, necessitating rapid – 
but still accurate - high-throughput systems. 
 
 Additionally, NPR was required to develop means of artemisinin purification from Artemisia 
annua L. dried leaf material. This meant monitoring the presence, in crude and semi-purified 
extracts, of other compounds, in particular the pharmaceutically inactive deoxyartemisinin – 
which frequently co-extracts with artemisinin, and has to be removed with minimal 
artemisinin loss.  
 
Finally, the possibility of adding value to an Artemisia annua L. crop, by demonstrating that 
other potentially useful compounds could be isolated from the leaf, was explored. To that end, 
the levels of chrysosplenetin, a flavonoid with potential anti-cancer activity, were monitored 
alongside artemisinin.   
 
 This thesis presents the results of investigations into meeting the above objectives, beginning, 
in Sections 2 – 6, with the analytical procedures which were developed for both field-based 
and laboratory based quality assessment of samples.  
 
Section 7 describes how the removal of the inactive derivative deoxyartemisinin from 
artemisinin was achieved. 
 
Section 8 discusses the levels of chrysosplenetin in Artemisia annua L, and this compound's 
potential use in cancer therapy. This section also presents evidence that levels of 
methoxylated flavonoid aglycones in Artemisia annua L. are quantitatively linked to 
artemisinin levels – providing an additional means of sample quality control.  
 
 Section 9 describes a small experiment into the use of exogenous farnesol as a means of 
increasing artemisinin levels in Artemisia annua L. hairy root cultures.  
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Section 10 discusses the artemisinin, deoxyartemisinin and chrysosplenetin content of herbal 
teas prepared from Artemisia annua L. dried leaf, and the quality of over-the-counter 
preparations of Artemisia annua L.  
 
Finally, the outcomes of the whole LINK project are discussed in Section 11.    
 
But first, a review of the current situation in malaria treatment will be presented, with 
emphasis on the need for new antimalarial drugs, the efficacy of artemisinins and the mode of 
action of the drugs, and the economics of the artemisinin supply chain. 
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1.1 Natural Products Research - a definition, and a brief history 
In colloquial terms, the discipline of natural products research (NPR) – also known as 
phytochemistry - could be considered to be the point at which herbal medicine meets modern 
chemistry. The natural products chemist typically takes a plant known, or expected, to have 
medicinal properties, and systematically attempts to isolate the chemicals within that plant 
that are responsible for the medicinal properties.  
 
The science has expanded, over time, to take in not just the medicinal plants, but also to 
consider microbiological sources of medicinal compounds. There are also elements of 
synthetic chemistry, in which the natural product is modified by the addition or removal of 
certain functional groups, creating a new semi-synthetic product with improved bioavailability, 
or reduced side-effect. Sometimes, the active region – or pharmacophore – of a natural 
product is taken as inspiration for the synthesis, via a process called combinatorial chemistry, 
of vast numbers of related compounds (a combinatorial library), which will then be screened 
for improved pharmacological action (Ferro and Gray, 2007).  
 
The recent development of artificial neural networks – computer algorithms in which the in 
silica activity screening of natural products can be performed – means that it is now possible to 
do natural products research without ever handling plant or microbiological material. But, in 
general, drug discovery within phytochemistry is usually performed as a multi-step process 
involving first a bioassay on a crude extract, followed by fractionation of the crude extract and 
further bioassays, and, finally, the isolation and identification – and bioassay – of a single, 
active compound. 
  
The first reports of the isolation of a pure, crystalline compound with demonstrable 
pharmaceutical properties – an active pharmaceutical ingredient (API), in modern industrial 
parlance – came in 1805, when the Austrian apothecary Friedrich Wilhelm Sertüner announced 
the isolation of what he called the “principium somniferum” from opium – opium being the 
dried latex of the opium poppy, Papaver somniferum. The principium somniferum was, of 
course, morphine (Sneader, 2005).  
 
 Although this isolation of morphine represents the first time an active pharmaceutical 
ingredient had been isolated from a medicinal plant, scholars do not consider Sertüner himself 
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the father of natural products research. That honour is, rather, given to two French 
pharmacists – Pierre-Joseph Pelletier and Joseph-Bienaimé Cavetou – who, in 1820, were 
responsible for the isolation of quinine from the “Peruvian bark”, Cinchona cordifolia. It was 
not so much their successful isolation of the active pharmaceutical ingredient of cinchona 
bark, but their encouragement of other pharmacists to study single pure compounds rather 
than crude herbal drugs,  that has led scholars to laud the two Frenchmen for setting the 
course of drug discovery in a new direction (Sneader, 2005). 
   
But it is important to note that this standard bioassay – fractionation – isolation process does 
not take into account the potential synergistic action of multiple active compounds within a 
crude, or partially purified, extract. Plants had been utilized in this crude manner, for relief 
from the various human maladies, long before natural products research began in its modern 
form.  
1.1.1 Plants as medicines 
 In its present form, humanity has been in existence for around sixty thousand years, it 
appears– sixty thousand years of inventing language, developing agriculture, building cities, 
and initiating philosophical investigations which would later become religion and science. And 
all this was achieved alongside sixty thousand years of parasitic infection, tuberculosis, 
cholera, influenza, a legion of STDs, childbirth, septic wounds and cancer. 
 
And yet, the human race has survived and prospered, and was able to construct something 
beyond survival – civilization. Certainly the systems of agriculture and animal domestication 
were major contributors to that, but we must also include the development, by early human 
societies all over the globe, of medical practice in whatever form it took. 
Wherever historical civilizations have developed some form of written record – be that 
papyrus, codex or cave painting – they have recorded the use of medicinal plants. It is a system 
that arose over and over again, all over the world, where local diseases were treated with local 
plants, and represents a human need to understand and classify illness, and our response to it 
– to make a seemingly random and frightening concept a little less so.  
 
Some of these early records are available to scholars: notably the systematic medicine 
developed in the great Islamic cities of Cairo and Alexandria, categorised and refined by Ibn 
Sina and his contemporaries. Less well studied are the codices of pre-Conquest and Conquest-
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era Central America: Spanish friars – notably Bernadino de Sahagún – made it their business to 
record for posterity the details of the daily lives of the Aztec people, in the face of a rapidly 
collapsing indigenous culture. Sahagún's monumental General History of the Things of New 
Spain (de Sahagún, 1963) stands alongside Martin de la Cruz’s Aztec Herbal of 1552 (de la Cruz, 
2000), and Hernandez’ later Rerum (Varey, 2000), as written testament to a sophisticated 
plant-based medicine. And, most relevantly to this thesis, we have the ancient system of 
Chinese medicine, systematically recorded by such ancient physicians as Ge Hong and Li-Shih-
Chen. These sources of information – still of great interest to natural product chemists – are 
discussed in more detail in Section 1.1.5.1. 
 
1.1.1.1 Modern plant-based medicine 
It would be incorrect to give the impression, from all this, that the use of crude herbal drugs 
has been consigned to history. In fact, a large proportion of the modern global population still 
relies on the use of herbs as a first line of medicine – sometime simply because of tradition, 
other times because of a lack of access to modern biomedical drugs - or, frequently in the case 
of indigenous cultures such as the Nahua of Mexico, a mixture of the two (Camey et al., 1996). 
And the European markets have seen, in recent years, a great upsurge in the use of over-the-
counter herbal medicines for self-medication.  
 
Natural products research has a vital role to play in the responsible use of such herbal 
medicines. In the case of indigenous medical systems, the analysis and identification of active 
ingredients can help to validate the traditional uses of medicinal plants, the preparation and 
use of which are often tied closely with ritual and religious cultural practises. Analysis can also 
help to establish effective means of harvest and preparation of traditional indigenous herbal 
medicines. 
Where Western use of over-the-counter herbal medicines is concerned, a system of quality 
control is increasingly important as the sale of such products continues to rise – hence the 
Traditional Medicines Directive which comes into force in 2011, requiring herbal drugs to be 
subject to the same stringent regulations as any other medication.  
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So, although natural products research – a science derived from the millennia-old use of 
medicinal plants – has many roles to play, perhaps the central role is that of drug discovery. In 
this, it has been remarkably successful.  
1.1.1.2 The current picture of plant-derived drugs in conventional medicine 
A recent large-scale review by Newman and Cragg (2007), revealed that active 
pharmaceuticals are still for a large part extracted from natural sources. Newman and Cragg 
calculated that in the time period ranging from January 1981 until June 2006, of the total of 
1010 new chemical entities approved for medicinal use, 275 were either natural products, or 
derived from natural products. Another 154 were inspired by natural products – that is, 
although the drugs were produced by total synthesis, the pharmacophore was based upon the 
skeleton of a natural product. If we just look at the drugs approved for the treatment of 
cancer, we see that of 100 approved drugs, almost half (43) were either natural products or 
derived from natural products, and in the case of antiparasitic drugs, of 14 new approved 
medications, exactly half were natural products or derived from such – including the 
artemisinins.    
 
1.1.1.3 Example: artemisinin 
A striking example of the successful application of a natural product to the treatment of a 
severe disease lies within the story of artemisinin. Currently existing as a number of semi-
synthetic derivatives – artemether, introduced in 1987, artesunate, in the same year, and now 
as a co-formulated artemisinin-combination therapy (Coartem®; Riamet®) - these drugs 
represent the latest in a series of drugs designed to destroy the causative agent of malaria: the 
protozoan Plasmodium parasite. 
 
 The parent compound of these drugs - artemisinin – is a secondary metabolite of the Chinese 
herb Artemisia annua L. The plant – under the Chinese name of qing hao, or huang hao, had 
been known in ancient China as an effective remedy for intermittent fevers, but the active 
principle was not isolated until the 1970s (Liao, 2009). In less than thirty years following 
discovery, this molecule has become the single most effective treatment for malaria anywhere 
in the world.  
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To appreciate the significance of this discovery, it is necessary to take a closer look at malaria 
as a disease: its toll on human populations, and the longstanding checkmate between human 
and parasite. 
 
1.1.2 Malaria: morbidity and mortality 
According to the WHO World Malaria Report 2008, there were an estimated 247 million 
reported cases of malaria in 2006, of which nearly one million were fatal. The deaths, in the 
main, involved children under 5 years of age. (WHO, 2008c).  
 
 
Figure 1. Map showing regions of the world in which the population lives at risk from malarial 
infection (WHO, International Travel and Health Report 2010). ©WHO 2010 
 
1.1.3 Types of malaria 
The numerous references, in the old herbals and early pharmacopoeias, to “intermittent” (as 
distinguished from “continuous”) fevers, indicate that the medical practitioners of the pre-
biomedical era recognised that more than one type of malaria existed. This can be seen in the 
sub categorization of intermittent fevers – often called the “ague” – into those of a quotidian, 
tertian or quartan nature. A quotidian fever presented with febrile attacks recurring every 24 
hours.  Tertian fevers were those in which the febrile attacks recurred every 48 hours, and the 
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quartan fevers, every 72 hours (Hearsey, 1905). It was these intermittent fevers that were 
known to recur, sometimes after long intervals, giving rise to the “recurring fever” also 
frequently described in the old herbals and pharmacopoeias.  
 
It is now known that the difference in frequency of the febrile attacks in tertian and quartan 
fevers is the result of infection of the red blood cells with different species of Plasmodium 
parasites – an infection with a Plasmodium species being the ultimate cause of malaria. The 
nature of the infection will be discussed in more detail below, using as an example the 
Plasmodium falciparum parasite, which causes the most severe form of malaria. These 
protozoa, responsible for 80% of all malaria infections and 90% of all deaths from malaria (de 
Ridder et al., 2008), trigger febrile attacks occurring every 36 to 48 hours: a tertian fever. 
 
Other notable Plasmodium species include P. vivax, common in the Americas and causing a 
benign but recurring tertian malaria, with recrudescence occurring even up to 5 years 
following infection; P. malariae, again causing a benign malaria, and P. ovale (de Ridder et al., 
2008). This latter is rather rare. In recent years, a new form of human malaria has been 
documented in Malaysian Borneo – P. knowlesi. This particular species – now identified as “the 
fifth human malaria species” – was historically confined to long-tailed and pig-tailed 
macaques, but has been shown to be naturally transmitted to humans by the Anopheles 
mosquito species latens and cracens. Although a close relative of P. vivax, P. knowlesi causes a 
24 hour – quotidian – fever, and can cause serious, even fatal, illness (van den Eede et al., 
2009).    
 
Finally, it is possible for a patient to be simultaneously infected with more than one species of 
Plasmodium. The WHO noted that in Thailand, an estimated third of patients presenting with 
acute P. falciparum infection were also infected with P. vivax. Similarly, 8% of patients 
presenting with acute P. vivax infection were also harbouring parasites of P. falciparum (WHO, 
2006). The treatment of these mixed infections will be discussed in Section 1.1.6. 
 
1.1.4 Discovery of the cause of malaria 
Despite millennia of malarial suffering, the actual cause of the disease remained a mystery 
until the late 19th Century. Previously, a correlation between the disease and stagnant water, 
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or foul air arising from such water, had been accepted – such an idea is expressed in the very 
name of the disease, mal aire, and perhaps also in the Aztec “aquatic fever of the night”. 
  
As recently as 1834, Mashall Hall, in his “The Principles of Diagnosis”, wrote that these 
intermittent fevers were caused by proximity to stagnant water, marsh gases, and general 
humidity (Hall, 1834). He was almost correct. Later that century, the causative agent of malaria 
was finally identified by a French military surgeon, Charles Louis Alphonso Laveran. He 
performed autopsies in 192 soldiers who were believed to have died from malaria, and found, 
in the blood of 148 of them, pigmented bodies with moveable filaments or flagella (Haas, 
1999). These flagellated bodies were found in the brain, spleen and liver of those soldiers, and 
led Laveran to hypothesize that these were parasites, and were the causative agent of malaria. 
Furthermore, he suggested that a species of mosquito could be the vector for transmission of 
this disease, but this was not demonstrated conclusively until a few years later. In 1897, 
Laveran’s student, Ronald Ross, discovered these same parasites within the stomach wall and 
salivary glands of the female Anopheles mosquito. The life cycle of the newly discovered 
parasite, from mosquito to human and back again, was elucidated by Ross and two other men, 
Patrick Manson and Giovanni Grassi. Finally, the cause of so much suffering was understood 
(Haas, 1999). 
 
Almost a century later, in 1976, the in vitro cultivation of P. falciparum was achieved, and with 
this, a new phase in malarial pharmacology was established: the rapid assay of potential new 
drugs (Wright, 2005).   
 
1.1.5 The Life Cycle of Plasmodium falciparum 
The causative parasite of falciparum malaria, Plasmodium falciparum, divides its time between 
the human body, and the malarial vector – the vector in this case being one of the 30-40 
species of Anopheles mosquito capable of harbouring the parasite. Across much of Africa, 
Anopheles gambiae s.s is the major vector. 
 
Table 1, overleaf, summarises the stages in the life cycle of Plasmodium falciparum. 
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Table 1. The life cycle of the Plasmodium falciparum parasite (Prescott et al., 2002) 
Stage of Parasitic Life Cycle Commentary Interventions and Medication 
The infected female mosquito, in 
search of a meal,  bites the human 
 • Use of insecticide 
• Use of mosquito nets  
• Use of mosquito 
repellent 
 
Sporozoites enter the human 
bloodstream from the mosquito’s 
saliva, and immediately head for the 
liver 
These stages are generally 
asymptomatic. 
 
One sporozoite can results in up to 
30,000 merozoites. 
• Antifolates 
Within the heptaocytes, the 
sporozoites reproduce asexually, in a 
process called schizogony, to form 
numerous merozoites 
• Tissue schizontocides  
• Antifolates 
The merozoites escape the 
hepatocytes and enter the 
bloodstream, heading for the 
erythrocytes 
 • Antifolates 
Within the erythrocyte, the merozoite 
enlarges, to from a trophozoite – a 
stage often described as “ring-form”. 
The trophozoite nucleus then divides 
repeatedly to form the multi-
nucleated schizont  
This is the erythrocytic stage, and the 
cyclic activity  of this stage (48-72 
hours, in P. falciparum) accounts for 
the cyclic nature of the acute 
symptoms – mainly chills, with 
shaking, and fever, with sweating. 
 
Nacher theorises that “Malaria 
symptoms offer the vector (the 
Anopheles mosquito) its favorite cues: 
increased skin 
temperature, increased lactates, 
sweating, and CO2 expiration.” 
• Antifolates 
Each schizont then divides, sharing out 
its nuclei, and forming, in an echo of 
the liver stage, mononucleated 
merozoites 
• Blood schizontocides 
(such as the 
artemisinin-derived 
drugs) 
• Antifolates 
 
The erythrocyte bursts, and the 
merozoites are released into the 
blood, heading for new erythrocytes. 
• Antifolates 
Some merozoites form gametocytes, 
which become full gametes upon 
ingestion by the mosquito 
 • Use of insecticide 
• Use of mosquito nets  
In the mosquito gut, gametes form 
diploid zygotes, called ookinetes 
This process takes 13 days, and is 
considered a “fragile segment” in the 
malaria cycle – the cycle is most likely 
to be broken at this point. 
Ookinetes then form oocysts 
Oocysts undergo meiosis, and 
sporozoites are once again formed. 
These migrate to the mosquito’s 
salivary gland, and wait for injection, 
whereupon the cycle begins again. 
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Figure 2. The parasitic life cycle. Image reproduced from the US National Institutes of Health (NIH) at 
http://history.nih.gov/exhibits/bowman/SSmalaria.htm 
 
1.1.6 Symptoms of malaria 
The disease, in each of its forms, typically presents initially as a low-grade malaise, 
accompanied by headache, muscular and joint aches and pains, and abdominal discomfort 
(WHO, 2006). The similarity of these symptoms to those of many viral infections is notable, 
and differential diagnosis can be difficult without access to blood tests.   
Shortly after the appearance of these vague symptoms of illness, the characteristic features of 
malarial infection begin to appear. Most striking of these are the periodic fevers and chills, 
with increased perspiration, vomiting and weight loss adding to the clinical picture.  
 
At this stage, the disease – once it has been confirmed as malaria – is defined as 
uncomplicated malaria. This indicates that although parasitemia is present, with the associated 
symptoms of malaria, the disease has not yet caused damage to the internal organs, and is not 
considered life-threatening. In fact, at this stage, the death rate for falciparum infection is 
around 0.1%, if suitable treatment is provided. If, however, treatment is withheld, or 
ineffective, the parasite levels in the body increase to the stage where the infection becomes 
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severe. Patients with severe malaria typically display one or more of the following: coma (i.e. 
cerebral malaria), metabolic acidosis, severe anaemia, hypoglycaemia, acute renal failure and 
acute pulmonary oedema. When the disease has progressed to this late stage, fatality rates 
can be as high as 20% even following administration of suitable medication – and without 
medication, the disease is invariably fatal (WHO, 2006). 
  
1.1.7 Immunity to malaria 
In regions where there is a consistently high level of malarial infection – defined as regions 
where each individual human is bitten by an infected mosquito more than ten times each year 
– the human population develops a degree of immunity – partial immunity - to the 
development of clinical disease. These individuals do develop parasitemia, but the level of 
parasites in the blood remains fairly low and the disease hence remains mild. This partial 
immunity is typically seen in sub-Saharan Africa. It must be noted, though, that this immunity 
is region-specific: if an individual leaves the area and moves to another malarial region, they 
are once more at risk of developing a serious infection. 
 
Additionally, this immunity takes time to develop in an individual, and until that time, the 
individual remains at risk of severe disease. It is for this reason that the greatest number of 
deaths from malaria occur in young children, usually under the age of 5.  
 
By contrast, in areas of low, or fluctuating, malarial infection, partial immunity does not 
develop in human populations. This is typically the case in most of Asia, and in Central and 
South America. In these regions – particularly if a malaria epidemic suddenly develops – 
individuals of all ages can succumb to the severe form of the disease.    
 
Incidentally, molecular biological evidence - the presence of haemoglobin S, giving rise to 
sickle-cell trait, which gives the carrier some resistance to P. falciparum infection, and the 
absence of the red blood cell Duffy antigen (the lack of which confers resistance to P. vivax) - 
indicates that the Plasmodium genus originated and diversified in West African populations, 
and from there spread to the rest of the world with human migrations (Carter and Mendis, 
2002). 
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1.1.8 Recurrence, Recrudescence and Relapse  
Although superficially similar in meaning, it is worth noting that the commonly used terms 
“recurrence”, “relapse”, and “recrudescence” do not mean the same thing where malarial 
infection is concerned. According to the WHO, a recurrence of malaria is defined as the 
recurrence of asexual parasitemia following treatment. Recurrence may be defined further as 
a recrudescence, a relapse (in P. vivax and P. ovale infections only) or a new infection. 
Following from this definition, a recrudescence is defined as a recurrence of asexual 
parasitemia after treatment of the infection, but, crucially, with the same infection that caused 
the original illness. This typically occurs when a course of drugs has not been completed, and a 
few parasites have survived. A relapse may occur in all types of malarial infection, but is more 
commonly seen in vivax and ovale malaria, when a relapse – sometimes several months after 
the intial infection - occurs when parasites have persisted in the liver, after the infection has 
been eliminated from the blood (WHO, 2006).  
 
1.1.9 Malaria in the 20th Century 
The 20th century saw a rapid decline in malaria levels worldwide, for a number of reasons. 
Chief amongst these – at least in European nations – was the improved living conditions of 
much of the population, leaving them less exposed to stagnant water and the attacks of the 
Anopheles mosquito.  
 
In addition to this was the deployment of highly effective insecticides against the Anopheles 
mosquito – notably DDT – and the use of these, in conjunction with effective and affordable 
quinine-based drugs against the parasite, led to the belief that malaria could actually be 
eradicated. In fact, by the early 1950s, malaria had actually been eradicated in large areas of 
previously high malarial infection, including North America and most of Europe (Hay et al., 
2004). In Central America, although malaria was not eradicated, the use of DDT ensured a 
great reduction in malarial infections. However, in South America, no such reduction was 
possible simply because of the remoteness of most of the malarial regions of the continent.  
 
Similarly, in Africa, the use of such insecticidal measures had little effect because of the sheer 
numbers of Anopheles mosquitoes and the continuous, intense level of malaria transmission. 
However, some reduction in mortality from malaria was observed in the time period ranging 
from the early 1950s to the late 1980s – but such a reduction did not last, and the spread of 
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chloroquine resistant strains of P. falciparum meant that malarial mortality was on the rise 
once again (Carter and Mendis, 2002). In fact, sub-Saharan Africa comprises the only region of 
the world in which malarial mortality has increased from the beginning to the end of the 20th 
Century: from 6% of all deaths in 1900, to 9% in 1997 – globally, the figures are 8% of deaths in 
1900, and 0.08% in 1997.   
 
It is certain that socio-economic factors in sub-Saharan Africa are a major reason for this rise in 
malarial mortality – and that, together with the prevalence in Africa of the most dangerous, 
falciparum form of malaria, has made Africa a focus of the latest attempts at the eradication of 
the disease – for example, the Roll Back Malaria programme, created in 1998 by the WHO, 
Unicef and the World Bank.  
1.1.10 Treatments for malaria 
1.1.10.1 China 
It is unsurprising that China, with its longstanding medicinal tradition, would have developed a 
range of medications for the treatment of malarial infection. The Chinese herbal 
pharmacopoeias described two plant species in particular that may have been efficacious 
against malaria. The first of these waschangshan, a Chinese hydrangea first recognised by the 
West in 1790 for use against “quotidian, tertian and quartan fevers” (Burns, 2008). The second 
– qing hao – is, of course, Artemisia annua L.  
 
As was the case elsewhere in the world, the civilisation of China had grown alongside an 
increasing knowledge of the ways to treat the common and serious illnesses that afflicted its 
population. First the Han and then the Ming dynasties saw the production of extensive herbals, 
of which three are particularly revered. The first of these is the Pen Ts’ao Ching, or Classic of 
Materia Medica - a product of the latter years of the Han dynasty,a time which spans the years 
200 BC to 220 AD - and authored by the Emperor Shen Nung (Wright et al., 2010). A great deal 
of mythology surrounds Shen Nung: he is regarded as the inventor of agriculture, and it has 
been claimed that his herbal in fact dates back to three millennia BC, although this is unlikely. 
What is known is that Shen Nung was the first to introduce the dual concept of warm and cool 
into Chinese medicine.  
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The second of the great Chinese herbals is the Huang Di Neijing, or Yellow Emperor’s Classic of 
Internal Medicine. This document was written around the same time as the Pen Ts’ao Ching by 
an unknown author, and introduces the concept of yin and yang (Entrikin, 1950).  
 
However, neither of these two documents appears to describe a plant bearing any 
resemblance to Artemisia annua L. For that, we have to look to a much older document:  
Recipes for 52 Kinds of Disease, unearthed in a West Han dynasty tomb dating from BC 168. 
This represents the first known reference to Artemisia annua L: identified by the unknown 
author as qing hao, or “blue-green herb”. But in this document, no reference to a disease 
resembling malaria exists in relation to the use of qing hao: in fact, the herb was intended to 
be used in the relief of haemorrhoids  
 
Evidence that qing hao was used in ancient China for the treatment of malaria comes from two 
other, more recent, documents. The first of these is Ge Hong’s “Handbook of Prescriptions for 
Emergency Treatments”, dating from some period between 281 and 340 AD. In this, and in Li 
Shih-Chen’s Pen Ts’ao Kang Mu, published in 1597, are found references t the use of qing hao 
in the treatment of feverish illnesses (Li et al, 2006).  This in itself, of course, is not evidence of 
antimalarial action: as in the West, Chinese medical practitioners of the pre-biomedical era 
considered “fever” to be an illness in itself, rather than the symptom of another illness of 
infection.  
 
1.1.10.1.1 Qing hao: the blue-green herb 
Botanical descriptions of qing hao led Chinese scientists working under the efforts of Program 
523 – an initiative sent in motion in 1967 with the objective of searching Chinese traditional 
medicine for potential sources of antimalarial drugs (Li et al., 2006)  – to Artemisia annua L; a 
mountainous annual herb, native to the Chahar and Suiyuan provinces of China, and 
naturalised in Vietnam. Evidence has been presented by Hsu, though, that in the old Chinese 
herbals, qing hao actually referred to a related species – Artemisia apiaceae. Artemisia annua 
L, in the herbals, was indicated by the name huang hua hao: “yellow-blossomed herb”. It 
seems that in the oldest herbals – Ge Hong’s, for example – qing hao actually indicated a 
herbal preparation rather than a defined species, and both A. annua and A. apiaceae were 
acceptable component of the drug qing hao. It was not until Li Shih-Chen’s time that the two 
types of Artemisia were distinguished by Chinese practitioners – and, surprisingly, it was A. 
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apiaceae, not A. annua, that was recommended for Li Shih-Chen for relief from fever (Hsu, 
2006).  
 
It is not clear, then, what exactly led Chinese researchers of Program 523 to A. annua – but it 
was serendipitous, as the “correct” herb – A. apiaceae – contains comparatively little (0.08% 
w/DW, compared to up to 1% w/w in A. annua) of what was discovered to be the active 
ingredient - artemisinin.  
 
1.1.10.2 The Americas 
Outside of China, other malarial populations had identified medicines based on local 
resources. Although it is generally accepted that the Americas were free of malaria before the 
Conquest, there are scholars who doubt this, and claim that that malaria did exist in the 
Americas before the arrival of the Conquistadors (Bruce-Chwatt, 1965) To support this claim, 
these scholars point to the numerous references to intermittent fevers and chills in the 
indigenous languages of Central and South America. Such references are particularly 
prominent in Nahuatl, the language of the Aztecs - perhaps most strikingly in the case of 
atonahuitzli. This Nahuatl word translates as “the aquatic fever of the night-time” - a disease 
well known to the Aztecs and characterised by intermittent fevers and chills, frequently 
complicated by splenomegaly. When splenomegaly is present the diagnosis changes to “nitic 
mocomaltia in atonahuitzli” - literally, “the aquatic fever turns to spleen inside [the patient]”. 
The Aztec Herbal, written in 1552, describes the symptoms of a severe fever as displaying 
“...various changes...[the face is] at times flushed, at times darkened, again blanched...the 
body jerks, he turns hither and thither”, and that treatment is needed every third or fourth day 
(de la Cruz, 2000).  
 
Furthermore, the presence of mosquitoes in pre-Columbian Mexico is clear from examples of 
pre-Columbian pottery depicting the insects, and from the diary of the Spanish conquistador 
Bernal Diaz. Diaz, in his memoirs, vividly recalls that “there were always many mosquitoes, 
both the long-legged ones, and the small ones which are called xexenes and are worse than 
the big ones; and together they gave us no sleep.” (Diaz, 1963). 
 
A search of the medicinal codices produced by the Spanish in the 15th to 17th centuries, 
intended to document all the new resources of the conquered American lands, reveals several 
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plant species identified by indigenous  healers as useful in the treatment of the intermittent 
fevers. The “aquatic fever” described earlier was typically treated with a combination of 
Tagetes lucida and Artemisia mexicana. An ethanolic extract of the latter has been 
investigated by Malagón et al., and was able to clear mice of Plasmodium yoelii yoelii infection, 
a model of human malaria. No artemisinin was detected in the extract, however (Malagón et 
al., 1997). 
 
Perhaps of most interest are the references to chillazotl. This particular plant species – with 
the Latin designation of Argemone mexicana, and colloquially known as the Mexican Prickly 
Poppy, is currently undergoing trials for use against falciparum malaria in parts of Africa, and 
the Malian  government has already approved decoctions of this species as a treatment for 
uncomplicated falciparum malaria (Graz et al., 2010). 
  
1.1.10.3 Europe 
It was around 1630 that Europe first became aware of a potential cure for the intermittent (as 
opposed to continuous) fevers: the “Peruvian bark”. This new medicine – known to us now as 
Cinchona officinalis – had been brought to Europe from Peru by Jesuit priests, who had noted 
how the indigenous people of the province of Quito would drink decoctions of the bark to 
treat and prevent feverishness and shivering. It should be noted, though, that amongst 
indigenous Peruvians the medicinal properties of the bark were not well known: only two 
tribes – the Paltas and the Zaraguros – made use of it, despite the existence in pre-Columbian 
Peru of a disease called, in Quecha, chucchu, or “chill and fever”. Numerous local plant species 
in both South and Central America were identified by the indigenous population as 
“chuchupatli”, or “fever-medicine”, but curiously, C. officinalis was not one of them (Bruce-
Chwatt, 1965).    
Despite widespread reports amongst colonials in Peru, and then in Spain and Rome, of the 
bark’s efficacy against “the tertian fever”, it was some time before the bark became widely 
adopted as a treatment for malaria. The first record of the bark being prescribed in the UK 
dates from 1658, when the Cambridge apothecary Professor Robert Brady administered the 
new medicine during a serious outbreak of the disease (Sneader, 2005).  
 
Efficacious as the Peruvian bark was, physicians soon began to notice that patients varied 
greatly in their response to the medicine, both in terms of cure rate, and in presence and 
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severity of unwanted side effects. An additional problem was noted by the 19th century French 
physiologist François Magendie, who had seen patients die of malignant fevers because they 
could not ingest sufficient quantities of bark to treat the disease.  Such difficulties in 
standardising this herbal medicine led, in the early 19th century, to attempts by the Portuguese 
physician Bernardino Gomez to isolate an “active principle” from the Peruvian bark. Gomez 
succeeded in his efforts: in 1812, using what would now be recognised as a forerunner of the 
Stas-Otto technique of extraction, he obtained from the bark an amount of silvery-white 
crystals, which he named cinchonin. 
 
Soon after, in 1820, two French pharmacists – Pierre-Joseph Pelletier and Joseph-Bienaimé 
Cavetou performed similar extractions of the Peruvian bark, and also of the bark of a related 
tree: Cinchona cordifolia. It was from this latter (colloquially known as the “yellow bark”) that 
the Frenchmen obtained the first pure sample of quinine. Following the announcement of 
their discovery of quinine in 1820, it was soon discovered that small amounts of this newly 
isolated compound could arrest the tertian fever, with much higher cure rates than the 
powdered bark - and moreover, was better tolerated by patients. The efforts of the two men 
to promote the use of this single compound, rather than the crude bark, has led some to 
describe their actions as forming “...the prototype for an entire scientific 
discipline...ethnopharmacology” (Burns, 2008). Quinine became the standard drug for any 
feverish illness, and quinine derivatives are, to this day, utilised in the treatment of malarial 
infection (Sneader, 2005).    
  
1.1.11 Current antimalarial drugs 
For the conventional treatment of uncomplicated falciparum malaria in adults, in which the 
objective is to reduce parasitemia and fever, the medical practitioner has a choice of three 
recommended regimens: 
 
1. Atovaquone-proguanil (Malarone®), 4 tablets, each containing 250 mg of atovaquone 
and 100 mg of proguanil hydrochloride, daily for 3 days (Joint Formulary Committee, 
2010); 
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2. Quinine sulphate, 600 mg every 8 hours,  plus a choice of one of the following: 
Doxycycline, 200 mg orally daily for 7 days; Clindamycin, 450 mg every 8 hours for 7 
days, or Sulfadoxine-pyrimethamine (Fansidar®), for use only in children (Joint 
Formulary Committee, 2010); 
 
3. Artemether-lumefantrine (Riamet®), 4 tablets, each containing  artemether at 20 mg 
and lumefantrine at 120 mg, at 0, 8, 24, 36, 48 and 60 hours (Joint Formulary 
Committee, 2010); 
 
For non-falciparum malaria, a choice of chloroquine or primaquine is available. Mixed malarial 
infections may be treated “principally for falciparum malaria, as quinine and artesunate are 
effective in all species, whilst resistance to chloroquine by P. falciparum is widespread” 
(Walker et al., 2009). 
 
Table 2 summarises the currently available drugs for the treatment of uncomplicated 
falciparum malaria: 
 
Table 2. Classes of antimalarial drugs (reproduced from “Human antiparasitic drugs: pharmacology 
and usage” by James and Gilles (James and Gilles, 1985) 
Drug Chemical classification Dynamic classification 
Quinine, mefloquine 4-quinolinemethanols Rapidly-acting blood 
schizontocides Chloroquine, amodiaquine 4-aminoquinolines 
Artemisinin and derivatives Sesquiterpene lactone 
Sulphadoxine, sulphalene Sulphonamides Antifolates (type 1) 
Dapsone Sulphone 
Proguanil, chlorproguanil Biguanides Antifolates (type 2) 
Pyrimethamine 2:4-diaminopyrimidine 
Primaquine 8-aminoquinoline Tissue schizontocide 
 
Severe falciparum malaria, in which the primary purpose of medical intervention is to save the 
life of the patient, is treated with either quinine or artesunate, both of which are administered 
parenterally. Where artesunate is licensed (in South East Asia and sub-Saharan Africa), it is the 
preferred drug, at a level of 2.4 mg/kg, at 0, 12, 24 hours, and then daily. The authors of a 
recent British review of current malarial treatment regimens suggest that artesunate will, in all 
likelhood,  become the standard treatment of severe disease in the UK (Walker et al., 2009).  
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The current unreliability of a source of artesunate, hinted at by the authors of the British 
report, is the reason for the work undertaken in this thesis.  The ultimate source of artesunate, 
and the other related antimalarials artemether and arteether, are derived from the parent 
compound artemisinin – a sesquiterpene lactone, found in the leaves of the Chinese herb 
Artemisia annua L.   
 
1.2 Discovery of artemisinin  
The active principle of Artemisia annua L was identified in 1972, in the research group of You-
You Tu - a phytochemist working at the China Academy of Traditional Chinese medicine  
(Liao, 2009). Tu’s isolation of the compound followed a cold diethyl ether extraction of the 
dried herbal material. Attempts had been made to isolate active compounds by preparing the 
dried herb according to the Chinese tradition, in which the material is boiled as a tea, but no 
pharmacological activity in rodent malaria models could be demonstrated in this manner. 
 
Following bioassay guided screening of the diethyl ether extraction, the antimalarial activity of 
the herb was traced to the presence of colourless, needle-shaped crystals.  The structure of 
this purified crystalline compound – a sesquiterpene lactone with 7 chiral centres and a 
tetracyclic 1,2,4-trioxane skeleton - was determined in the late 1970s (Liu et al., 1979). Clinical 
trials followed, and the new drug was given the accolade of “national scientific discovery” by 
the Chinese Government. In 1986, artemisinin – under the Chinese name of qing hao su – was 
awarded its “new drug certificate”(Liao, 2009), meaning that the drug was now licensed – and 
the era of artemisinin had begun.  
 
The new compound had a most unusual feature – an endoperoxide bridge which, it would 
later be discovered, was vital for the pharmacological activity of the molecule.   
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Figure 3. Artemisinin 
 
1.3 Biosynthesis of artemisinin 
Although the total synthesis of artemisinin has been achieved in the laboratory, the complex 
procedures required, and the low yields obtained – 10% in the most recent reported synthesis 
(Yadav et al., 2003) - mean that for the foreseeable future, Artemisia annua itself will remain 
the only source of the drug. Of particular interest in this regard is the fact that, although  128 
stereoisomers  of artemisinin are theoretically possible, only one stereoisomer of the 
antimalarial artemisinin is biosynthesized in Artemisia annua L. plants (Julsing et al., 2006).  
 
So, what is known about the biosynthetic pathway to artemisinin? 
 
The biosynthesis of a compound called isopentenyl diphosphate (IPP) is absolutely necessary 
for the downstream synthesis of the sesquiterpenoids, of which artemisinin is one. Two 
pathways within the plant cell are capable of synthesising IPP: the mevalonate (MVA) pathway 
and the deoxyxylulose (1DX) pathway, so named after  the crucial intermediates mevalonic 
acid and deoxyxylulose 5-phosphate, respectively.  
 
 
Figure 4. Isopentenyl diphosphate (IPP) 
 
An important difference between the two pathways lies in the fact that the MVA pathway 
contains all the steps needed to produce artemisinin, whereas the deoxyxylulose pathway 
does not. This difference will be discussed in more detail in Sections 1.3.1. – 1.3.2., below. 
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1.3.1 The MVA  pathway 
Unlike the 1DX pathway, the enzymes of the mevalonate pathway are localised in the cytosol – 
the aqueous liquid sea in which cell organelles, including the plastids, are embedded. The 
genes for this pathway are thought to have evolved originally in the Archaebacteria - these 
prokaryotic cells being the most ancient of the bacterial life forms (Lange et al., 2000).  
 
The activity of the MVA pathway begins when acetyl CoA joins with acetoacetyl CoA, forming 
the intermediate compound β-hydroxy-β-methylglutaryl-CoA (HMG-CoA). Then, the enzyme 
HMG-CoA reductase brings about the irreversible two step reduction of HMG-CoA, forming  
mevalonic acid (MVA) - the first committed step in the production of the terpenoids. 
 
 
 
MVA then undergoes a series of phosphorylations, ultimately forming isopentenyl diphosphate 
(IPP). This latter undergoes geometrical isomerism, resulting in dimethylallyl diphosphate, or 
DMAPP. 
 
Figure 5. L; IPP. R: DMAPP 
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The linking of DMAPP with IPP creates a new compound – geranyl diphosphate. The addition 
of a further IPP unit to geranyl diphosphate then creates farnesyl diphosphate - the starting 
point for the biosynthesis of the sesquiterpenes, of which artemisinin is one (Dewick, 2001).  
 
 
Figure 6. Geranyl diphosphate (GPP) links with isopentenyl diphosphate (IPP) to form farnesyl 
diphosphate (FPP) 
 
1.3.2 The Deoxyxylulose (1-DX) Pathway 
Unlike the MVA pathway, the 1DX pathway – also called the mevalonate-independent pathway 
- is localised in the plastids. Results of genetic studies provide evidence that this plastidic 
pathway evolved more recently than the mevalonate pathway, deriving from the Eubacteria – 
and that the genes for this pathway were actually derived from the cyanobacterial ancestor of 
plastids (Lange et al., 2000).  
 
The1DX pathway begins with the condensation of D-glyceraldehyde-3-phosphate with 
activated acetaldehyde – the latter compound  itself derived from pyruvate (Dewick, 2001). 
This condensation forms deoxyxylulose 5-phosphate, and it is from this compound, via a series 
of steps not fully elucidated, that the two important isomers DMAPP and IPP are formed.  
 
 
Figure 7. Deoxyxylulose 5-phosphate 
 
Within the deoxyxylulose pathway, still inside the plastid, these two compounds – DMAPP and 
IPP - can lead to the formation of the chlorophylls, carotenoids, monoterpenes, and abscisic 
acid (ABA). IPP is, in addition, able to condense with its isomer, DMAPP, to form the 10-carbon 
compound geranyl diphosphate (GPP), and the 20-carbon geranyl geranyl diphosphate. The  
 
Introduction 
 
48 
 
former compound is the starting point for the biosynthesis of the monoterpenes; the latter, for 
the chlorophylls and carotenoids (Dewick, 2001). 
 
However, the plastidic deoxyxylulose pathway cannot lead to the formation of artemisinin, or 
any other sesquiterpene for that matter. The deoxyxylulose pathway results in mono- , di- and 
hemi-terpenes, but sesquiterpene biosynthesis is a function of the MVA pathway (Eisenreich et 
al, 2001). 
 
It can be seen (Figure 9) that in the mevalonate pathway, IPP remains within the cytosol and 
continues on down the mevalonate branches, one of which leads to the sesquiterpenes - 
including artemisinin. But in the deoxyxylulose pathway, some IPP can be transported out of 
the plastid and into the cytoplasm, to be added to the mevalonate pathway’s supply of IPP. 
This “crosstalk” between the two pathways is a subject of much research interest (Towler and 
Weathers, 2007). Figure 9 illustrates this proposed process.  
 
1.3.3 The relative contribution of both pathways to artemisinin biosynthesis 
It is known that isopentenyl diphosphate (IPP) is a vital intermediate in the biosynthesis of 
artemisinin. It is also known that IPP may be supplied by both the mevalonate and the DX 
pathways. Given that the mevalonate pathway carries all the necessary machinery to 
synthesise artemisinin, what evidence is there for the aforementioned “crosstalk” between the 
two pathways? Is it certain that at least some of the pool of IPP is contributed from the 
plastidic 1DX pathway? 
 
Several researchers have looked into this question, making use of labelled intermediates and 
selective inhibitors for each of the two pathways.  The most recent study, published in 2009, 
found evidence that artemisinin had a mixed biosynthetic origin, but was largely made from 
(E,E)-farnesyl diphosphate (FPP) in which the whose central isoprenoid unit came from the     
1-DX pathway (Schramek et al,  2009). 
 
The proposed mechanism of mixed biosynthesis is that  
 
1. DMAPP of mevalonate origin is transferred to the plastid,  
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2. Within the plastid, DMAPP then joins with an IPP unit of 1-DX origin, forming geranyl 
diphosphate (GPP) 
3. This  GPP is then exported back to the cytosol and converted into farnesyl diphosphate 
(FPP), using IPP from the mevalonate pathway.  
4.  FPP is then further modified to form amorpha-4,11-diene, and, ultimately, artemisinin 
(Schramek et al,  2009). 
 
1.3.3.1 Farnesyl diphosphate 
Farnesyl diphosphate can be converted into amorpha-4,1-diene; the first step along the 
sesquiterpene branch of the mevalonate pathway, and the road to artemisinin. In fact, it has 
recently been demonstrated that the overexpression of farnesyl diphosphate synthase in 
whole plants of A. annua results in 34.4% more artemisinin compared to control plants (Han et 
al., 2006).  
 
Farnesyl diphosphate is cyclised to form amorpha-1-diene: the first committed step of the 
artemisinin biosynthetic pathway. The enzyme, amorpha-4,11-diene synthase,  has been well 
characterized, following its discovery in A. annua in 1999 (Bouwmeester et al., 1999). From 
farnesyl diphosphate, the enzyme catalyses the production of a number of sesquiterpenes, of 
which the major product, at 93% in the 1999 study, was amorpha-4,11-diene.  
 
 
Figure 8. Amorpha-4,11-diene 
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Figure 9. The mevalonate and deoxyxylulose 5-phosphate pathways (reproduced from Towler and 
Weathers, 2007) 
 
1.3.3.2 From amorpha-4,11-diene to artemisinin 
The most recent literature presents evidence that there is a large degree of spontaneous, non-
enzymatic conversion in the latter stages of the pathway. But at least one enzyme has been 
identified in the earlier stages of the artemisinin biosynthetic pathway. 
 
Covello et al. and Teoh et al. (Covello et al., 2007, Teoh et al., 2006) independently presented 
evidence that a single, CYP-type enzyme, can catalyse multiple conversions in the latter stages 
of the artemisinin biosynthetic pathway. Following earlier evidence (Bertea et al., 2006) that a 
cytochrome P450 enzyme from A. annua leaf material was involved in the conversion of 
amorpha-4,11-diene to artemisinic alcohol, both research groups isolated RNA from leaf and 
flower glandular trichomes, and this isolated RNA eventually led to the discovery of a new 
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gene, with a coding sequence similar to enzymes of the CYP71D subfamily. The protein product 
– the enzyme itself - was designated CYP71AV1.  
 
Expression of this enzyme in Saccharomyces cerevisiae, followed by substrate feeding, showed 
that in the presence of NADPH this new enzyme could catalyse the following: 
 
1. Conversion of amorpha-4,11-diene to artemisinic alcohol; 
2. Conversion of artemisinic alcohol to artemisinic aldehyde (although this reaction could 
also be catalysed by a non-membrane-bound enzyme in trichome supernatant); 
3. Conversion of artemisinic aldehyde to artemisinic acid. 
 
Artemisinic alcohol, artemisinic aldehyde and artemisinic acid also exist in the reduced forms: 
dihydroartemisinic alcohol, dihydroartemisinic aldehyde, and dihydroartemisinic acid, 
respectively.  
 
The final steps from artemisinic acid to artemisinin are still controversial. Is artemisinic acid 
first converted into dihydroartemisinic acid, which is then converted into artemisinin? Or is 
artemisinic acid directly converted to artemisinin, as Covello’s research suggests? Li (Li et al., 
2006) suggests that the 11,13 double bond reduction – ultimately observed in the saturated 
11,13 bond in artemisinin – may occur at a late stage, perhaps via arteannuin B or 
artemisitene. But Brown (Brown and Sy, 2007) theorises that high artemisinin levels indicate a 
good degree of early stage 11,13 reduction, not a late stage reduction. So, there are still a 
number of questions to be answered. 
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Figure 10. Artemisinin 
 
So that takes care of the alcohols, aldehydes and acids. But extracts of A. annua also contain 
several other compounds, sometimes in respectable amounts – for example, arteannuin B, 
arteannuins H to M, and dihydroarteannuin B (Brown and Sy, 2007, Brown and Sy, 2004, Li et 
al., 2006).  
 
Feeding of stable isotope labelled artemisinic acid and dihydroartemisinic acid to whole plants, 
via cut stems and roots respectively (Brown and Sy, 2004; Brown and Sy, 2007), provided 
evidence that these acidic compounds do not go almost directly to artemisinin, as had been 
thought in earlier studies. In fact, it was found that arteannuin B – illustrated in Figure 11 - was 
the major metabolite of artemisinic acid conversion and six other minor metabolites were 
observed: annulide, isoannulide, deoxyarteannuin B, seco-cadinane, artemisinic acid methyl 
ester, and epi-deoxyarteannuin B.   
 
When labelled dihydroartemisinic acid was fed to cut plants, 16 labelled metabolites were 
observed, of which the major ones were dihydroarteannuin B, dihydro-epi-deoxyarteannuin B, 
and an un-named keto-aldehyde, compound 14. The others were identified as artemisinin, 
arteannuin M, a tertiary hydroperoxide of dihydroartemisinic acid called compound 15, 
dihydro-deoxyarteannuin B, a B-epoxy alcohol called compound 17, deoxyartemisinin, 
arteannuin K, arteannuin L, arteannuin H, arteannuin I, arteannuin J, a-epoxy-
dihydroartemisinic acid, and dihydro-epi- arteannuin B. The latter was reported as a natural 
compound for the first time. 
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A unified form of these arguments implies that  
 
• amorpha-4,11-diene synthase catalyses the conversion of farnesyl diphosphate to 
amorpha-4,11-diene, and this is the first dedicated step towards artemisinin.  
• Following this, a cytochrome P450, designated CYP71AV1, catalyses a series of 
reactions from amorpha-4,11-diene to artemisinic acid. What is perhaps not yet clear 
is how the reduced forms of these compounds come about, although in at least one 
case (conversion of artemisinic alcohol to artemisinic aldehyde), evidence exists for a 
non-membrane bound enzyme catalysis in trichome supernatant.  
• Artemisinic acid can then be converted, perhaps via spontaneous autoxidation, into 
arteannuin B, and dihydroartemisinic acid can be converted, also non-enzymatically, 
into a lot of compounds, with the major three being dihydroarteannuin B, dihydro-epi-
deoxyarteannuin B, an un-named keto-aldehyde, and artemisinin  
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Figure 11. A unified biosynthetic pathway to artemisinin.  ADS: amorphadiene synthase; CYP: 
reactions catalyzed by CYP71AV1; TS: Trichome Supernatant-catalyzed single step reactions (Teoh et al, 
2006;Covello et al, 2007). 
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1.3.4 Trichomes – site of artemisinin biosynthesis 
Although the exact site of artemisinin biosynthesis in the plant is unconfirmed, evidence 
suggests that the latter stages of the pathway, at least, occur within leaf surface structures 
called glandular trichomes.  
 
Microscopic examination of the leaf epidermis reveals two types of trichome: a distinctive non-
glandular T-shaped trichome, looking rather like a windmill, sticking out from the leaf surface – 
and also observed in other Artemisia species -, and an oval-shaped glandular secretory 
trichome (GST), embedded within the leaf (Fig 7). The latter, with its clear biserate (double-
cell) structure, is considered to be the major organ of biosynthesis and storage of artemisinin. 
The structure of the GSTs has been well studied: they consist of one pair of apical cells, three 
pairs of subapical, photosynthetic cells, and one pair of basal cells, all on a stalk (Lommen et 
al., 2006). Surrounding the three pairs of subapical cells and the apical cells is a secretory 
cavity, where the oily material is stored.  
 
Much evidence suggests that the synthesis of monoterpenes, at least, is dependent upon the 
activity of photosynthetic plastids such as are found in the subapical cells ((Duke and Paul, 
1993). This dependence has of yet not been demonstrated for the sesquiterpenes: indeed, as 
we have seen, the monoterpenes are produced in a different pathway to the sesquiterpenes. 
There is enzymatic evidence (the isolation of CYP7AV1 from GST libraries) that the precursors 
of artemisinin, at least, are made actually within the GSTs (Covello et al., 2009), but we don’t 
know exactly where – although it is known that artemisinin is stored in the subcuticular 
secretory space, with the monoterpenes (Duke and Paul, 1993).  
 
As an aside, Tellez et al., (Tellez et al., 1999) analysed both normal and glandless (that is, 
absent in GSTs) A. annua leaves for volatile oil content, and found that in the glanded plants, 
the oil was predominantly monoterpenoid. But in glandless plants, sesquiterpenes - mainly 
germacrene-D and Β-caryophyllene – predominated. 
 
Finally, Duke, in 1994, described how mutant plants, missing glandular trichomes, do not 
produce artemisinin (Duke, 1994).  
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Figure 12. Light microscopy image (x 40) of leaf surface of A. annua, showing glandular secretory 
trichomes (GSTs) and T-trichomes 
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1.4 Artemisinin-based pharmaceuticals 
1.4.1 Use of the drugs 
Several licensed forms of artemisinin-derivatives are now widely available in South East Asia 
and Africa. Artemether-lumefantrine (Coartem®) is the only internationally licensed co-
formulated medicine – adopted in the US in 2009 - and also the only form to include 
artemether.  Other licensed artemisinin-based treatment regimes are based around the 
administration - in separate tablets - of artesunate with amodiaquine (used in African 
countries); artesunate with mefloquine (used more in Asia), and artesunate with sulfadoxine-
pyrimethamine, used in Afghanistan (Greenwood et al., 2005). 
 
It is worth noting that the artemisinins are not suitable for malaria prophylaxis.    
 
1.4.2 Semi-synthetic derivatives of artemisinin, and metabolism thereof 
There are five artemisinin-type compounds approved for use in the treatment of malaria: one 
of these is artemisinin itself. The remaining four are derivatives in which the lactone ring has 
been modified in some way. The modifications serve to vary the solubility of the compound, 
and hence affect the means of administration, and are listed below: 
 
a) Dihydroartemisinin (DHA). This compound is actually a metabolite of artemisinin, on 
which the lactone’s oxygen is bonded to a hydrogen atom, forming a lactol (Bhakuni et 
al., 2002). In addition to being a metabolite the compound can be administered as a 
drug itself, for oral or suppository use. In fact, it has been shown to be three times 
more active against P. falciparum than artemisinin itself.  DHA, additionally, is the first 
step in the synthesis of the other three derivatives: 
b) Arteether, the β-ethyl ether isomer of DHA: an oil-soluble intramuscular form of the 
drug; 
c) Artemether (Figure 13), the β-methyl ether of DHA - another oil-soluble compound for 
intramuscular or oral use, and the most active of the semi-synthetic derivatives ; 
d) Artesunate (Figure 13), which is, more accurately, sodium artesunate: a water-soluble 
form for oral, intramuscular, intravenous or suppository use. 
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Figure 13. L: Artemether. R: Artesunate 
 
 
Artemisinin itself is not commonly used in the treatment of malaria; studies show that 
artemisinin takes longer to achieve parasite clearance, and results in a higher rate of 
recrudescence, than the semi-synthetic derivatives described above. Alin et al. (1996) found 
that patients infected with P. falciparum who were administered oral artemisinin, at 500 mg 
on day one, followed by 250 mg twice daily for four days and ending with a final 500 mg dose 
on day 6, took 31 hours (+- 3.6) to reach full parasite clearance, compared to 26.4 hours (+- 
3.6) for those receiving oral artesunate at 100mg on day one, followed by 50 mg twice daily for 
5 days. Recrudescence in the artemisinin group was 21.6% (+- 4.6), as compared to 18.9 % (+- 
4.0) in the artesunate group (Alin et al., 1996). These differences are small, but clearly 
significant.  
 
The artemisinin-derived drugs (and artemisinin itself) do act rapidly, reaching maximum 
plasma concentrations in as little as 1 hour. Alin reported that a Cmax of 260 ng/ml was 
obtained 1 hour after dosing with 400 mg of oral artemisinin – a very high figure when it is 
considered that the IC50 for artemisinin against P. falciparum in mice is as low as 3.9 ng/ml ( 
Mueller et al., 2004) The drugs are also eliminated rapidly, though, with typical elimination 
half-lives of 1-2 hours when drugs are given orally – one reason why these drugs are given as 
combination therapy, together with a longer-lasting drug. Intramuscular forms are available, 
with typically longer times to elimination, but absorption of drug when delivered in this form 
has been found to be erratic.  
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An important difference between artemisinin itself, and the artemisinin-derived drugs, lies in 
the metabolic products of the compounds. Artemisinin is metabolised in the liver to inactive 
products - “deoxyartemisinin, deoxydihydroartemisinin, 9,10-dihydrodeoxyartemisinin, and so-
called crystal 7) are formed primarily by polymorphic CYP2B6”, according to a 2009 study 
published in the Lancet (Kerb et al., 2009) -  but artesunate and artemether are metabolised 
first to dihydroartemisinin (DHA), which is more active against P. falciparum than the parent 
compounds. In fact, the WHO states that DHA contributes nearly all the antimalarial activity 
following artesunate administration (WHO, 2000). DHA is then further metabolised to inactive 
products. 
 
1.4.2.1 Artemisinin Combination Therapy (ACT) 
Typically, these compounds would be administered in combination with a drug with a longer 
half life: most commonly, mefloquine. The WHO approves the following combinations for 
uncomplicated falciparum malaria:  
 
▪ artemether + lumefantrine (Coartem®)  
▪ artesunate + amodiaquine  
▪ artesunate + mefloquine 
▪ artesunate + sulfadoxine–pyrimethamine(WHO, 2006).  
 
However, this requires, for outpatients with uncomplicated malaria, the taking of two different 
tablets (hospital patients suffering severe malaria would receive the intramuscular or 
suppository forms), and there is a risk of non-compliance: a patient may take only the 
artemisinin, and not the second drug. There is the additional factor of self-medication: it has 
been reported that, in areas far from the nearest clinic, individual artemisinin capsules are sold 
as monotherapy by individuals with little or no medical training: against the advice of the 
WHO, who disapprove of monotherapy, but state that if it is to be used, then a full 7 day 
course of treatment is required (WHO, 2006). It is probable that many patients cannot afford 
this treatment regimen. 
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To counter this problem, tablets containing both artemisinin and the second drug – the so-
called “fixed dose ACTS” – have been introduced. The first WHO-approved fixed-dose ACT was 
developed by Sanofi-Aventis as combination of two antimalarial drugs in a single tablet. The 
medicine, Coarsucam®, is a combination of artesunate and amodiaquine, which, like 
artemisinin, is a blood schizontocide. It was approved for marketing in 2007, and was given 
WHO prequalification status in 2008. 
 
A fixed dose ACT combining artemisinin and a different longer-acting medicine - naphthoquine 
– has been trialled in Papua New Guinea for the treatment of uncomplicated malaria. Each 
tablet contained 125 mg of artemisinin and 50 mg of naphthoquine, and eight tablets were 
administered as a single dose. This treatment, the authors of the study report, cleared 
parasitemia in 50% of the patients within 24 hours (Hombhanje et al., 2009).  
 
Finally, in 2009 the US Food and Drug Administration (FDA) approved the use of its Novartis’ 
Coartem® (a fixed-dose combination of artemether and lumefantrine) for the treatment of US-
based cases of uncomplicated falciparum malaria. 
 
1.4.2.2 Synthetic peroxides 
The most well-characterised of the new generation of synthetic peroxide antimalarials are the 
adamantane-based 1,2,4-trioxanes  reported by Tripathi et al., in 2007 – when these were 
administered to rhesus monkeys infected with P. knowlesi  (a simian malaria that has recently 
jumped to humans) total parasite clearance was achieved in a dose regimen of 80 mg/kg for 5 
days. However, this is quite a high dose when it is considered that typical artemisinin doses are 
in the region of 2.4 – 10 mg/kg (Tripathi et al., 2007).  
 
So far, no synthetic peroxide has been licensed for use in the treatment of malaria, although 
one such compound, designated OZ439, is currently in Phase 1 clinical trials (MMV, 2007). The 
basic structure of the OZ series of compounds is shown in Figure 14. 
 
Figure 14. Basic structure of the OZ series of synthetic peroxides (Charman, 2007) 
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1.4.3 What the drugs do 
Artemisinin and its derivatives are known to act on the human blood stages of the Plasmodium 
life cycle: in fact, the drugs are classed as blood schizontocides, putting them in the same class 
as mefloquine and chloroquine (James and Gilles, 1985). 
 
1.4.3.1 Rapid reduction of parasitemia 
 The major advantage of the artemisinin-derived drugs – other than the fact that they are able 
to reduce parasitemia in patients who do not respond to the older antimalarial drugs – is their 
rapidity of action. The artemisinins are quick to act and very efficaceous against Plasmodium 
parasites, including the youngest (ring form) stages. The drugs also show activity against the 
precursors of the sexual stages and early stage (I-III) gametocytes (Golenser et al., 2006). 
Gametocytes, when sequestered in the spleen and bone marrow, pass through 5 
morphological stages (Hayward et al., 1999).  
 
The drugs can reduce parasite numbers by a factor of approximately 10,000 in each asexual 
cycle – a remarkable figure, when it is considered that other antimalarials reduce parasite 
numbers 100- to 1000-fold per cycle (WHO, 2006) As an aside, parasite numbers in 
uncomplicated falciparum malaria can be over 10,000 per cubic millilitre of blood (Dondorp et 
al., 2009). It has been reported that the artemisinins can resolve fever and clear parasitemia 
within 48 hours following the start of treatment – unlike other drugs, which can take several 
days.  
 
This rapidity of action, though, comes with a complication: rapidity of clearance. Artesunate, a 
water-soluble derivative, can be eliminated from the body in as little as 10 minutes, although 
the drug is metabolised to a compound called dihydroartemisinin. However, even this 
metabolite is eliminated within one hour. So, the artemisinins would typically be administered 
in combination with a longer-lasting antimalarial. This form of artemisinin combination therapy 
(ACT) is discussed in more detail in Section 1.4.2.1. 
 
1.4.3.2 Reduction of transmission 
Other advantages of the artemisinins compared to other antimalarials have been discussed in 
the literature, including that of reducing transmission of malarial parasites from patient to 
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mosquito: the WHO reports that “Artemisinins are the most potent gametocytocidal drugs 
among those currently being used to treat an asexual blood infection” (WHO, 2006). Such an 
action would reduce transmission of the disease, because these mature, circulating 
gametocytes must be ingested by a mosquito before they can become mature gametes. 
Clearly, destroying a young gametocyte before mosquito ingestion will break this step of the 
cycle.   
 
However, a note of caution is needed here: although the artemisinins effectively destroy 
immature gametocytes, as reported by Golenser and described earlier in this section, they 
cannot destroy those gametocytes that have gone beyond stage III, but have not yet been 
ingested by a mosquito. So, even with the use of artemisinins, some parasites will survive to 
reproduce in the mosquito gut, and transmission will continue to some degree. In fact, the 
only antimalarial that is used specifically for its inhibitory effect on transmission is primaquine: 
this drug is able to act on mature gametocytes (WHO, 2006).  
 
1.4.3.3 Reduction of cytoadherence 
A newly-discovered advantage of artesunate and artemether lies within this drug’s ability to 
reduce a pathological phenomenon called cytoadherence. 
  
The mortality rate of severe malaria, as discussed in Section 1.1.1., can be as high as 20%, even 
following hospital admission and appropriate treatment. These deaths typically occur within 
24 hours following admission, and are thought to be the result of the binding of infected red 
blood cells to the microvasculature of the body’s internal organs. As a direct result of this 
sequestration, blood vessels are blocked and local inflammatory responses can be triggered, 
with death following from organ failure.  
 
It is known that cytoadherence is mediated by the parasite protein PfEMP-1 – a protein that is 
expressed to a greater degree in more mature parasites (in the trophozoite stage) compared 
to younger (early-trophozoite, or ring, stage) parasites. Since artesunate and artemether act 
on the younger parasites – unlike the older antimalarials, such as lumefantrine, quinine and 
piperaquine, which act by disrupting the detoxification of haem in mature trophozoites – the 
drugs prevent the parasites maturing to a stage where cytoadherence is a problem  
(Hughes et al., 2010).  
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1.4.4 Mechanism of action 
Although the precise mechanism of action of artemisinin against the Plasmodium parasite has 
not been elucidated, the body of evidence is increasing. Current theories postulate both 
parasite-specific and non-specific mechanisms of action: the former including putative targets 
in the Plasmodium biochemistry, and the latter based upon free radical reactions against a 
wide range of proteins. The latter will be discussed first. 
1.4.4.1 Non-specific reactions 
In 2001, Posner wrote that there was now “evidence for a reaction between haem and 
artemisinin (qinghaosu)...for the haem–iron-mediated generation of free radicals from 
artemisinin...for the alkylation of haem and proteins...for a unified chemical mechanistic 
paradigm involving carbon-centred radicals; [and] for the putative antimalarial role of a high-
valent iron–oxo reactive intermediate” (Posner and Meshnik, 2001). The details of such steps 
in the mechanism of action of artemisinin will now be discussed in a little more detail. 
 
1.4.4.1.1 The peroxide structure 
The necessity of the endoperoxide group for anti-plasmodial action has long been noted: 
deoxyartemisinin, in which the peroxide bridge has been modified to a single oxygen, in an 
ether-type structure, displays greatly reduced action against the parasite in vitro. 
 
 Additionally, artemisinin appears to react, in infected red blood cells, with haem in the Fe(II) 
form (and also, to a lesser degree, with cytochrome c), in a form of the Fenton reaction – a 
mechanism that centres upon the reaction of  a peroxide moiety with ferrous (II) iron – or 
ferrous haem, in this case. This hypothesis is further supported by the fact that 
desferrioxamine, a scavenger of Fe(II), inhibits the antiplasmodial action of peroxides (Krishna 
et al., 2004).  
 
Further evidence that artemisinin reacts with haem lies with the discovery that artemisinins 
concentrate in the parasite’s food vacuole, where haemoglobin is digested. The parasites 
consume the globin portion of the haemoglobin molecule so that they can make use of the 
amino acids therein, but the haem – which is useless and indeed toxic to the parasite – is 
converted into an inert crystalline polymer, in the Fe(III) form, called haemozoin (the so-called 
“malaria pigment” so visible under the microscope).  
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1.4.4.1.2 The Fenton reaction 
These two pieces of evidence: the need for a peroxide group, and the apparent link with 
ferrous haem - led numerous researchers to hypothesise that a Fenton-type reaction was 
responsible for artemisinin’s ability to destroy the parasite.  
The presence of Fe(II), whether as part of haem or in the free iron form, is necessary for the 
Fenton reaction to proceed. In the Fenton reaction, a peroxide group reacts with ferrous iron 
(such as that found in haem), in the presence of an acid, producing the hydroxyl radical: 
 
Fe2+ + H2O2 → Fe3+ + OH• + OH− 
(Lloyd, 1997) 
 
Current theories postulate the following sequence of events when artemisinin encounters 
ferrous haem (see also Figure 16): 
 
1. An electron is transferred from the haem Fe(II) ion to the peroxide bridge of 
artemisinin, forming an artemisinin-haem adduct; 
 
2. The peroxide bond then breaks in one of two homolytic ways, depending on which of 
the two oxygen atoms the haem has bonded with – designated, for this purpose, O1 
and O2.  
 
 
Figure 15. Artemisinin, showing O1 and O2 
 
3. If the haem binds with O1, then a sigmatropic 1,5-H shift takes place, creating a C4 
radical intermediate, and in the process, releasing Fe(IV)=O, an iron-oxo species that 
has been implicated in anti-plasmodial activity (Kapetanaki and Varotsis, 2000). The C4 
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radical intermediate is quite stable, and has been hypothesised to be the anti-
plasmodial species. 
 
 
4. An intermediate epoxide is formed, with the loss of the unpaired electron (which is 
accepted by the Fe3+ ion).  
 
5. The epoxide structure undergoes rearrangement to 3-hydroxydeoxoartemisinin, the 
end product of this O1-based reaction(AG Taranto, 2002)  
 
6. If, however, the haem binds to O2, then a different series of reactions follows., A β-
scission of the bond between carbons C3 and C4 takes place, which opens the ring and 
ultimately creates arteannuin G via a C4 radical intermediate (Wright, 2002, Meshnick 
et al., 1996).   
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Figure 16. Rearrangement of artemisinin (1) leading to 3-hydroxydeoxoartemisinin (5), following 
electron transfer to O1. (Taranto et al., 2002) 
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1.4.4.1.3 Radical intermediates 
Although other reactions, following both O1 and O2-haem binding, are possible, evidence 
supports the prevalence of steps 3 – 4, leading to deoxygenated artemisinins via radical 
intermediates.  It is the intermediate products (the carbon radicals and Fe(IV)=O) that mediate 
the toxicity within Plasmodium parasites (Wright, 2002). As Krishna writes, deoxyartemisinin 
does not demonstrate antimalarial activiy - and thus antimalarial activity is “claimed to reside 
in the radicals...by their reacting with ‘sensitive biomolecules’ in the parasite” (Krishna et al., 
2004).  
 
Essentially, it is the formation of an artemisinin-haem adduct, with the binding being between 
the epoxide bridge and the haem structure, that instigates parasite destruction – brought 
about by the subsequent generation of intermediate radical species, which mediate parasite 
death through the alkylation of proteins. “The alkylation of intraparasitic proteins by 
artemisinin derivatives” has been shown in vitro, and is “dependent on the presence of the 
endoperoxide bridge”, according to a 1998 study (Bhisutthibhan et al., 1998). 
 
1.4.4.1.4 Mechanisms of toxicity 
The activation of artemisinin, described above, would imply that artemisinin, and its 
derivatives, are not so much drugs in their original state but prodrugs, requiring activation – in 
this case, by ferrous haem – to exert their action. Of course, the idea of “prodrugs” is not new: 
the metabolic activation of methoxylated flavones is theorised to play an important role in 
cancer prevention.  
 
In this radical-mediated mechanism of action, damage to parasitic proteins by alkylation is the 
means by which the drug destroys parasites. In fact, the damage is not just directed at proteins 
- haem itself is vulnerable to alkylation by artemisinin-derived radicals. Haem alkylation, 
caused by the artemisinin: haem reaction, actually prevents detoxification of haem - normally 
accomplished by the formation of haemozoin1 - within the parasite. Haem is both “the trigger 
and the target of artemisinin”, write Selmeczi et al. (Selmeczi et al., 2004).  
 
 
1 Haemozoin is a polymer composed of haem monomers 
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Incidentally, this would explain why the artemisinins are more active against younger 
parasites: artemisinin can react only with haem, not with haemozoin. The bodies of older 
parasites contain more haemozoin relative to free haem, in their bodies, when compared to 
younger stages. 
 
Artemisinin does not damage uninfected red blood cells, because the concentrations of free 
haem in healthy cells do not reach high levels – unlike the situation in the food vacuole of the 
parasite, wherein haem accumulates before being detoxification. 
 
1.4.4.2 Parasite-specific mechanisms 
1.4.4.2.1 SERCAs 
Several papers have been published in the last five years highlighting putative parasite-specific 
targets of artemisinin and its derivatives. One of these targets – an intracellular pump of the 
sarcoplasmic/endoplasmic reticulum Ca2+ATPase (SERCA) type, encoded for in P. falciparum by 
the gene pfatp6 – was singled out because it is inhibited by a compound called thapsigargin, 
structurally very similar to artemisinin. Thapsigargin (Figure 17) is itself a plant-derived 
sesquiterpene lactone, found in the roots of the Mediterranean species Thapsia garganica. 
Derivatives of thapsigargin are undergoing trials for the treatment of prostate cancer 
(Denmeade et al., 2003).  
 
 
Figure 17. Thapsigargin  
  
SERCAs help to maintain appropriate calcium ion concentrations across organelle membranes, 
and inhibition of such a protein disrupts cell signalling and protein folding in the parasite. In a 
2003 study published in Nature (Eckstein-Ludwig et al., 2003), it was shown that artemisinin 
and dihydroartemisinin could inhibit the P. falciparum SERCA pump, when the protein was 
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expressed in Xenopus laevis oocytes (a standard model system for the analysis of protein 
function (Heikkila et al., 2007)). Other antimalarials tested had no such inhibitory actions. 
Moreover, the inhibition of SERCA by artemisinin was specific: even at comparatively high 
(50µM) levels of artemisinin, no other membrane pumps were inhibited. Finally, it was shown 
by the Nature study that thapsigargin and artemisinin derivatives were antagonistic to each 
other, strongly suggesting that both drugs have the same target.  
 
A later study by Uhlemann et al., in 2005, demonstrated that the sensitivity of the plasmodial 
SERCA to artemisinin could be altered by a single amino acid mutation in the protein. They 
discovered that an L263E replacement of a malarial by a mammalian residue abolished 
inhibition by artemisinins (Uhlemann et al., 2005). The L263 residue is found in the region of 
the protein where thapsigargin is known to bind, further implying that artemisinin binds to the 
Plasmodial SERCA in the same manner.  
 
1.4.4.2.2 The mitochondrial electron transport chain 
Another parasite-specific mechanism that has been proposed is that of interference with 
mitochondrial respiration. It has been demonstrated that artemisinin can inhibit the electron 
transport chain in mitochondria by inducing a depolarisation of the mitochondrial membrane 
(Li et al., 2005). Such disruption of membrane potential in mitochondria has also been 
reported when artemisinin is administered to neuronal cell cultures (Schmuck et al., 2002) – 
perhaps providing insight into the occasional reports of neurotoxicity in patients following 
treatment with the artemisinins.  
 
A genetic study demonstrated the involvement of the nde1 and ndi1 genes, which code for 
NADH dehydrogenases in the yeast electron transport chain, in sensitivity to artemisinin. 
Deletion of these genes induced resistance to artemisinin in yeast, whereas over expression of 
the same induced increased sensitivity. The ndi1 gene has an orthologue in P. falciparum. The 
author of the 2005 yeast study proposes the following mechanism: 
 
1. Artemisinin is activated by iron present in the mitochondria; 
2. This triggers induction of radical species, as discussed in Section 1.6.4.1.; 
3. The radical species trigger depolarisation of the mitochondrial membranes (li et al., 
2005). 
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The mitochondrial disruption hypothesis is supported by a 1999 study by Krungkrai et al., who 
discovered that artemisinin could inhibit the mitochondrial respiratory chain of both asexual 
and sexual stages of P. falciparum (Krungkrai et al., 1999). As mitochondria are expressed 
continually, not just in young stages of the parasite, this indicates that artemisinins posses 
some activity against all Plasmodial stages.  
 
1.4.4.2.3 Pyrimidine biosynthesis 
Krungkrai and colleagues, in a more recent paper, noted that the P. falciparum parasite 
depends on a de novo pyrimidine synthesis pathway: the parasite cannot harvest pyrimidines 
from the human host. The existence of this pathway obviously suggests a target for 
antimalarial drugs, and Krungkrai’s group discovered differences in the dihydroorotase 
(DHOase) enzyme in the parasite, and in mammals. This is an enzyme that catalyses ring 
closure in the pyrimidine biosynthetic pathway.  Krungkrai’s group reported that specific 
inhibitors can limit the pyrimidine nucleotide pool in the parasite, without affecting the human 
host (Krungkrai et al., 2008). However, current drugs targeting the dihydroorotase enzyme – 
such as Leflunomide, used in rheumatoid arthritis, inhibit mammalian forms of the enzyme, 
including those present in T-lymphocytes (Ruckemann et al., 1998), and may or may not be 
suitable. 
 
1.4.4.2.4 Binding to PfHRP II 
The histidine-rich proteins of P. falciparum - designated PfHRP I, II, III, etc – are capable of 
binding haem monomers, and play a role in the detoxification of haem in the parasite’s food 
vacuole. Kannan et al. (2002) have shown that the artemisinin-haem adduct binds to PfHRP II, 
and hence inhibits the detoxification of haem within the parasite(Kannan et al., 2002) This is 
an example of how haem is, in fact, both a trigger and a target for the mechanism of action of 
artemisinin.  
 
1.4.5 Resistance to artemisinin 
2009 saw the first reports of resistance to artemisinin-based therapy (Dondorp et al., 2009). 
The reports came from Pailin, near the Thai-Cambodian border, a region previously known as a 
cradle for Plasmodium strains resistant to older drugs, and, crucially, where artemisinin-based 
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monotherapy has been used for more than 30 years. (Pailin is characterised by low-level 
seasonal transmission of falciparum malaria, indicating that no immunity is likely to be present 
in the adult population, and hence severe illness can result from infection). According to local 
news reports, resistance to antimalarials has been a problem in Pailin because the regions 
mining prospects attract foreign migrants with low immunity, who tended not to seek 
professional medical help upon infection, but self-medicated (Win, 2010).  
 
It had been predicted that resistance to the artemisinins would eventually emerge– hence the 
WHO’s disapproval of artemisinin monotherapy and restriction of the drugs to the areas of 
greatest need. In 2005, the Lancet reported, from French Guiana, the first known case of in 
vitro resistance of P. falciparum to artemether – in parasites originally obtained from patients 
and then cultivated in the laboratory. In this case, resistance was defined as greatly increased 
IC50 in vitro. However, the resistance was not manifested in vivo, for reasons which remain 
unclear (Jambou, 2005).  
 
1.4.5.1 In vitro resistance 
In 2006, three years before the emergence of in vivo resistant Plasmodium falciparum, it was 
demonstrated that parasites of the rodent malaria model Plasmodium chabaudi chabaudi 
could develop stable – that is, heritable and transmissible – resistance to artemisinin and 
artesunate under “drug pressure”. These rodent parasites – cloned from an artemisinin 
sensitive strain - were cultivated under pressure from increasing levels of either artemisinin or 
artesunate, and those parasites that survived the highest doses of drug (up to 300 mg/kg per 
day) were identified as resistant.  
 
Because the new resistant strain was originally cloned from a drug-sensitive strain, it is clear 
that, as the authors of the study wrote, the drug-sensitive and drug-resistant parasites were 
genetically identical except for any mutations involved in resistance (Alfonso et al., 2006). It 
should then, theoretically, be possible to compare the genetic sequence of the two strains and 
identify the mutated nucleotide sequences.  
 
Alfonso et al., (2006), searched the nucleotide sequences of the resistant strain of P. chabaudi 
chabaudi for mutations in four genes hypothesized to be potential mediators of artemisinin or 
artesunate resistance. These were: 
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a and b) mdr1 and crt, orthologues of pfmdr1 and pfcrt -  genes for Plasmodium 
falciparum multi-drug resistance and Plasmodium falciparum chloroquine resistance 
transporter respectively, encoding membrane transporter proteins located in the 
membrane of the parasite’s food vacuole. In Cambodia, high copy numbers of pfmdr1 
in P. falciparum have been associated with resistance to mefloquine, and have also 
been implicated in the small decrease in artemisinin sensitivity reported in the Lancet  
(Price et al., 2004); 
 
c) tctp; a gene responsible for the production of translationally-controlled tumour 
protein. This protein, with the ability to bind artemisinin, was found to be increased in 
a resistant strain of P. yoelii yoelii. However, the resistance was unstable. It has been 
demonstrated that artemisinins can bind, via alkylation of cysteine residues, to the 
protein TCTP. The significance of this is not yet known, as levels of TCTP ate highest at 
the trophozoite stage, and so far, all tests have indicated that artemisinins are most 
active against the younger, ring-stages (Bhisutthibhan et al., 1998); 
 
d) atp6, a gene encoding a sarcoplasmic and endoplasmic reticulum calcium ATPase 
(SERCA)-type protein. It has been suggested that this protein is the major target of 
artemisinin-type drugs. In 2005, a mutated form of this gene in P. falciparum isolates 
obtained from patients in French Guiana (a substitution mutation at S769N) this was 
shown, in vitro, to be an indicator of resistance to artemether, characterised by a 
greatly increased IC50 value for the drug in vitro (Jambou, 2005).  
 
However, despite the successful induction of drug resistance that remained stable despite 
cloning, freeze-thawing, passage in the absence of drug and transmission through mosquitoes 
(Alfonso et al., 2006), no mutations could be observed in any of the genes examined that 
would explain the resistant phenotype.  
 
1.4.5.2 Clinical resistance in Pailin 
And similarly, a study of the artesunate-resistant P. falciparum parasites that developed in 
Pailin failed to firmly identify a genetic basis for the resistance. The researchers compared the 
genotype of the resistant parasites – wherein resistance was defined clinically as failure to 
Introduction 
 
73 
 
clear parasitemia within 3 days following the start of treatment, or recrudescence after 7 days 
following the end of treatment – with the genotype of sensitive parasites taken from patients 
in north-west Thailand. The authors did not detect the PfSERCA L263E and S769 N 
polymorphisms, which are proposed to confer artemisinin resistance (Dondorp et al., 2009) – 
although it was discovered that 80% of parasite isolates from patients in Pailin had the mutant 
codon Y184F within the pfmdr1 gene, compared to only 30% of isolates taken from north-
western Thailand. But no further research has yet been undertaken regarding this particular 
mutation. 
 
So, at the moment, it remains unclear precisely how the artemisinin-resistant phenotype 
develops.  It is striking, though, that the two regions where resistant P. falciparum parasites 
have been identified in patients – French Guiana and Pailin – are both regions of “antimalarial 
drug pressure” (Krishna et al., 2006), where parasites are typically resistant to several 
antimalarials, and where artemisinin monotherapy has been used.  
 
Krishna et al. propose a hypothetical “cascade” scenario following on from the detection of in 
vitro resistance, beginning with a key mutation in the target enzyme, followed by accumulation 
of additional mutations, ultimately resulting in High rates of clinical drug failure (Krishna et al., 
2006). A similar scenario is proposed by Golenser et al., who suggest that since pfmdr1 has a 
generalised importance in antimalarial drug resistance, “induction of resistance to one drug 
may be followed by resistance to other drugs that are not active by the same mechanism” 
(Golenser et al., 2006). Such a scenario complicates the search for single mutations mediating 
artemisinin resistance.   
 
On a related topic, it has been reported that the clinical efficacy of artemether/lumefantrine  
formulations varies according to the proportion of fat in the patient’s diet – a low fat diet, 
typical in rural parts of South East Asia, can inhibit absorption of lumefantrine (Mukhtar et al., 
2007), result in failure of therapy (in effect, an artemether monotherapy was delivered, which 
is inadvisable in areas prone to artemisinin-type resistance.  
1.4.5.3 In vitro and in vivo resistance - discrepancies 
In an inversion of the French Guianan situation, parasite isolates from Pailin showing 
resistance to artesunate remained susceptible to the drug in vitro. (It will be recalled that in 
French Guiana, in vitro resistance was observed whilst in vivo resistance was not). The authors 
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of the Pailin study explain this apparent discrepancy by suggesting that resistance to 
artesunate developed only in young, ring-stage parasites. (As previously discussed, 
artemisinin-derived drugs act on the young ring-stage parasites, preventing their maturation 
into the mature trophozoite stage). As in vitro tests typically utilise parasite samples ranging 
from young ring-stage to mature trophozoite, it is suggested by the authors that only a small 
percentage of these parasites – the ring-stage – would show resistance to the drug. However, 
there would seem to be an obvious problem with this explanation. As artesunate acts only on 
the ring-stage parasites, it is of no consequence that the remainder of the in vitro sample 
consists of mature parasites: these mature stages would not be susceptible to artesunate 
anyway, and therefore it would be expected that an in vitro sample consisting of a proportion 
of young, artesunate-resistant parasites mixed with a range of older stages, would in fact not 
be susceptible to the drug.  
 
1.4.6 WHO advice for the prevention of artemisinin resistance 
In the absence of understanding of how resistance to the artemisinin-derived drugs develops, 
it is crucial that the advice of the WHO regarding administration of these drugs – that they 
should always be used in combination with an effective partner drug, which has a different 
mechanism of action - is followed wherever possible. 
 
 The use of artemisinin monotherapy is almost certain to hasten the spread of resistance – 
indeed, one study has shown that where artesunate monotherapy was used to treat non-
immune individuals, the IC90 value of the drug against recrudescent parasites was 5 times 
greater than in the initial infection (Jambou, 2005): strongly implying that the parasites that 
survived the initial infection were in fact resistant to artesunate. The concomitant use of an 
additional antimalarial would have been likely to destroy these survivors – as the WHOs 
treatment guidelines explain: “The use of drugs in combination, specifically with artemisinin 
derivatives, will remove the survival advantage conferred on parasites resistant to a particular 
drug by the use of that drug as monotherapy... The use of an artemisinin derivative with an 
effective partner drug will delay the selection and spread of drug resistance” (WHO, 2006). 
  
Of particular concern is the availability, without prescription, of a range of products claiming to 
contain artemisinin – typically, capsules containing powdered Artemisia annua L, or pure 
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artemisinin itself. A number of US and UK-based websites sell such products to the general 
public, and the implications of this will be further discussed in Section 10 of this thesis. 
 
1.5 The economics of artemisinin 
In 2006, the total global production of artemisinin from Artemisia annua L reached 150 tons, 
but by 2009 annual production had fallen to 40 tons. However, the number of artemisinin-
based treatments needed per annum has increased in that time, from 100 million in 2006 to 
120 million in 2009. Estimates from NGOs suggest that by 2014, 250 million treatments will be 
needed. Although after 2014, the estimated requirements for artemisinin are expected to 
reduce – mainly because of expanded use of mosquito nets and other physical interventions, 
such as spraying of insecticide – the estimated demand for artemisinin is expected to remain 
above 200 million treatments, and there is no guarantee that sufficient crops of Artemisia 
annua L will be produced to meet this demand (Grewal, 2009).  
 
The understanding that developing countries are entitled to access the medicines that they 
need to survive malaria is not a recent one: as far back as 1926, Professor Emile Perrot of the 
Faculty of Pharmacy in Paris wrote of the necessity to “look for the solution, if it exists, to the 
problem of supplying the poor nations with a medicine to fight malaria” (Burns, 2008). But the 
fact remains that today, in parts of Africa in particular, many populations either cannot obtain 
sufficient quantities of artemisinin-based therapies, or cannot afford the drugs – of the “250 
million individuals are infected annually.only 3% have access to ACTs” (Talisuna et al., 2009). 
Mutabingwa, in a similar vein, explains that high costs and an imbalance between supply and 
demand are major problems in accessing ACTs (Mutabingwa, 2005).  
 
Solutions proposed to this imbalance between supply and demand range from the small-scale - 
self-medication with locally grown Artemisia annua L. teas, for example - to the global: c.f. the 
Roll Back Malaria programme, which considers that the “scale-up in cultivation of the plant 
[Artemisia annua L.] and capacity to process it are crucial to worldwide malaria control 
efforts.” (Traore, 2005).  
 
The cultivation of the crop in malarial endemic regions has several advantages, not least of 
which is as a source of employment. Additionally, it is generally the case that transport costs 
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are reduced if herbal raw material can be grown and processed near the site of intended use. 
However, two problems in the cultivation of A. annua in Africa, in particular, remain: 
 
1. At the moment, few facilities exist in malaria-endemic regions for the processing (i.e. 
extraction and purification) of artemisinin from A. annua L. So shipping costs – to 
Europe or China, where production of the pharmaceutical dose-form takes place – are 
high; 
2. Tests – (see section 5.3.1.) - have shown that herbal material grown in Tanzania and 
Ghana contains relatively high levels of deoxyartemisinin, when compared to 
European-grown herbal material.  
 
So until processing facilities in malaria-endemic improve – and this improvement is another 
objective of the Roll Back Malaria programme – the establishment of a UK-based artemisinin 
supply chain, from field to active pharmaceutical ingredient, would have a significant role to 
play in the stabilisation of the global artemisinin supply. 
   
1.6 Final words 
This thesis presents evidence that 
 
1. Artemisinin levels in Artemisia annua L. can be rapidly and accurately assessed 
both in-field and in the laboratory, using high-pressure liquid chromatography-
mass-spectrometry (HPLC-MS) in the laboratory and densitometric thin-layer 
chromatography in the field (Sections 2, 3 and 6);  
2. Deoxyartemisinin can be separated from artemisinin on thin-layer 
chromatography, and on a gram-scale using a simple and inexpensive flash-
chromatography technique (Sections 5 and 7); 
3. Breeding for increased artemisinin content results in concomitant increases in 
chrysosplenetin content, as demonstrated by HPLC-diode array detection (DAD) 
potentially increasing the value of the crop (Section 8); 
4. High-pressure liquid chromatography coupled to diode-array detection (DAD), a 
UV-based detection method, can be used indirectly to quantify artemisinin levels 
in herbal material (Section 8). This is based upon the direct correlation between 
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flavonoid content and artemisinin content, and the fact that flavonoids are strong 
UV-light absorbers. 
5. Teas prepared from Artemisia annua leaf, and most over the counter preparations 
of Artemisia annua, are very low in artemisinin content. Additionally, the presence 
of iron salts in water used to prepare teas does not have a detrimental effect on 
artemisinin content of the tea (Section 10).  
 
Section 9 briefly discusses an attempt to increase artemisinin yields in hairy root cultures of A. 
annua by applying exogenous farnesol. The thesis concludes, in Section 11, with a discussion of 
the outcomes of the whole LINK project.
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Prologue to Sections 1 - 6: Development of analytical methods 
Between 2005 and 2006, a Defra-funded pilot project – “Field cultivation of Artemisia annua 
and enhanced extraction of artemisinin used in novel antimalarial treatments” - ran. This 
project examined the feasibility of establishing, in the UK, an artemisinin supply chain, from 
crop in the field to active pharmaceutical ingredient (or, more memorably, from farmer to 
Pharma).  
 
One of the outcomes of project NF0613 was the identification of the need for an improved 
analytical system – one that could handle the large sample numbers (in the hundreds or 
thousands) that are generated by these kinds of breeding projects. The requirements for the 
improved system were: 
 
1. Greater accuracy and precision (i.e. less variation between replicated analyses, and a 
more reliable value for artemisinin content); 
2. Faster - the current HPLC-DAD based method having a 25 minute run-time, as well as 
requiring much in the way of sample clean-up.  A TLC method was in place, but was 
semi-quantitative at best; 
3. More economical; HPLC solvents being expensive to purchase and dispose of. 
 
Additionally, the requirement for a portable, field-based, means of artemisinin quantification 
was identified. Such a method would not need the high levels of accuracy of the so-called high-
throughput laboratory-based analytical system described in points 1-3, above. It would merely 
need to be able to give a comparative indication, to a plant grower, of artemisinin level. A 
device like this would be useful not only in large-scale commercial crops, allowing the user to 
make on-site, rapid decisions about harvesting times, but also for the small grower in the 
malarial-endemic regions, who frequently do not have access to laboratory equipment.   
 
Section 2, as well as Sections 3, 4, 6 and, indirectly, 8, discuss new means of reliably 
quantifying artemisinin levels within leaf material, crude extracts, and purified material.
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2 Modifications to HPLC-DAD technique for the 
separation and quantification of artemisinin 
 
Synopsis 
Throughout the one-year pilot project (NF0613), the quantification of artemisinin in dried leaf 
material had utilised the International Pharmacopoeia’s HPLC-DAD-based method (which was 
intended for the analysis of pharmaceutical-grade, crystalline material). Artemisinin’s lack of a 
strong chromophore, together with the presence in crude leaf extracts of many other UV-
absorbing compounds, meant that before this method could be used, time-consuming clean-
up had to be performed for each sample analysed. Given that the new four-year LINK project 
was expected to generate samples in the thousands, a complex clean-up stage for each sample 
would be unfeasible. As part of this LINK project, the author was asked to investigate whether 
modifications to the HPLC-DAD method could be made that would improve artemisinin 
separation to the extent that such clean-up was unnecessary. 
 
Several modifications to mobile and stationary phases were made, and column quality (as 
quantified by theoretical plates) was monitored. It was found that by keeping theoretical 
plates above a critical level, reasonable precision and accuracy for artemisinin level could be 
obtained when analysing crude leaf extracts. However, it was concluded that HPLC-DAD, whilst 
suitable for the quantification of partially-purified and crystalline artemisinin, was unsuitable 
for the assay of crude leaf material, and that other avenues (notably HPLC-MS) should be 
explored.  
 
2.1 Introduction 
Sample analysis during Project NF0613 had relied on a high pressure liquid chromatographic 
(HPLC) separation system, coupled to a diode array detector (DAD) detection system, which is 
based on the absorption of ultra-violet (UV) light by parts of a molecule of interest. The 
particular method was adapted from that given in the International Pharmacopoeia (IP) for the 
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quality assessment and quantification of artemisinin in pure, or almost pure, crystalline form 
(WHO, 2003). Although the technique had been validated for such a purpose, the UV-based 
quantification of artemisinin is by no means an ideal technique.  Artemisinin, containing no 
real chromophore, does not strongly absorb UV light. In addition, the wavelength of UV that 
the molecule does absorb - 214 nm – is very close to the UV maxima of acetonitrile, the 
primary constituent of the mobile phase recommended by the IP.  
The net result of this poor UV absorbance, in a region where solvent absorbance is also 
observed, is that artemisinin can only be reliably quantified by UV-based methods when high 
(>1 mg/ml) concentrations of highly purified (> 90% w/w) artemisinin are assayed. HPLC-UV 
shows its limitations when artemisinin must be quantified in a less clean matrix – a crude plant 
extract, for example. To fulfil the requirements of this LINK project, thousands of Artemisia 
annua L plants needed to be assayed for artemisinin level. The unfeasibility of purifying 
thousands of crude extracts to >90% purity before analysis became quickly apparent.  
 
As a large number of samples would be generated on a regular basis, it was necessary to 
develop a rapid, reliable, and economical procedure that would quickly provide useful data 
from dried herb. Discussions with consortium members raised a number of potential methods 
(densitometric thin layer chromatography [TLC], high performance liquid chromatography-
diode array detection [HPLC-DAD], HPLC-mass spectrometry [HPLC-MS] , immunological 
techniques), many of which had already been successfully trialled in previous work by 
consortium members. Other researchers have also made use of an artemisinin derivatisation 
procedure, which uses “0.2% (by weight) NaOH solution and then 0.08 M acetic acid” to 
produce a compound which absorbs UV at 260 nm (Qian et al., 2005). However, in the 
interests of simplicity – and in order to reduce preparation time - for this large-scale analysis of 
samples, a modified HPLC-DAD assay, with simplified extraction of dried herb, was developed 
and tested.   
 
 
The next section will describe attempts that were made to improve the DAD system. Initially, 
the robustness of the IP method for the analysis of crude extracts was examined. Following 
this, modifications were made in an attempt to improve robustness. 
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2.2 Materials and Methods 
2.2.1 HPLC-DAD: initial parameters 
An Agilent 1100 Series HPLC separation system with diode array detection was utilised for the 
separation and quantification of artemisinin. An isocratic mobile phase of 60% acetonitrile and 
40% water (both HPLC grade, purchased from Fisher) was run at a flow rate of 1ml/minute 
through a Phenomenex RP-C18 octadecylsilane (ODS) column of dimensions 250 mm x 4.6 
mm, and a particle size of 5 µm. The column oven was set to 30°C, and columns were 
protected with the Phenomenex Security Guard cartridge system.  Artemisinin was quantified 
at 214nm.  
 
These initial HPLC-DAD parameters are based on those of the International Pharmacopeia. 
2.2.1.1 Generation of calibration curve 
 
The response factor of artemisinin was calculated, and a calibration curve of artemisinin across 
a range of concentrations (0.078 – 5 mg/ml) was generated. 
2.2.1.2 Extraction of dried Artemisia annua leaf 
 
Dried leaf material was powdered in a pestle and mortar, and mixed with solvent in a 1/10 
ratio. Mixtures were macerated under dark conditions over 24 hours, at 27°C, with gentle 
shaking. 
2.2.1.3 Sample Analysis 
 
The crude extract (10µl) was injected onto the column for artemisinin quantification. Samples 
were bracketed (every 10 samples) with reference samples of artemisinin at 2.5 mg/ml. 
Theoretical plates were counted before and after each batch analysis. 
 
2.3 Results 
2.3.1 Testing of IP method 
2.3.1.1 Retention time of artemisinin 
Using this system, artemisinin had a retention time of 9.8 minutes. 
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2.3.1.2 Response factor of artemisinin by DAD 
The units of UV absorbance produced by a single µg of artemisinin were calculated for the 
HPLC method described above (of course, if the flow rate or solvent composition of a method 
is changed, then the response factor must be re-calculated. It is a function of solute and 
solvent). It was calculated that 1µg of artemisinin gave rise to a mean value of 52 (with a 
standard deviation of 0.6) units of UV absorbance. 
 
2.3.1.3 Calibration curve by DAD 
The DAD response to artemisinin was linear in the range used for the calibration curve (0.078 – 
5 mg/ml), with a R2 value of 0.999 and an equation of y = 557.64x – 3.653 (Figure 18). 
However, asymmetry of peaks was detected at artemisinin levels of 2.5 mg/ml and above 
(Table 3). 
 
 
Figure 18. Calibration curve of artemisinin by HPLC-DAD 
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Table 3. Artemisinin peak symmetry, width and N, by HPLC-DAD at 214 nm, across a range of sample 
concentrations. † Samples were analysed in the order:  least concentrated →most concentrated, over 
a 24 hour period. Therefore the drop in N may reflect column conditions deteriorating slightly 
throughout the sequence, rather than being a function of sample concentration. An asterisk (*) 
indicates peak tailing. 
 
Conc. artemisinin 
(mg/ml) 
Symmetry Peak Width  Plate Count† 
0.078 0.87 0.1633 66315 
0.15 0.86 0.1633 65823 
0.31 0.85 0.1650 64075 
0.625 0.82 0.1650 63991 
1.25 0.77 0.1667 62946 
2.5 0.69* 0.1689 60652 
5.0 0.56* 0.1689 56224 
 
2.3.1.4 Theoretical plates 
One parameter found to be vital in the reliable use of DAD to quantify artemisinin was to keep 
track of the column’s performance, by calculating theoretical plates (N). N is a numerical 
measure of how good a column is at resolving closely eluting peaks (i.e. compounds), as 
calculated by a simple formula: 
 
N = ([retention time of compound/peak width]2) x 16 
 
 Variation in reported artemisinin levels in crude extracts, even across replicated samples, 
dogged much of the initial DAD-based work described in this section.  This variation could be 
traced to deterioration in N: when this value dropped below 30,000, the reported results for 
artemisinin level in a sample could not be relied upon to be accurate. Table 4 illustrates this. 
 Crude extracts of Artemisia annua were assayed for artemisinin content, in triplicate, on three 
occasions over a three-week period. Samples labelled as beginning with F were Frontier 
samples, those beginning with N were NIAB samples, and GBR was a sample of A. annua 
obtained from a local herbalist, and included here for comparative purposes. The table shows 
reported artemisinin content in each sample, on the three occasions of analysis. It also shows 
the column plate count (N) as calculated at the beginning and end of each batch analysis. 
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 Table 4. Variation in reported artemisinin content of 10 samples of Artemisia annua L. leaf, related to 
N 
 
The greatest standard deviation in reported artemisinin content is observed in Week 2 – when 
the plate count was at its lowest. It will be noticed that the reported artemisinin levels in Week 
2 differ (typically being reported as higher) from the levels in Weeks 1 and 3. After Week 2, a 
new guard column was connected to the HPLC column, thus increasing the plate count on 
Week 3.   
 
 If such a DAD-based system were to be used to quantify artemisinin in crude extracts, a report 
of column performance – based on plate count for artemisinin - calculated before and after 
each batch analysis would be advisable. 
2.3.2 Modifications to IP method 
 
2.3.2.1 Modified Parameters 
 
Modifications were made to mobile phase composition, stationary phase, column oven 
temperature, flow rate, and gradient of flow rate were made. HPLC-grade methanol was 
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purchased from Fisher, as was formic acid. Hichrom RP C8 and RP C6 (150 x 4.6 mm, 5 µm) 
columns were a gift from Nicola Wilsher of the DMU Cancer Drug Discovery Group. 
 
2.3.2.2 Further attempts at utilization of DAD 
The temperature of the column oven was varied in steps from 5 °C to 50 °C, but at no point 
was an improvement in artemisinin separation seen. 
 
2.3.2.3 Solvent extraction of dried leaf material 
A consideration of the solvents used by other research groups for the extraction of artemisinin 
found that the most widely used were toluene, n-hexane, n-hexane and acetonitrile, 
chloroform, or petroleum ether. Several  solvents were tested for artemisinin extraction 
efficiency, by simple maceration. A “compromise” solvent was reached, for use in high-
throughput screening: acetonitrile. Over a 24-hour maceration, acetonitrile was not quite as 
efficient as a 1:1 mixture of methanol dichloromethane (DCM), but was as efficient as ethyl 
acetate and more efficient than hexane. It was cleaner than a methanol: DCM mixture and 
much easier to use,, as the marc could simply be HPLC-ed without further ado. This method is 
similar to that of Elferaly et al. (Elferaly et al., 1990), who extract the herb into hexane and 
then partition into acetonitrile to obtain clean artemisinin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 2: HPLC-DAD 
 
86 
 
Table 5. Literature survey of A. annua extraction solvents (Flockhart et al., 2005); (Hao et al., 2002);  
(Hsu, 2006, Kumar et al., 2004, Quispe-Condori et al., 2005, Van Nieuwerburgh et al., 2006, 
Vandenberghe et al., 1995, Bilia et al., 2006) 
 
Author Extraction Clean-Up 
Bilia et al. (2006) Maceration of dried aerial 
parts with hexane or 
dichloromethane for 72 
hours (room temperature). 
Dried under vacuum. Re-
suspended in acetonitrile. 
Sonicated for 20 minutes 
and filtered through PTFE 
(0.45µm). 
Flockhart et al. (2005) 
 
 
Toluene or methanol: 
chloroform (1:1) maceration 
for 24 hours. 
SPE from 100% heptane to 
15% ethyl acetate in 
heptane. Dry under nitrogen 
and re-suspend in 
acetonitrile or mobile phase. 
Hao et al. (2002) Microwave-assisted with pet 
ether (30-60°C, 60-90 °C) 
cyclohexane, hexane, 
trichloromethane, ethanol, 
No. 6 solvent oil, 120 solvent 
oil. 
 
Hsu (2006) Soak entire plant in water, 
then wring out the plant and 
ingest the juice.  
Soak entire plant in urine. 
 
Kumar et al. (2004) Hexane extraction of dried 
powdered material. 
 
Quispe-Condori et al. (2005) Supercritical carbon dioxide 
extraction of leaves. Hexane 
Soxhlet extraction. 
 
Van Nieuwenbergh et al. 
(2006) 
Immersion of fresh leaf in 
chloroform for 1 minute. 
 
Vandenberghe et al. (1995) Toluene extraction of dry 
herb with sonication (x 2). 
Silica gel SPE preconditioned 
with toluene, then washed 
with pet ether: ethanol 
(discarded). Eluted with 
MeCN. Eluate evaporated 
under nitrogen and re-
suspended in 1ml ethanol: 
water (1:1).  
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Hexane was commonly employed by other researchers as an extraction solvent, but a simple 
comparison (Table 6) of hexane with acetonitrile for the extraction of artemisinin from dried 
leaves showed that hexane was the poorer: 
 
Table 6. Comparison of hexane and acetonitrile as A. annua extraction solvents 
Sample Artemisinin % w/w (hexane 
extract) 
Artemisinin % w/w 
(acetonitrile extract) 
NIAB 25 0.4 0.8 
NIAB 30 0.3 0.7 
NIAB 35 0.2 0.5 
NIAB 110 0.2 0.5 
 
Other combinations were tried (hexane: butylmethylether, 50/50; hexane: ethyl acetate, 
85/15; 100% methanol, 100% DCM), but consistently, the cleanest extracts, combined with the 
most efficient artemisinin extraction, were obtained with acetonitrile.  
2.3.2.4 Sample mass 
Sample mass as a factor influencing variability was also considered, as was the variation 
between powdered vs. non-powdered samples. It was found that sample mass used - between 
100 mg and 1400 mg – were unimportant, as long as lower samples sizes were powdered. 
Slight variability was observed when 100 mg samples were not powdered, but this variability 
disappeared upon powdering with a pestle and mortar.  
2.3.2.5 Gradient of mobile phase 
As artemisinin separation by the isocratic IP method was reasonable, as long as other factors 
(namely N) were considered, it was decided to keep the gradient separation quite gentle and 
fairly close to the conditions of the isocratic method, whilst trying to eliminate the 
characteristic problems of isocratic separations: a lot of peaks in the first few minutes, a “dead 
zone” in the middle of the run where little elutes, and a few wide peaks towards the end 
(Figure 20). 
Incidentally, extreme gradients (from 10% water to 90%, for example) were not at all ideal for 
these crude extracts and were eliminated as possibilities early on. 
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After much trial and error, the following method was found to produce the best separation of 
all compounds, when used with a GraceSmart narrow-bore column of 150 x 2.1 mm, 3µm 
particle size: 
 
Time Solvent A % Solvent B% Flow (ml/minute) 
0.00 70 30 0.5 
10.00 0 100 0.75 
15.00 50 50 0.75 
20.00 70 30 0.5 
22.00 70 30 0.5 
 
Where solvent A was comprised of 33% acetonitrile and 66% water, and Solvent B was made 
up of 66 % acetonitrile and 33% water. But this separation still had two drawbacks: 
 
a) although the overall separation was better, artemisinin, being a small peak in a crude 
extract, was still not reliably separated; 
b) baseline drift with increasing acetonitrile was a persistent problem (Figures 21 and 22). 
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Figure 19. HPLC separation of artemisinin reference using the IP method, and read at 214 nm. 
Artemisinin elutes at 9.8 m. 
 
 
Figure 20. HPLC separation of a crude extract of Artemisia annua, using the IP method, and read at 
214 nm. Artemisinin (Peak 1) elutes at 9.9m, and chrysosplenetin (Peak 2) at 5.6 m 
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Figure 21. HPLC separation of artemisinin using the newly developed gradient narrow-column 
separation method, read at 214 nm. Artemisinin elutes at 3.2 min. An impurity is visible at 4.5 min. 
 
 
Figure 22. HPLC separation of a crude extract of Artemisia annua using the newly developed gradient 
narrow-column separation method, read at 214 nm. Artemisinin (Peak 1) elutes at 3.2 min. 
Chrysosplenetin elutes at 4.2 min. 
 
Baseline drift, when the chromatogram was viewed at this low UV region, rendered the 
gradient method unsuitable for the analysis of artemisinin. However, it was noted that the 
flavonoid constituents – identified by reference chrysosplenetin, and by UV-profile of unknown 
flavonoid-type compounds, separated well by this new method. The method was, therefore, 
taken as a starting point for a flavonoid separation system, discussed more fully in Section 8. 
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2.4 Discussion 
The use of HPLC-DAD for the quantification of artemisinin is by no means ideal: artemisinin has 
no strong chromophore. Where it does absorb UV - at 214 nm - the absorbance is 
uncomfortably close to the absorbance of acetonitrile (and indeed all other reverse-phase 
HPLC solvents), a major component of reverse-phase HPLC mobile phases. It is this low 
absorbance that has so far prevented the improvement of peak resolution and shortening of 
the analytical time via a solvent gradient - as acetonitrile levels increase throughout a gradient 
run, the baseline drifts so far to high absorption as to render the quantification of artemisinin 
unreliable. Subtracting a blank run improved the chromatogram, but not to the extent desired. 
Despite the efforts made, it was concluded that HPLC-DAD would, no matter how well 
optimized, never be a suitable means by which to quantify artemisinin in crude extracts of 
Artemisia annua L – a conclusion similarly reached by the Malaria Medicines Venture (MMV), 
who in a recent report state that after experimentation, they cannot recommend the use of 
HPLC-UV for the quantification of artemisinin in extracts, but only for determination of the 
purity of isolated artemisinin (Lapkin et al., 2009).  
 
As artemisinin is easily detected by ESI (electrospray ionization) mass spectroscopy (MS), and a 
machine of this type had been made available in the department, it was decided that future 
attempts at the high-throughput quantification of artemisinin would be based on LCMS.   
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3 HPLC-MS (ESI) separation and quantification of 
artemisinin 
Synopsis 
HPLC-MS, using an Agilent 1100 system with electrospray ionisation, was used to develop a 
high-throughput analytical method for the quantification of artemisinin in dried Artemisia 
annua leaf. The method was externally validated, and was capable of accurately assaying more 
than 100 samples per day.  
 
3.1 Introduction 
Having established that reliable quantification of artemisinin in crude extracts of Artemisia 
annua was not feasible using HPLC-DAD, attention was turned to the use of HPLC-mass 
spectrometry (HPLC-MS). This had been used by several groups as a means of quantifying 
artemisinin metabolites in human plasma (Naik et al., 2005), in particular artesunate and 
dihydroartemisinin, and occasionally for the quantification of artemisinin in crude plant 
extracts, but at the time that this project began (2006), no validated methods had been 
published for high-throughput MS-based assay of crude extracts. 
 
At the time of writing, though (March 2010), several recent papers are available detailing such 
methods, including those by Han et al. (Han et al., 2008) and Lapkin et al. (Lapkin et al., 2009).   
 
As for HPLC-DAD, the International Pharmacopeia method was taken as a starting point, and 
modifications were made from that point.  
 
A further advantage of HPLC-MS is was expected to be that the method can, unlike HPLC-DAD, 
discriminate between artemisinin and the pharmaceutically inactive (but co-eluting) 
deoxyartemisinin.  
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3.2 Materials and Methods 
3.2.1 Extraction and analytical procedure - LCMS 
Extraction. Dried Artemisia annua leaf material was powdered using a pestle and mortar, and 
macerated in acetonitrile for 24 hours under dark conditions, with gentle shaking, at a 1/10 
weight-to-volume ratio.  
 
Sample Preparation. Analytical samples were prepared by the dilution of 25 µl of original 
extract in 875 µl of acetonitrile, with addition of 100 µl of santonin stock solution at 0.1 mg/ml 
– i.e., 10 µg/ml as a final concentration.  
 
3.2.2 HPLC-MS parameters 
Artemisinin was quantified using an Agilent Technologies 1100 Series high-performance liquid 
chromatography system, with a GraceSmart RP18-HPLC column (150 mm x 2.1 mm; pore size 
of 3 mm), coupled to an Agilent Technologies G1946 single quadruple mass spectrometer with 
electrospray ionization (ESI), used in positive ion mode, with single ion monitoring (SIM). HPLC 
separation was achieved with an isocratic mobile phase of 60% acetonitrile and 40% HPLC-
grade water, with 0.1% v/v formic acid, at a flow rate of 0.2 cm3, with a run time of 8 minutes. 
The column oven was set at 25°C. 
 
Following flow injection analyses (FIA), the ESI spray chamber and mass spectrometer 
parameters were set as follows: nitrogen flow at 8 L3/minute; drying gas temperature 350°C; 
capillary voltage 2800 V in positive mode, 3500 V in negative mode; nebulizer pressure 40 psig; 
and a fragmentor voltage of 70 V. The mass spectrometer was calibrated and, if necessary, 
tuned daily, using  Agilent’s Electrospray Tuning Mix, to ensure peak performance. Generation 
of calibration curve. Santonin was used as an internal  standard, with ions monitored at 173.3 
and 247.3. The monitored artemisinin ions were 283.3 and 209.3. 
 
3.2.3 Generation of calibration curve 
A calibration curve was generated, in which artemisinin concentration ranged from 2 to 16 µg/ 
ml, and in which santonin, as an internal standard, was kept constant at 10 µg/ml. All 
calibration levels were prepared in triplicate and analysed three times per sample. The ratio of 
artemisinin to santonin was calculated for each analysis; linear regression of the resulting 
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scatter plot was used to establish the calibration curve. The upper limit of quantification was 
given as the highest level of the calibration curve: beyond this, saturation of response 
rendered quantification less reliable. The lower detection limit was taken as five times the 
standard deviation of the measured response to the lowest calibration level, and was 
calculated to be 0.8 ng. 
 
3.3 Results 
3.3.1 Choice of ions for SIM-based quantification 
Following assay of artemisinin and santonin references under single ion monitoring (SIM) 
mode, quantifier and qualifier ions of 265.2 and 283.2, respectively, were selected for the 
single ion monitoring (SIM) of artemisinin. For santonin, quantifier and qualifier ions were 
247.3 and 174.3, respectively. 
 
3.3.2 New column and reduction in mobile phase 
The IP HPLC-DAD method utilised a column of dimensions 250 mm x 4.6 mm (particle size: 5 
µm), with a flow rate of 1ml/minute. This resulted in a column pressure of ¬80 bar. As this flow 
rate would have been a little high for electrospray ionisation, a column of smaller dimensions 
was chosen. The mobile phase composition – 60% acetonitrile, 40% water, with 0.1% v/v 
formic acid – was kept the same, but using a GraceSmart RP18 narrow-bore column, of length 
150 mm and internal diameter of 2.1 mm (particle size: 3µm), allowed reduction of flow rate 
to 0.2 ml/minute whilst retaining a column pressure of 80 bar. 
 
On this new system, run times were shortened from 25 minutes to 10 minutes, with 
artemisinin eluting at 4.8 minutes. 
 
3.3.3 Generation of calibration curve 
The calibration curve (Figure 23) was linear in the artemisinin range 2.5 – 20 µg/ml, with a 
slope of y = 0.057x + 0.024, and a linear regression of 0.993.  
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Figure 23. LCMS calibration curve of artemisinin, using santonin as internal standard 
 
The vertical axis shows the ratio of artemisinin to santonin in each reference sample 
(calculated as the peak area for artemisinin divided by the peak area for santonin). The 
horizontal axis shows the artemisinin concentration, in µg/ml, of each reference sample. 
 
3.3.4 Precision and accuracy 
It was noted that, when using ESI without formic acid in the mobile phase, that the line of least 
squares did not quite intercept at zero. This phenomenon was observed each time the 
calibration curve was prepared. Naturally, this meant that at artemisinin levels below a certain 
threshold, quantification became unreliable – in fact, error became larger, the smaller the 
artemisinin concentration.  Table 7 illustrates this. 
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Table 7. Actual vs. reported artemisinin content of samples assayed by LCMS 
Artemisinin 
Response/Santonin 
Response 
Reported 
artemisinin content 
of sample (µg/ml) 
Actual 
artemisinin 
content of 
sample (µg/ml) 
Actual artemisinin content of 
sample,  as a percentage of 
the  reported value 
0.2 2.8 1.77 63.9 
0.3 4.7 3.69 78.7 
0.4 6.6 5.6 84.8 
0.5 8.5 7.5 88.2 
0.6 10.4 9.41 90.4 
0.7 12.3 11.53 92.0 
0.8 14.2 13.23 93.0 
0.9 16.1 15.14 93.8 
1 18.0 17.05 94.5 
 
 
When the artemisinin content of the sample reaches 18 µg/ml, actual artemisinin content is 
almost 95% of the reported value – an acceptable level of error. But at the lowest artemisinin 
levels (0.3 µg/ml, and lower), the actual artemisinin content if the sample is significantly lower 
than the reported value. For this reason, it is recommended that if the reported artemisinin 
value falls in the range below 0.4 µg/ml, the sample should be re-analysed at a lower dilution 
factor, to bring it within the reliable limits of quantification. This problem was not observed 
following addition of formic acid to the mobile phase. 
 
3.3.5 Precision 
Samples of crude Artemisia annua were prepared in triplicate, and analysed by the new 
method. Each preparation was injected three times onto the column. Table 8 illustrates the 
results. 
 
Table 8. Repeatability of sample injections 
Sample Injection 1 Injection 2 Injection 3 Mean SD 
1186 A 1.8 1.8 1.8 1.8 0.03 
1186 B 1.7 1.7 1.8 1.7 0.07 
1186 C 1.7 1.9 1.9 1.8 0.09       
1243 A 2.0 1.9 2.1 2.0 0.1 
1243 B 1.9 1.9 1.9 1.9 0.03 
1243 C 2.1 2.0 2.0 2.0 0.09 
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3.3.6 External validation of LCMS technique 
Several samples of dried leaf material, which had previously been assayed for artemisinin 
content using the newly developed LCMS technique, were sent to Sensapharm Ltd, a UK 
company focused on the development, supply and support of malaria associated drug 
reference standards and drug detection systems. Samples were randomised and sent to 
Sensapharm with no information as to the expected artemisinin content. 
 
The artemisinin levels reported by Sensapharm are shown in Table 9, and compared with the 
levels reported at DMU. 
 
Table 9. Comparison of DMU and Sensapharm results for identical samples 
 
Sample Artemisinin % 
w/w (DMU 
Analysis) 
Artemisinin % w/w 
(Sensapharm 
Analysis) 
African 1 0.41 0.45 
African 2 0.50 0.39 
African 3 0.43 0.34 
African A 0.53 0.69 
African B 0.50 0.59 
African C 0.52 0.53 
876 1.20 1.21 
869 1.10 1.12 
A. annua 
shoot culture 
Trace 0.03 
981 2.27 2.04 
984 2.55 2.28 
991 2.46 2.39 
1013 2.46 2.52 
1029 2.55 2.43 
1053 2.41 2.31 
1091 2.36 2.40 
1097 2.55 2.47 
1102 2.46 2.22 
Mean 1.60 1.55 
P value 0.097 
 
Using a paired t-test, no significant difference between the two sets of data was observed. 
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3.4 Discussion 
Using high-pressure liquid chromatography coupled to an electrospray ionisation mass 
spectrometer, a high-throughput means of artemisinin quantification in plant material was 
developed. The use of a narrow-bore column greatly reduced solvent usage and the cots that 
are inherent with such usage. In addition, the method was the rapid, requiring less than 10  
minutes per run, and selective, in that deoxyartemisinin - which co-elutes with artemisinin and 
can, by UV, lead to overestimation of artemisinin content – can be screened out with the use 
of selective ion monitoring.  
 
Unlike HPLC-DAD, it was noticed that at lower sample concentrations, percentage error 
became unacceptably large – a phenomenon caused by the fact that the line of least squares 
did not intercept the y axis at zero. The addition of formic acid to the mobile phase improved 
accuracy of sample reporting in this respect.  
 
Using this method, over 100 samples could be assayed per day assuming the machine was in 
use for 20 hours per day. It is feasible that the use of smaller columns could further reduce 
sample run time, and thus increase sample throughput.
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4 PCA and PLS-DA analysis of artemisia annua L. leaf 
samples 
Synopsis 
 
NMR-based Principal Components Analysis (PCA) and Partial Least Squares-Discriminant 
Analysis (PLS-DA) was investigated for potential use in the quality control of dried Artemisia 
annua L. leaf samples.  
 
Using raw NMR, poor samples (i.e. those containing no artemisinin, or very little) could 
immediately be discerned from those containing high levels of artemisinin. However, the 
discernment of fine grades of artemisinin content was not possible by simply observing raw 
NMR spectra.  
 
 PCA was able to cluster samples by age and post-harvest treatment, but not by artemisinin 
content. PLS-DA was able to classify most samples into expected groupings based on sample 
pre-treatment and harvest dates, but validation of this method is needed.  
 
4.1 Introduction 
Multivariate analysis was performed on 46 samples of Artemisia annua grown within the 
consortium. This was done using principal components analysis (PCA) and partial least squares 
discriminant analysis (PLS-DA), based on data obtained by nuclear magnetic resonance (NMR) 
of crude herbal extracts. The objective behind this analysis was to ascertain whether NMR-
based multivariate analysis could allow the rapid identification of high-artemisinin material at 
all stages of the harvest season, with a minimum of sample preparation. This process could 
also, in theory, identify the genetic and geographical origins and growth conditions of an 
unknown sample.   
 
4.1.1 Principal components analysis (PCA) 
PCA is a statistical technique used when a large amount of data is to be handled – in this case, 
every signal generated in more than 50 proton NMR spectra. The PCA process correlates 
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variables (i.e. NMR signals) in a similar way to a simple x vs. y scatterplot. However, because of 
the very large number of variables (NMR signals) generated by this method, a 2-D scatterplot, 
which can only correlate 2 variables, is insufficient. So, using a mathematical concept called 
hyperspace, in which data can be plotted in more than three spatial dimensions, a 
multidimensional scatterplot is generated. Statistical software will then identify a regression 
line – in the same way as in a 2-D scatterplot – that displays the variation between the samples 
along this line.  The line that lies across the greatest degree of variation in the scatterplot is 
designated as the first principal component, or PC1 – sometimes also called a factor (Alt, 
1990). 
 
After the first PC has been created, carrying information as to most of the sample variation, 
the software will then identify further regression lines that travel through the remaining 
variation. The generation of these PCs is done via the rotation of graphical axes.  PC2 will 
always be orthogonal to PC1, to ensure that the greatest degree of variation is covered by the 
PCs.  
 
Typically, 3 or 4 PCs are sufficient to explain all of the variation within the sample data, with 
PC1 explaining most of the variation, and PCs 2, 3 and 4, progressively less2 (Jansen et al., 
2010).  
 
PCs may be considered as combined variables – they show how individual signals from the 
molecules in the samples vary in combination with all the other signals3. Principal components 
express in simplified form the relationship between all of the variables in a sample – i.e., the 
whole metabolome. 
 
 
2 Geometrically, PCA involves the rotation of graphical axes on a multi-dimensional graph. Axis 
one – or PC 1 – is the axis along the length of which most variation in samples can be observed. 
PC2 is the axis along which the second greatest degree of variation can be observed, and so 
on. 
 
3 Each variable (i.e. NMR signal, representing part of a molecule in the extract) will correlate to 
each principal component either negatively, positively, or not at all.   
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The principal components (that is, combined variables) may, in the case of plant extracts, 
relate to terpenoids, or sugars, or lipids, to name a few examples. The advantage of generating 
principal components is that the multidimensional scatterplots that are initially needed to 
display all the variables generated by NMR – and which are imposible to visualise – can be 
greatly simplified, by combining all the variables into a much smaller number of PCs . This 
means that the more familiar 2-D scatterplots can be used - PC1 will be displayed on the x-axis, 
and PC2 or PC3 on the y-axis. In this way, it is possible  
 
a) to determine whether the PCs are linked  
b) to cluster related samples 
 
Each sample analysed by NMR will correlate to the principal components differently, because 
each sample varies to a greater or lesser degree in levels of artemisinin, or chrysosplenetin, or 
sucrose, for example. So, by looking at how two or more different samples relate to the same 
principal components, similar and differing samples can be easily clustered together.  
 
4.1.1.1 Scores plots and loadings plots 
 
PCA typically generates scores plots and loadings plots. A scores plot shows the co-ordinates of 
each sample on the axis system of the PCs, and looks like any scatter plot, in that related 
samples will cluster together. A loadings plot gives information as to which original variables – 
in NMR, which ppm values – are responsible for the differences between samples (Jansen et 
al., 2010). 
 
PCA is an unsupervised technique – the samples are analysed “blind”, and the statistical 
software is given no information as to the nature or expected clustering of the samples. On a 
scores plot, observed clusters merely show that samples are related in some way – no 
information on the nature of the relationships between the samples, or the chemical content 
of the samples, is obtained. Loadings plots, however, do give some chemical information, and 
can help to identify chemical similarity between clustered samples (Schripsema, 2010). 
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4.1.2 Partial least squares discriminant analysis (PLS-DA) 
PLS-DA is a supervised technique that has similarities to PCA – the major similarly being that 
PLS-DA also involves rotating axes to give the greatest spread along an axis. But the two 
techniques differ in a major way, and the clue to the difference is in the designation 
“supervised”.  
 
Whereas in PCA, the axes are rotated so that the greatest sample spread is observed, and the 
software is not given any information as to the expected results, in PLS-DA, the axes are 
rotated to give the optimal discrimination between sample groups (Colquhoun, 2007). The 
algorithm will be told which samples belong to which group, and will be validated according to 
how well it clusters samples in this group. Another way of saying this is that PCA clusters 
samples by dependent variables (those variables that depend on what treatment they received 
– for example, glyphosate-treated plants should contain more artemisinin than those that 
were not treated. Artemisinin level is a dependent variable). On the other hand, PLS-DA 
attempts to cluster samples by independent variables – those variables, such as harvesting 
early or late, that are created by the experimenter and are not a result of the experiment itself 
(Colquhoun, 2007).   
 
PLS-DA, rather than placing PCs on the axes, creates latent variables (LVs) which are for most 
purposes similar to PCs (Ciosek et al., 2005).  
 
4.1.3 This study 
It was hypothesised that using PCA, samples of Artemisia annua L. with a high concentration of 
artemisinin would cluster; as would samples containing low levels of artemisinin. It was further 
hypothesised that, ultimately, NMR-based principal components analysis – in particular, PLS-
DA - would allow the quality assessment of “blind” samples of Artemisia annua L  
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4.2 Materials and Methods 
4.2.1 Sample preparation 
 
Dried, powdered leaf (100 mg) was macerated in 1 ml 70% deuterated methanol for one hour. 
Samples were then centrifuged at 1200 rpm for 5 minutes, and the supernatant thus obtained 
was used for NMR analysis. 
4.2.2 NMR analysis 
 
Samples were analysed by as per Belton et al., 1998. 500 MHz 1H NMR spectra were recorded 
at 27°C using a Bruker DRX-500 spectrometer. For quantification, the 1.44 ppm signal 
(corresponding to H-15 of the methyl group) was used. 
4.2.3 Principal components analysis 
 
PCA was carried out as per Belton et al., 1998, in that preliminary data processing was carried 
out using FELIX software, version 2.30 (Molecular Simulations),  on a Silicon Graphics Indigo 
workstation. Bucketing into bins of 0.04 ppm was carried out using Bruker Biospin’s AMIX 
software, and the spectra that resulted were transferred to a PC for data analysis (Colquhoun, 
2007). 
 
4.3 Results and Discussion 
 
Table 10 shows the samples that were assayed for this part of the research:  
 
Table 10. Samples assayed by multivariate analysis. Samples identified only by numbers indicate NIAB 
(Cambridge-grown) material. All samples, except 49-50, were of Artemisia annua L. GLY: indicates 
samples were sprayed with Glyphosate before harvest 
 
Sample No. Details 
(Sample ID) 
Artemisinin (% 
w/w) 
Cross Harvest 
Date  
Treatment 
1 1 0.8 1015 31/07/2008 
 
2 846 1 1015 22/09/2008 
 
3 876 1.2 1015 22/09/2008 GLY 
4 8 0.7 1001-1 31/07/2008 
 
5 853 Unknown 1001-1 22/09/2008 
 
6 878 1.1 1001-1 22/09/2008 GLY 
7 20 0.7 1001-3 31/07/2008 
 
8 865 0.9 1001-3 22/09/2008 
 
9 879 1 1001-3 22/09/2008 GLY 
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10 6 0.6 1012-10 31/07/2008 
 
11 851 0.7 1012-10 22/09/2008 
 
12 875 0.8 1012-10 22/09/2008 GLY 
13 3 1 1038-1 31/07/2008 
 
14 848 0.9 1038-1 22/09/2008 
 
15 874 1.3 1038-1 22/09/2008 GLY 
16 18 0.8 1045-3 31/07/2008 
 
17 863 0.9 1045-3 22/09/2008 
 
18 886 1.2 1045-3 22/09/2008 GLY 
19 15 1 1046-7 31/07/2008 
 
20 860 1.1 1046-7 22/09/2008 
 
21 873 1.3 1046-7 22/09/2008 GLY 
22 7 1.2 1062-1 31/07/2008 
 
23 852 1.4 1062-1 22/09/2008 
 
24 871 1.7 1062-1 22/09/2008 GLY 
25 12 1 1062-4 31/07/2008 
 
26 857 1.2 1062-4 22/09/2008 
 
27 872 1.5 1062-4 22/09/2008 GLY 
28 14 1.4 1053-1 31/07/2008 
 
29 859 0.8 1053-1 22/09/2008 
 
30 881 1.3 1053-1 22/09/2008 GLY 
31 21 0.9 1053-2 31/07/2008 
 
32 866 0.9 1053-2 22/09/2008 
 
33 883 1.3 1053-2 22/09/2008 GLY 
34 9 0.8 1053-4 31/09/2008 
 
35 854 1.2 1053-4 22/09/2008 
 
36 869 1.1 1053-4 22/09/2008 GLY 
37 989 (2007) 1.1 1015 27/09/2007 
 
38 1159 (2007) 1.1 1015 05/10/2007 
 
39 145 (2007) 0.6 1043-1 01/08/2007 
 
40 557(2007) 0.7 1043-1 30/08/2007 
 
41 AA15593 
 
Brown 
herb 
060207-01 
 
42 AA 16195 
 
Green 
herb 
 060207-3 
 
43 Moroccan  0.5 
 
 160708-01 
 
44 Moroccan  0.5 
 
 160809-02 
 
45 Spent herb a None 
 
 060606-01 
 
46 Spent herb b None 
 
 060424-01 
 
47 Shoot Not known 
 
Shoot 
culture 
 
48 Shoot Not known 
 
Shoot 
culture 
 
49 T. lucida N/A 
   
50 A. absinthium N/A 
   
51 Artemisinin 
2mg 
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Figure 24. NMR spectra of extracts of 2 A. annua samples of differing artemisinin content, against artemisinin reference of 1mg/ml. Note signal at 1.44 ppm 
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Figure 25. NMR spectra of two samples of spent herb compared to two samples containing artemisinin 
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Figure 26. Scores plot 1. Scores plot of samples on PC1 and PC2 
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Figure 27. Scores plot 2. Scores plot of samples on PC1 and PC3 
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Figure 28. Partial least squares-discriminant analysis scores plot of samples on latent variable (LV) 1 and LV2 
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This was a short experiment, designed to test whether, in principle, NMR-based multivariate 
analysis would be of use in the quality control of Artemisia annua field samples.  
 
Initially, it was observed that simply comparing the relative heights of the artemisinin signals in 
the raw NMR spectra, with no data manipulation, could clearly distinguish material of different 
quality. Figure 24 shows raw NMR data for pure artemisinin, and then three samples of 
differing artemisinin content, ranging from 0.8% w/w to 1.2% w/w. Differences in the height of 
the 1.4 ppm signal, which arises from the H-15 methyl group, are apparent, and the height 
correlates positively to increasing artemisinin level. Raw NMR data could also immediately 
spot a poor sample, as Figure 25, showing spent herb (that which has been treated to remove 
artemisinin) shows. It is clear that in the upper two spectra of this image – representing spent 
herb – the artemisinin signal at 1.4 ppm is absent. However, it is unclear that this method 
would be able to discriminate fine grades of artemisinin content – whether a sample 
containing artemisinin at 1.4 % w/w could be distinguished from another sample at 1.6 % w/w, 
for example. 
 
In addition, if using raw NMR spectra to quantify artemisinin in sample, it is important to 
ensure that the signal chosen for quantification are indeed exclusive to artemisinin, and not 
shared by artemisinin and deoxyartemisinin.  Castilho et al., (Castilho et al., 2008) for example, 
used the 1.44 and 5.86 ppm signals to quantify artemisinin– signals which arise from the H-15 
methyl and H-5 proton respectively, and, as Section 7.3 discusses, do differ slightly from the 
deoxyartemisinin signals. 
 
4.3.1 Principal components analysis (PCA) 
Initially, samples were assayed using principal components analysis (PCA), an unsupervised 
clustering technique in which multiple variables are combined into a smaller number of 
principal components – in this case, three. 
 
 PCA involves the rotation of graphical axes on a multi-dimensional graph. Axis one – or PC 1 – 
is the axis along the length of which most variation in samples can be observed. PC2 is the axis 
along which the second greatest degree of variation can be observed, and so on. 
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PCA typically generates scores plots and loadings plots. A scores plot shows the co-ordinates of 
each sample on the axis system of the PCs, and looks like any scatter plot, in that related 
samples will cluster together. A loadings plot gives information as to which original variables – 
in NMR, which ppm values – are responsible for the differences between samples. 
 
In this short experiment, only scores plots were generated. But clustering of samples can be 
observed. If Scores Plot 1 (Figure 26) is considered, one thing becomes immediately apparent:   
that a positive correlation exists between PC1 and PC2. Samples with a relatively high figure 
for PC1 also have a fairly high figure for PC2. However, this tells us nothing about the quality of 
the samples in terms of artemisinin content: although most of the samples fall into an oblong 
cluster (from the lower left to the upper right of the plot, the samples within that cluster 
appear randomly distributed in artemisinin content. Clearly, something else is being correlated 
here – perhaps related to the age of the material, as the upper right quadrant contains mainly 
early-harvested material.  
 
Scores plot 2 (Figure 27) is more interesting. PC1 is still on the x-axis, but the y-axis is now PC3. 
This time, an inverse correlation is observed: as a sample’s correlation to  PC1 decreases, its 
PC3 value increases.  
 
On first glance, it appeared that PC3 had pulled out high-artemisinin material: most of the 
samples in the upper left quadrant are high (>1.3 % w/w) in artemisinin, and most in the lower 
right quadrant are relatively low (<0.9 % w/w) – in fact, these lower-right quadrant samples 
are mostly early-harvested material. 
 
 But upon closer inspection, it was noticed that, in fact, almost all the samples in the upper left 
quadrant are actually those samples that were Glyphosate-treated. In addition, the lower left 
and right quadrants – apparently containing samples of lower artemisinin yield – do contain a 
number of high-yielding samples, but those samples were not Glyphosate-treated. So it seems 
that PC3 relates, somehow, to this post-harvest treatment, rather than directly to artemisinin 
content.  
 
So a foolproof way of using PCA to pull out high-yielders has not been achieved in this limited 
study – perhaps because the extraction solvent used (70% deuterated methanol) is not ideal 
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for the extraction of artemisinin, and is likely to extract more polar compounds such as 
glycosides.  But what both scores plots do show is that the wild cards were easily identified: 
samples 46 and 50 on both plots were “spent herb” – wherein the plant material had been 
pre-treated to remove the artemisinin – and a sample of A. absinthium, respectively. Both 
these samples lie far outside the clusters, using all three PCs. But is should also be noted that a 
sample of Tagetes lucida, a Mexican marigold with some chemical similarity to A. annua, and 
indicated on the plots as sample 49, did not fall outside the general cluster, whereas two 
samples of A. annua shoot cultures – samples 47 and 48 – did. If loading plots had been 
generated, the reasons for these anomalies may have become apparent. In a metabolomic 
study of the quality of Artemisia annua plant extracts, Van der Kooy et al. (2008) found, using a 
loadings plot, that the signals 0.99, 1.21 and 1.44 (representing the three methyl-hydrogens of 
artemisinin: see Section 5.1.2.3) provided most of the effect of PC1 in their analysis (van der 
Kooy et al., 2008), but, because of the lack of affinity of artemisinin for the extraction solvent 
used, this is unlikely to be the case in this study. 
 
4.3.2 Partial least squares discriminant analysis (PLS-DA) 
On the PLS-DA plot (Figure 28), an example of supervised clustering can be seen. The software 
was told of three major groupings (early harvest, late harvests, and late glyphosate-treated 
harvests). Additionally, a number of samples were left “unmodelled” – that is, the software 
was not told to which groups these samples belonged. This latter is to act as a means of 
validation – as PLS-DA does have a tendency to result in false-positive groupings if unvalidated. 
 
The x-axis shows LV1, and the y-axis, LV2. The three sample groupings – early harvests, late 
harvests and late glyphosate-treated harvests – are distinctly clustered. But the unmodelled 
samples do not appear to have strong relationships to the clusters into which they have been 
arranged. Samples 38, 39 and 40 have all fallen into the “early-harvest” group, even though 
these were all harvested late in the season. It should be noted, though, that these latter three 
were samples from season 2007, not 2008, unlike the other modelled samples in the cluster. 
Additionally, samples 45 and 46 were duplicate samples, containing almost no artemisinin, and 
yet despite being duplicates, are separated by this algorithm.  
 
However, it is notable that samples that are clearly not clustered – 47, 48, 49 and 50 – were 
very different from all other samples in nature. Samples 47 and 48 represent shoot cultures of 
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Artemisia annua, which contained very little artemisinin. Samples 49 and 50 were samples of 
Tagetes lucida and Artemisia absinthium respectively.  
 
So, although some discrimination was possible using PLS-DA, it is clear than more validation is 
needed before this technique could be used to confidently assay Artemisia annua field 
samples.  
 
4.3.3 Summary of multivariate analysis 
 
Multivariate analysis looks at the full range of components in a given sample, and compares 
this to the full range of components in any number of other samples. There are reasons why 
this would be useful, and they are mainly to do with quality control and sample identification. 
Samples of Artemisia annua with similar biological properties – all harvested in Cambridge in 
July 2008, for example, or all high in artemisinin – should have a fairly similar metabolic profile, 
and therefore outliers will be immediately apparent.  
 
But, importantly, it was found that this technique is not faster than LCMS-based quantisation.  
In fact, each sample needed 10 minutes per NMR scan, which is the same length of  time that 
the LCMS needs per sample -  and NMR is much less sensitive than LCMS, so more compound 
is required to give a signal. This, coupled with the complex interpretation, means that NMR-
based multivariate analysis is unlikely to offer any great advantage for the simple 
quantification of artemisinin.  
 
Where the method does come into its own, though, is in the classification of samples, and the 
identification of compounds that correlate either positively or negatively to artemisinin – 
information that may be useful for biosynthetic studies. The technique has also found 
application in the prediction of anti-plasmodial activity of Artemisia annua extracts, as a 2004 
paper by Bailey et al. demonstrated. In Bailey’s study, samples extracted in 1,1,1,2-
tetrafluoroethane could be clustered, using PCA, according to their IC50 values for P. falciparum 
strain 3D7 (Bailey et al., 2004). Such studies demonstrate that NMR-based multivariate 
analysis is an area with great potential in the quality assessment of herbal material, although 
as it stands the technique is not yet suited to the purposes of this project.  
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5 Separation of Artemisinin and Deoxyartemisinin by 
TLC 
Synopsis 
 
Deoxyartemisinin is a pharmaceutically inactive artemisinin degradation product. The 
compound occurs naturally in the plant, and can also be formed during storage of the leaf and 
extraction of Artemisia annua L. Deoxyartemisinin typically co-elutes with artemisinin in 
chromatographic systems, and, in TLC, can result in overestimation of artemisinin content. To 
date, no means of separating the two compounds by TLC have been reported. 
 
This section reports on a new TLC system which can separate the two compounds, thus 
increasing the accuracy of TLC-based artemisinin quantification.   
 
5.1 Introduction 
 
Although the artemisinin molecule is a fairly complex structure, its anti-plasmodial activity 
resides within a single moiety: the endoperoxide bridge. A change to this bridge – as occurs in 
the closely related compound deoxyartemisinin – renders the molecule useless for the 
treatment of malaria. 
 
 
Figure 29. Artemisinin 
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Figure 30. Deoxyartemisinin 
 
Deoxyartemisinin is missing one of the oxygens from the endoperoxide bridge, resulting in an 
ether moiety (and a reduced melting range, from 152 – 156 °C for artemisinin to 110 °C for the 
deoxyartemisinin). Incidentally, deoxyartemisinin is not to be confused with the semi-synthetic 
deoxoartemisinin (McChesney, 1990) – the names may be similar, but deoxoartemisinin has 
lost the oxygen from the lower ring, not the endoperoxide, and so retains its anti-plasmodial 
action4. The generation of deoxyartemisinin within the leaf is controversial. It is known that 
incubation of artemisinin with microbial cultures can result in the metabolism of artemisinin to 
deoxyartemisinin (Lee et al., 1989). So it could be that the deoxy-form occurs as a result of 
microbial colonisation of the plant in the field. It may also be triggered by the presence of iron 
within the plant - incubation of artemisinin with ferrous iron ions has been demonstrated to 
result in a degradation to deoxyartemisinin (Creek et al., 2005).  
 
 Investigations of UK-grown A. annua by the author have shown that deoxyartemisinin is 
present in dried plant material at levels averaging 5% of the artemisinin level. African grown 
material, again investigated by the author, typically shows levels of about 8% of the 
artemisinin level – even when the material is of the same genetic stock as UK-grown material. 
It has been hypothesised that the iron-rich soils of Africa are the cause of this relative increase 
in deoxyartemisinin. 
 
 
 
4 Similarly, deoxoartemisinin is not to be confused with 3-hydroxydeoxoartemisinin. The latter has lost 
an oxygen from the endoperoxide bridge, and hence has no anti-plasmodial activity – see Section 
10.5.1.2.1 
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But whatever the cause, its presence is a problem. In many chromatographic systems, 
deoxyartemisinin co-elutes with artemisinin, as reported by Christen and Veuthey (Christen 
and Veuthey, 2001): “deoxyartemisinin and [artemisinin] are not separated at all and therefore 
[artemisinin] is systematically overestimated” in HPLC-DAD and TLC. This does, inevitably, 
result in an over-estimation of artemisinin content of the sample in question.  
 
Although the use of single ion monitoring (SIM) in LCMS does get around this problem, this is 
of little help to the many laboratories and field scientists who have no access to such an 
expensive piece of kit. Ideally, a simple and inexpensive means of separating the two 
compounds is needed. The obvious solution is thin layer chromatography. 
 
5.2 Materials and Methods 
5.2.1 LCMS for quantification of artemisinin and deoxyartemisinin 
5.2.1.1 Reference standards 
Reference artemisinin was provided by AECS, and found to have a melting range of 154 – 156 
°C, and a purity of > 98%. Identity of artemisinin was confirmed by electrospray 
mass spectrometry and 1H nuclear magnetic resonance on a Bruker 400-mHz Ultrashield 
machine. 
 
5.2.1.2 HPLC-MS Conditions  
Artemisinin was identified using an Agilent Technologies 1100 Series high-performance liquid 
chromatography system, with a GraceSmart RP18-HPLC column (150 mm x 2.1 mm; 
pore size of 3 mm), coupled to an Agilent Technologies G1946 single quadruple mass 
spectrometer with electrospray ionization (EI), used in positive ion mode, with single ion 
monitoring (SIM). HPLC separation was achieved with an isocratic mobile phase of 60% 
acetonitrile and 40% HPLC-grade water at a flow rate of 0.2ml/minute, with a run time of 8 
minutes. The column oven was set at 25°C. 
 
The EI spray chamber and mass spectrometer parameters were as follows: nitrogen flow at 8 
L3/minute; drying gas temperature 350°C; capillary voltage 2800 V in positive mode, 3500 V in 
negative mode; nebulizer pressure 40 psig; and a fragmentor voltage of 70 V. The mass 
Section 5: Separation of Artemisinin and Deoxyartemisinin by TLC 
 
118 
 
spectrometer was calibrated and, if necessary, tuned daily, using Agilent’s Electrospray Tuning 
Mix, to ensure peak performance.  
 
5.2.1.2.1 Generation of artemisinin calibration curve 
Santonin was used as an internal standard, with ions monitored at 173.3 and 247.3. The 
monitored artemisinin ions were 283.3 and 209.3. 
 
A calibration curve was generated, in which artemisinin concentration ranged from 2 to 16 
µg/ml, and in which santonin, as an internal standard, was kept constant at 10 µg/ml. All 
calibration levels were prepared in triplicate and analysed three times per sample. The ratio of 
artemisinin to santonin was calculated for each analysis; linear regression of the resulting 
scatter plot was used to establish the calibration curve. The upper limit of quantification was 
given as the highest level of the calibration curve: beyond this, saturation 
of response rendered quantification less reliable. The lower detection limit was taken as five 
times the standard deviation of the measured response to the lowest calibration level, and 
was calculated to be 0.8 ng. 
 
5.2.1.2.2 Generation of deoxyartemisinin calibration curve 
Santonin was used as an internal standard, with ions monitored at 173.3 and 247.3. The 
monitored deoxyartemisinin ions were 203. 2 and 267.2. 
 
A calibration curve was generated, in which deoxyartemisinin concentration ranged from 2.5 
to 15 µg/ml, and in which santonin, as an internal standard, was kept constant at 10 µg/ml. All 
calibration levels were prepared in triplicate and analysed three times per sample. The ratio of 
deoxyartemisinin to santonin was calculated for each analysis; linear regression of the 
resulting scatter plot was used to establish the calibration curve. The upper limit of 
quantification was given as the highest level of the calibration curve: beyond this, saturation 
of response rendered quantification less reliable. The lower detection limit was taken as five 
times the standard deviation of the measured response to the lowest calibration level, and 
was calculated to be 0.8 ng. 
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5.2.2 TLC separation of artemisinin and deoxyartemisinin 
 
Artemisinin was purified from a crude extract, using counter current chromatography, by Les 
Brown of AECS QuickPrep. Deoxyartemisinin was a gift from Neil Sullivan at Sensapharm Ltd.  
 
Silica plates (G260, 0.2 mm with fluorescent indicator) were purchased from Sigma. Solvents 
were purchased from De Montfort University Chemical Stores and purified by distillation.  
Spots were visualised with a vanillin-based spray reagent, prepared by dissolving 2g vanillin in 
100 ml of ethanol, and acidifying with 2 ml of concentrated sulphuric acid. Plates were dipped 
in the solution for a few seconds, and then heated in an oven at 105°C for 2 minutes. 
Alternately, plates can be sprayed with the visualization reagent, but coverage can be less 
uniform than when the dipping procedure is used. 
 
Hexane was taken as the base for the mobile phase, and a range of solvents – beginning with 
the very polar (isopropanol) and including ethyl acetate, dichloromethane, dioxane, butyl 
methyl ether and toluene – were added, either alone or in pairs, and in a range of 
volume/volume ratios, to build up a large number of 2- or 3-component mobile phases. Each 
of these phases was tested for its ability to separate a mixture of reference artemisinin and 
deoxyartemisinin.  
 
5.3 Results 
5.3.1 Deoxyartemisinin in UK and African-grown material 
 
Table 11. Deoxyartemisinin content of UK-grown Consortium material (1435, 1437, 1440, 1nd 1442), 
Moroccan-grown UK material (Moroccan A and Moroccan 1), Ghanaian-grown Ghanaian material 
(Ghana 1 and 2), and Tanzanian-grown Anamed material (Anamed 1 and Anamed 2) 
 
Sample Artemisinin 
% w/w 
Deoxyartemisinin % 
w/w 
Deoxyartemisinin as a 
percentage of artemisinin 
1435 (2007) 1.4 0.08 5.7 
1437(2007) 1.6 0.08 5.0 
1440(2007) 1.4 0.09 6.4 
1442(2007) 1.4 0.09 6.4 
Moroccan A  0.4 0.03 7.5 
Moroccan I  0.5 0.04 8.0 
Ghana 1 0.5 0.07 14 
Ghana 2 0.5 0.09 18 
Anamed 1 0.8 0.07 8.8 
Anamed 2 0.8 0.06 7.5 
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Table 11 shows that African-grown Artemisia annua L. contains a higher proportion of 
deoxyartemisinin when compared to UK-grown material. This is illustrated by the fact that UK-
grown samples 1435, 1437, 1440 and 1442, and Moroccan samples A and 1, are actually the 
same variety of Artemisia annua.  
   
5.3.2 Separation of deoxyartemisinin from artemisinin by TLC 
 
After a great deal of trial and error, it was found that the solvent system consisting of hexane: 
butyl methyl ether: ethyl acetate, at the ratio 80: 15: 5, produced the optimal separation of the 
two compounds. Deoxyartemisinin elutes with a retention factor (Rf) of 0.41, and artemisinin 
moves slightly slower, with an Rf of 0.33. The two compounds respond slightly differently to 
the visualization reagent: deoxyartemisinin derivatises to a light green, whilst artemisinin is 
dark green or even blue, depending on the freshness of the visualization reagent (Figure 31).  
 
Figure 31. TLC separation of deoxyartemisinin from artemisinin. L-R: deoxyartemisinin, extract from a 
Tanzanian-grown variety of A. annua, and artemisinin. 
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5.4 Discussion 
 
Despite the close similarity in structure – with deoxyartemisinin differing from artemisinin only 
by the lack of one oxygen atom – it has been possible to clearly separate the two spots by thin 
layer chromatography, using standard silica plates and commonplace laboratory solvents. Such 
a technique should prevent the overestimation of artemisinin content during TLC-based 
sample analysis – in particular, when extracts of African grown Artemisia annua L (in which 
deoxyartemisinin levels can reach 18% w/w) are analysed.
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6 Artemisinin quantification by TLC densitometry 
 
Synopsis 
 
There is a need for a simple, rapid means of Artemisia annua quality control that can be used 
at the site of crop growth, with a minimum of user training and outlay.  This section describes 
the validation of TLC densitometry for such a purpose. Unlike other TLC-densitometric 
methods in the literature, the method reported here made use of a simple desktop scanner 
and inexpensive (costing less than £200) Quantiscan® densitometric scanning software.  
 
The TLC-densitometric technique was found, when used carefully, to be comparable in 
accuracy to LCMS – but the potential for error is greater compared to LCMS. Nonetheless, 
when used correctly, TLC densitometry with Quantiscan® software is a realistic means of 
Artemisia annua quality control for those without access to the laboratory. 
 
6.1 Introduction 
 
The need for a field-based means of artemisinin quantification, relatively inexpensive and 
simple to use whilst retaining  high levels of reproducibility and accuracy, is apparent from the 
fact that Artemisia annua L. is often cultivated on a small scale in remote areas that are far 
from the nearest laboratory. Besides this, even those growers with access to a QA laboratory 
may wish to perform frequent assays throughout a growth season, in order to determine the 
ideal time for harvest, without sending numerous samples through to a perhaps expensive 
external assessment.  
 
A portable lateral flow device for field-based artemisinin quantification has been developed by 
a UK company, and is soon to be brought to market. But such a system is not cheap, and there 
is room for other, perhaps less complex, means of quantification. One such technique is thin 
layer chromatography (TLC) coupled with a densitometric scanner – or TLC-densitometry, for 
short.  
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Thin-layer chromatography, as applied to artemisinin quantification, is suitable for the semi-
quantitative analysis of samples of Artemisia annua, but has its limitations. Primary amongst 
these is that although the human eye alone, looking at a developed and visualised TLC plate, 
can discriminate samples containing high levels of artemisinin from those containing low 
levels, the eye cannot easily discern between samples displaying small differences. In 
quantitative terms, the eye cannot discern accurately between samples containing 1.2 % w/w 
artemisinin, for example, as compared to 1.4% w/w.  
 
However, the use of densitometric scanning software can overcome such difficulties of human 
subjectivity. In these types of device, a developed and visualised TLC plate is scanned by a 
plate reader, and areas of densest staining – indicating the presence of extracted compounds - 
are converted into numerical values, which will naturally be of greater of lesser magnitude 
depending on the intensity of the spot. In this way, a numerical value is produced for each 
stained spot on the plate, and that value, in theory, correlates positively to the quantity of 
compound present.  
 
Densitometric scanners (usually with ultra-violet imaging) are commercially available – they 
are used routinely in the reading of electrophoresis gels. TLC densitometry also finds a place in 
the quantification of natural products (Bodoki et al., 2005) and pharmaceuticals – in 2007, 
Tayade and Nagarsenker validated the technique for the quantification of artemether in 
pharmaceutical formulations (Tayade and Nagarsenker, 2007).  But the devices are typically 
bulky (and hence not portable), and also expensive – the Camag TLC Scanner III, used by 
Tayade and Nagasenker, retails at over €2000, even second-hand.  
 
For this project, Quantiscan® densitometric software was purchased from Biosoft® - this is a 
quantitative scanning program that currently retails at less than £200, and runs using any 
desktop scanner. The software enables the scanner, with a standard PC, to be used for 
quantitative densitometric analysis of developed TLC plates. 
 
To monitor the precision and reproducibility of this new technique, 218 samples were analysed 
both by TLC densitometry, and by HPLC-MS. 
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6.2 Materials and Methods 
6.2.1 Extraction and analytical procedure – LCMS 
 
Extraction:  Dried Artemisia annua leaf material was powdered using a pestle and mortar, and 
macerated in acetonitrile under dark conditions, with gentle shaking, for 24 hours at a 1/10 
weight-to-volume ratio.  
 
Sample Preparation: Analytical samples were prepared by the dilution of 25 µl of original 
extract in 875 µl of acetonitrile, with addition of 100 µl of santonin stock solution at 0.1 mg/ml.  
 
LCMS Parameters: After this time, artemisinin in samples was quantified using an Agilent 
Technologies 1100 Series high-performance liquid chromatography system, with a GraceSmart 
RP18-HPLC column (150 mm x 2.1 mm; particle size of 3 µm), coupled to an Agilent 
Technologies G1946 single quadruple mass spectrometer with electrospray ionization (ESI), 
used in positive ion mode, with single ion monitoring (SIM). HPLC separation was achieved 
with an isocratic mobile phase of 60% acetonitrile and 40% HPLC-grade water at a flow rate of 
0.2 cm3, with a run time of 8 minutes. The column oven was set at 25°C. 
 
The EI spray chamber and mass spectrometer parameters were as follows: nitrogen flow at 8 
L3/minute; drying gas temperature 350°C; capillary voltage 2800 V in positive mode, 3500 V in 
negative mode; nebulizer pressure 40 psig; and a fragmentor voltage of 70 V. The mass 
spectrometer was calibrated and, if necessary, tuned daily, using Agilent’s Electrospray Tuning 
Mix, to ensure peak performance. 
 
Generation of calibration curve. Santonin was used as an internal standard, with ions 
monitored at 173.3 and 247.3. The monitored artemisinin ions were 283.3 and 209.3. A 
calibration curve was generated, in which artemisinin concentration ranged from 2 to 16 
µg/ml, and in which santonin, as an internal standard, was kept constant at  
10 µg/ml. All calibration levels were prepared in triplicate and analysed three times per 
sample. The ratio of artemisinin to santonin was calculated for each analysis; linear regression 
of the resulting scatter plot was used to establish the calibration curve. The upper limit of 
quantification was given as the highest level of the calibration curve: beyond this, saturation of 
response rendered quantification less reliable. The lower detection limit was taken as five 
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times the standard deviation of the measured response to the lowest calibration level, and 
was calculated to be 0.8 ng. 
6.2.2 Extraction and analytical procedures: TLC-densitometry 
 
Quantiscan® Scanning Software. The Quantiscan® for Windows software was purchased from 
Biosoft, PO Box 1013, Great Shelford, Cambridge, CB22 5WQ, UK.  
 
Extraction and sample preparation. Dried Artemisia annua leaf material was powdered using a 
pestle and mortar, and macerated in acetonitrile under dark conditions, with gentle shaking, 
for 24 hours at a 1/40 weight-to-volume ratio. After this time, 5µl of extract were loaded as a 
single spot onto the baseline of the plate. Analytical samples were bracketed with reference 
samples at 0.2 and 1 mg/ml.  
 
Generation of calibration curve. Reference samples of artemisinin in acetonitrile - ranging from 
0.05 mg/ml to 1 mg/ml - were prepared in quadruplicate Using these, four TLC plates were 
prepared, on which 5 µl of each calibration level was applied as a single spot. 1.5 cm were 
allowed between spots. Plates were developed as described below. 
 
TLC development and visualisation conditions. Silica gel plates (aluminium backed; 60A, 0.2 
mm thickness with F254 fluorescent indicator) were purchased from Fisher. Plates were kept 
under desiccation until use. Plates were developed using a mobile phase prepared from diethyl 
ether: hexane (7:3). After development, plates were dried naturally for 5 minutes, and then 
dipped for 5 seconds in a 2 % v/v solution of vanillin in acidified ethanol (prepared by adding 
2g vanillin to 98 ml of ethanol, and then adding – over ice – 2 ml of concentrated sulphuric 
acid). Plates were heated in a fan oven set to 105°C for precisely 120 seconds. Plates were 
removed and allowed to stand for 15 minutes before reading.    
 
TLC Scanning Conditions. Biosoft’s Quantiscan® software package (illustrated in Figure 34)was 
used with a Mustek desktop scanner to calculate artemisinin in analytical samples, based on 
the calibration curve.  
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6.3 Results 
6.3.1 Calibration curve of artemisinin by TLC densitometry 
 
The calibration curve for artemisinin was linear (y = 2552x 161.6, R2: 0.990) in the 
concentration range 0.05 – 0.4 mg/ml, where 5 µl of reference solution are spotted onto the 
plate (Figures 32 and 33).  
 
 
Figure 32. Calibration curve of artemisinin by TLC-densitometry 
  
 
 
Figure 33. Calibration of artemisinin by TLC densitometry. Samples range from (L-R) 1 - 0.05 mg/ml 
artemisinin, where 5 µl were spotted onto plate. Plate scanned and imaged using Biosoft® software. 
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Figure 34. Example of data obtained from Biosoft program. Top left image: scanned TLC plate showing 
extracts of A. annua, with artemisinin spot approximately two-thirds of the way up the plate. Top 
right image: a profile showing spot density (y-axis). The lower table gives the numerical data for spot 
density. 
 
6.3.2 Sample analysis 
Table 12 shows the data (artemisinin as % w/w) for 218 samples, as assayed by TLC-
densitometry and LCMS.  
Table 12. Comparison of data obtained on 218 samples of dried A. annua by TLC-densitometry and 
LCMS. All data represents artemisinin % w/w 
 
Sample TLC MS Sample TLC MS Sample TLC MS Sample TLC MS Sample TLC MS 
1 1.0 0.9 51 0.2 0.7 101 0.7 0.8 151 0.9 0.7 201 1.1 0.7 
2 0.5 0.4 52 0.3 0.8 102 0.7 0.7 152 0.9 0.8 202 1.1 0.9 
3 0.8 0.7 53 0.4 0.9 103 0.8 0.9 153 0.8 0.6 203 1.2 0.8 
4 0.7 0.7 54 0.3 0.6 104 0.7 0.9 154 0.8 0.7 204 1.2 1.1 
5 0.8 0.8 55 0.4 0.7 105 0.8 1.4 155 0.9 0.9 205 1.3 1.3 
6 0.8 0.8 56 0.4 0.9 106 0.6 0.7 156 1.0 1.1 206 1.1 0.9 
7 1.1 1.0 57 0.4 0.8 107 0.8 0.9 157 0.8 0.8 207 0.8 0.8 
8 0.4 0.3 58 0.5 1.0 108 0.8 0.9 158 1.3 0.9 208 0.8 0.9 
9 0.7 0.5 59 0.3 0.8 109 0.8 0.7 159 1.5 1.0 209 1.3 0.7 
10 0.8 0.8 60 0.5 1.1 110 1.0 0.9 160 1.1 0.7 210 1.4 0.8 
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11 0.9 0.6 61 0.6 0.7 111 0.7 0.7 161 1.1 0.9 211 1.1 1.1 
12 0.5 0.4 62 0.8 1.0 112 0.7 0.8 162 1.2 0.8 212 0.7 0.7 
13 1.2 0.9 63 0.8 0.8 113 0.7 0.8 163 1.2 1.1 213 0.7 0.7 
14 1.1 0.9 64 0.7 0.8 114 0.9 1.0 164 1.3 1.3 214 0.9 0.8 
15 1.2 1.2 65 0.7 1.0 115 0.7 0.7 165 1.1 0.9 215 1.1 0.9 
16 0.6 0.6 66 0.5 0.8 116 0.6 0.6 166 0.8 0.8 216 1.3 1.1 
17 0.8 0.9 67 0.6 0.8 117 1.1 1.2 167 0.8 0.9 217 1.1 0.8 
18 1.0 1.1 68 0.4 0.6 118 1.1 0.9 168 1.3 0.7 218 1.5 1.0 
19 0.8 0.7 69 0.5 0.9 119 0.8 0.9 169 1.4 0.8 
   
20 0.7 0.6 70 0.9 0.9 120 0.7 0.8 170 1.1 1.1 
   
21 1.0 0.8 71 0.8 0.8 121 0.6 0.7 171 0.7 0.7 
   
22 1.0 0.8 72 1.0 1.2 122 0.4 0.4 172 0.7 0.7 
   
23 1.0 1.1 73 0.8 0.9 123 0.7 0.6 173 0.9 0.8 
   
24 0.8 0.8 74 0.5 0.6 124 1.0 0.9 174 1.1 0.9 
   
25 1.0 0.9 75 0.5 0.5 125 1.1 1.1 175 1.3 1.1 
   
26 0.9 0.6 76 0.8 0.8 126 0.9 0.9 176 1.1 0.8 
   
27 0.7 0.7 77 0.7 0.7 127 0.8 0.9 177 1.5 1.0 
   
28 1.4 1.2 78 0.9 0.8 128 0.9 1.0 178 1.0 0.9 
   
29 1.3 1.4 79 0.7 0.7 129 1.0 0.9 179 0.8 0.6 
   
30 0.7 1.1 80 1.0 0.9 130 0.6 0.5 180 1.3 1.1 
   
31 0.7 0.7 81 0.9 0.8 131 0.8 0.9 181 1.0 0.7 
   
32 0.5 0.5 82 1.0 1.1 132 0.8 0.8 182 1.1 0.7 
   
33 0.7 0.7 83 0.7 0.6 133 0.7 0.6 183 1.0 0.8 
   
34 0.7 0.7 84 0.9 0.9 134 1.1 1.1 184 1.0 1.0 
   
35 0.7 0.7 85 0.8 0.8 135 0.9 0.9 185 0.9 1.0 
   
36 0.8 0.8 86 0.7 0.7 136 1.1 1.0 186 0.8 0.8 
   
37 0.7 0.8 87 0.8 0.7 137 1.0 0.9 187 1.0 1.2 
   
38 0.5 0.6 88 0.7 0.7 138 0.8 0.6 188 1.2 1.1 
   
39 0.7 0.7 89 0.8 0.8 139 1.3 1.1 189 0.9 0.7 
   
40 0.8 1.1 90 0.7 0.7 140 1.0 0.7 190 0.8 0.7 
   
41 0.9 0.8 91 0.8 0.9 141 1.1 0.7 191 0.9 0.8 
   
42 0.7 0.7 92 0.7 0.8 142 1.0 0.8 192 0.9 0.7 
   
43 0.7 0.7 93 0.8 1.0 143 1.0 1.0 193 0.9 0.8 
   
44 0.9 0.9 94 0.6 0.7 144 0.9 1.0 194 0.8 0.6 
   
45 0.7 0.6 95 0.9 1.1 145 0.8 0.8 195 0.8 0.7 
   
46 0.8 0.9 96 0.7 0.9 146 1.0 1.2 196 0.9 0.9 
   
47 0.8 0.8 97 0.5 0.7 147 1.2 1.1 197 1.0 1.1 
   
48 0.9 1.0 98 0.7 1.0 148 0.9 0.7 198 0.8 0.8 
   
49 0.8 0.8 99 0.5 0.8 149 0.8 0.7 199 1.3 0.9 
   
50 0.7 1.0 100 0.9 0.9 150 0.9 0.8 200 1.5 1.0 
   
 
An examination of the degree of difference in reported artemisinin content between LCMS and 
TLC-densitometric assays  showed that in 26 cases, reported artemisinin content by TLC was 
underreported by between 10 and 19% compared to LCMS data. In 45 cases, reported 
artemisinin content by TLC was either the same as by LCMS, or underreported by up to 9%. In 
42 samples, reported artemisinin content by TLC was between 1 and 10% higher than the 
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LCMS result, and in 37 samples, reported artemisinin content by TLC was between 11 and 20% 
higher than the LCMS result (Figure 35). 
 
 
Figure 35. Differences in reported artemisinin content of 217 samples, expressed as (difference 
between TLC and MS value/TLC value) x 100.  
 
 
However, a comparison of the mean values obtained by TLC-densitometry and LCMS – 0.86 
and 0.84 respectively – shows that the two assay methods produce comparable results. 
Although the nature of the samples analysed – which were expected to range from low (0.6 % 
w/w) to high (1.2 % w/w) would naturally produce some variance from the mean, statistical 
analysis does show that the TLC-densitometry results show more variance than the MS results. 
In particular, the distribution of the differences between the two test methods shows that TLC 
can show large underestimations of the data (if we assume that the MS method was the “gold 
standard”, and therefore more likely to be correct). But there was a strong positive correlation 
coefficient (0.7) between the data obtained from the two methods.  
 
Using a paired t-test, a P-value of 0.054 was observed, indicating no significant difference 
between LCMS and TLC-densitometric data. 
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6.3.3 “Leaf-Spot” technique for sample application 
 
A highly experimental, and as yet unvalidated, procedure for very quick quality control of fresh 
Artemisia annua was developed. In this technique, fresh leaves taken from the plant are 
pressed directly onto the TLC plate, with no extraction step. To ensure that the same area of 
leaf is pressed onto the TLC plate for each sample, a filter paper with identically-sized holes 
(cut using a hole-punch) is placed over the plate, and the leaf is pressed over the hole, as 
illustrated below. The TLC plate is then run and visualised as usual (Figures 36 – 41): 
 
 
 
Figure 36. Left: filter paper with holes in base. 
Right: TLC plate. 
 
  
Figure 37. Placing filter paper over TLC plate. 
 
 
Figure 38. Placing fresh leaf over hole in filter 
paper. 
 
Figure 39. Pressing on leaf to deposit trichome 
content onto TLC plate. 
 
 
Figure 40. Running plate as usual. 
 
 
Figure 41. Developed plate. L-R: Artemisinin, 
1015, 1012-12, 1046, Artemisinin. 
 
 
Clearly, this method has limitations: it is only useful if all samples are taken from the sample 
region of the plant (e.g. the tips) at the same time, to ensure comparability. But the developed 
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TLC plate, below, indicates that the technique can discriminate between high- and low-quality 
plants. On this plate, the second spot from the left shows artemisinin from a high-quality plant 
1015 (1.2% w/w DW); the third spot from the left is from a poor quality plant, 1012-12 (0.6% 
w/w DW), and the fourth from the left is from a plant of intermediate quality, 1046 (1.0 % w/w 
DW). Differences in intensity of artemisinin spot can be discerned. 
 
 
Figure 42. TLC plate comparing three varieties of Artemisia annua L. assayed using the LeafSpot 
technique 
 
 
6.4 Discussion 
 
This TLC-densitometric method has three major advantages for field laboratories; the two 
major advantages being the price of the software, and the fact that is can be used on any PC. It 
currently costs less than £200 – far cheaper than purchasing specialised densitometric 
apparatus. The third advantage is the rapidity and simplicity of analysis: no specialised training 
is required, and data can be obtained within one hour.  
 
It must be borne in mind, though, that there is potential for error when using this method, if 
certain procedures are not followed correctly – particularly in relation to the visualisation step. 
It is essential that calibration curves are used, and that control samples, of a known 
artemisinin concentration, are included on every plate, as occasionally environmental variables 
(particularly, variations in oven temperature and humidity) can alter the degree of 
visualisation, resulting in falsely high or low values being given for artemisinin content. The 
presence of control samples are essential in correcting for these variables.  
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Additionally, samples must be prepared so that expected artemisinin level falls within the 
range of accurate quantification. This method has a detection limit of 0.05mg/ml artemisinin, 
and at levels above 0.6mg/ml, quantification becomes inaccurate due to saturation effects.  
 
The solvent-free “leaf-spot” method, perhaps, has potential in the in-field rapid analysis of 
fresh material, in combination with a validated densitometric scanning programme, but 
requires further investigation. 
 
Despite these limitations, though, the Quantiscan software, used appropriately, could provide 
a reliable and economical means of rapid plant quality control for the small-scale grower. 
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7 Deoxyartemisinin and artemisinin separation on a 
preparatory scale 
Synopsis 
 
Deoxyartemisinin is a pharmacologically inactive degradation product of artemisinin. As the 
two compounds are very similar in structure, differing only in the former’s lack of an oxygen 
molecule in the 7-membered ring, they tend to co-elute in chromatographic systems, and can 
also co-crystallise. This can result in the overestimation of artemisinin content in samples, and 
in the incorporation of inactive deoxyartemisinin in pharmaceutical preparations.   
 
This section describes a means of separating and crystallising the two compounds, using flash 
column chromatography. From 4g of crude Artemisia annua extract, 350 mg artemisinin and 
35 mg deoxyartemisinin were separated and purified. Purity of separated compounds was 
confirmed by melting point analysis and 1H NMR, and differences in the NMR signals of 
artemisinin and deoxyartemisinin were noted. 
 
7.1 Introduction 
 
Section 5 presented a method for the thin-layer chromatography (TLC)-based separation of 
artemisinin from its inactive cousin, deoxyartemisinin. Such a technique is of use to the general 
laboratory, where more selective techniques such as LCMS are unavailable, as it prevents the 
overestimation of artemisinin content in sample analysis.  But it does not solve an equally 
pertinent problem: having ascertained that the sample – be it a crude extract, or crystalline 
matter – does contain a degree of deoxyartemisinin, how can the unwanted deoxyartemisinin 
be removed on a useful scale? Can the TLC method be adapted for column chromatography, 
allowing the removal of deoxyartemisinin from gram quantities of impure samples? This 
chapter will attempt to answer that question. 
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7.2 Materials and Methods 
7.2.1 Column chromatography conditions 
 
Silica (70 – 200 mesh, 60 angstroms) was purchased from Sigma-Aldrich, as was 
Chromatography Grade silica (35 – 70 mesh, 60 angstroms). Solvents were purchased from De 
Montfort University Chemical Stores and purified by distillation.  
 
Hexane extract of Tanzanian-growth Artemisia annua – which, by TLC, had appeared to be 
comparatively rich in deoxyartemisinin – was a gift from Ian Flockhart and Colin Hill of 
Botanical Developments Ltd.  
 
Columns were prepared using 50 g of silica in a column of height 35 cm and internal diameter 
of 3.5 cm. Silica was mixed with initial mobile phase as a slurry and poured into the column.  
 
Column 1 was prepared using silica with a particle size of 70 – 200 µm. 4g crude A. annua 
extract was dried onto 5g silica and placed on the top of the column. A gradient mobile phase 
was used, consisting of the following solvent mixtures: 
 
Solvent Mixture Volume 
Hexane 100%  100 ml 
5% ethyl acetate in hexane 100 ml 
10% ethyl acetate in hexane 100 ml 
20% ethyl acetate in hexane 100 ml 
30% ethyl acetate in hexane 100 ml 
40% ethyl acetate in hexane 100 ml 
50 % ethyl acetate in hexane 200 ml 
 
Fractions of 20 ml were collected. Following TLC of the fractions, those fractions containing 
artemisinin and deoxyartemisinin were pooled and concentrated.  
Crystalline matter from the pooled fractions was washed with hexane, re-dissolved in 50% 
ethyl acetate in hexane, and dried onto 1g of 35 – 70 µm particle size silica.  
 
Section 8: Prep-scale separation of artemisinin and deoxyartemisinin 
 
 
135 
 
Column 2 was prepared using silica with a particle size of 35 – 70 µm. The column was 
otherwise prepared as above, with an isocratic mobile phase of hexane: butyl methyl ether: 
ethyl acetate (80: 15: 5). The artemisinin/deoxyartemisinin mixed crystals – dried onto silica – 
were placed at the top of the column.  A mobile phase reservoir was placed over the column, 
filled with solvent (Figure 43), and the sample was eluted from the column using flash 
chromatography. Fractions of 10 ml were collected, and analysed by TLC. 
 
Fractions containing artemisinin were pooled and crystallised, as were those containing 
deoxyartemisinin. 
 
 
Figure 43. Flash column, used to separate deoxyartemisinin from artemisinin 
 
7.2.2 LCMS conditions  
 
LCMS techniques for the quantification of artemisinin and deoxyartemisinin are described fully 
in Section 5.2.1.2.  
7.3 Results 
 
Using column 1, with a gradient of ethyl acetate in hexane, a crude extract of A. annua was 
fractionated. Using this system, it was possible to separate artemisinin and deoxyartemisinin 
from the other sample components, but not from each other. Pooled and concentrated 
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fractions containing both these compounds were allowed to stand overnight, and from this 
liquor, 450 mg of opaque, off-white needles (Figure 44), with a melting range of 125 - 141°C, 
were obtained. TLC analysis showed that the needles were a mixture of artemisinin and 
deoxyartemisinin, with a small level of other contaminants.  
 
 
Figure 44. Impure crystals containing both deoxyartemisinin and artemisinin. 
 
These impure crystals were fractioned by flash chromatography on column 2, and TLC of the 
resulting fractions showed that deoxyartemisinin had been largely separated from artemisinin: 
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Figure 45. TLC of fractions obtained by flash chromatography of impure crystals of artemisinin and 
deoxyartemisinin. 
 
Figure 45 shows the TLC plate. Fractions 19 – 23 contained deoxyartemisinin, and a small 
amount of another compound, and fractions 24 – 39 contained artemisinin. It can be seen that 
there is a small degree of overlap – fractions 23 and 24 contain both compounds, so baseline 
separation was not obtained. Fractions 19 – 22 were pooled and concentrated on a rotavapor 
at 60°C, as were fractions 25 – 39.  
 
Upon concentration to ~ 3 mls, crystals – in the form of opaque white needles - readily formed 
from fractions 25 – 39.  Crystals formed whilst solvent was still warm, and continued forming 
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as the solvent cooled. After 1 hour, no further crystal development was seen and crystals were 
dried and weighed. 355 mg of crystals were obtained, with a melting range of 152 – 156°C. 
 
Fractions 19 – 22, containing deoxyartemisinin and another impurity, were reduced in volume 
on a rotavapor at 60°C. When the volume was ~1 ml, the liquor was allowed to stand. Within 
30 minutes, clear white needles had begun to form in the liquor, and within 1 hour no further 
crystallization was seen. Crystals were dried and weighed. 35 mg of crystals were obtained, 
with a melting range of 108 - 110°C – identical to that given in the literature for 
deoxyartemisinin (Bhattacharya et al, 2007). By TLC, a retention factor comparable to a 
deoxyartemisinin reference was observed. A very small trace of artemisinin could be seen.  
 
 
Figure 46. Left image, L-R. A: artemisinin reference, 1: crude extract prior to chromatography, 2: 
pooled artemisinin and deoxyartemisinin after column 1; 3: pooled deoxyartemisinin fractions after 
column 2 (but before sample concentration and crystallization), 4: pooled artemisinin fractions after 
column 2 (but before sample concentration and crystallization), D: deoxyartemisinin reference. Right 
image. A: artemisinin reference, XL: deoxyartemisinin after crystallization; L: mother liquor of 
deoxyartemisinin, D: deoxyartemisinin reference.   
 
7.3.1 1H NMR 
1H NMR analysis of these crystals, purported to be deoxyartemisinin, showed signals at ppm 
values of 1.63 (m, 1H, H-3), 5.70 (s,1H, H-5), 3.19 (m, 1H, H-11), 1.20 (d, 3H, Me-13, J = 7.2), 
0.94 (d, 3H, Me-14, J = 5.6) and 1.53 (s, 3H, Me-15).  2-D 1H NMR showed clear interaction 
between the H11 and H13 protons. 
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TLC analyses confirmed that the crystals with a melting range on 152 - 156°C were a single 
compound, with a TLC retention factor comparable to that of an artemisinin reference. 1H 
NMR analysis of these crystals, purported to be artemisinin, showed signals (Figure 49) at ppm 
values of 2.44 (m, 1H, H-3), 5.87 (s, 1H, H-5), 3.39 (m, 1H, H-11), 1.21 (d, 3H, Me-13, J = 7.2), 
1.00 (d, 3H, Me-14, J = 5.8), and 1.44 (s, 3H, Me-15). These signals match those given in the 
literature for artemisinin (Blasko and Cordell, 1998). Interaction between the H11 and H13 
protons could clearly be seen by 2-D 1H NMR, as could interaction between H3 and H15.  Small 
but distinct differences in the ppm values could be observed between artemisinin and 
deoxyartemisinin (Figure 50), particularly in H-3, H-5, H-11 and H-15.  
 
Table 13. Comparison of 1H NMR shifts, in CDCL3, from artemisinin and deoxyartemisinin 
Proton   Artemisinin (ppm) Deoxyartemisinin (ppm) 
H-3 2.44 (1H, ddd, J = 
14.5, 13.3, 3.6) 
1.80 (1H, m) 
H-5 5.87 (1H, s) 5.70 (1H, s) 
H-11 3.39 (qd, J = 1.4.5.6, 
7.2)  
3.19 (1H, ddd, J = 4.6, 7.2, 
11.8) 
H-13 (Methyl) 1.21 (3H, d, J = 7.2) 1.20 (3H,d, J = 7.2) 
H-14 (Methyl) 1.00 (3H, d, J = 5.8) 0.94 (3,d, 5.6) 
H-15 (Methyl) 1.44 (3H, s) 1.53 (3H,s) 
 
 
 
 
Figure 47. The numbering of the artemisinin molecule 
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Figure 48. Deoxyartemisinin 
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Figure 49. 1H NMR of artemisinin 
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Figure 50. 1H NMR of deoxyartemisinin 
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7.3.2 Purity by LCMS 
 
LCMS quantification of artemisinin and deoxyartemisinin showed that artemisinin had been 
purified to 95% w/w, and deoxyartemisinin, to 91% w/w.   
 
7.4 Discussion 
 
Using simple laboratory equipment, it has been demonstrated that it is possible to separate 
artemisinin from the inactive contaminant deoxyartemisinin. A two step column 
chromatography set-up is needed: step 1, to isolate the two compounds from the other 
constituents of a crude extract, and step 2, to pull the two compounds away from each other. 
For this last step, two modifications to the standard column chromatography set-up were 
required: 
 
1. The use of silica with a particle size of 35 – 70 µm (as distinguished from the more 
usual 70 - 200 µm size); 
2. The use of flash chromatography. 
 
Use of silica with a finer particle size - and hence a larger surface area - allows for a greater 
degree of interaction between solute and stationary phase. Figure 51 graphically illustrates the 
difference in quality between the standard and chromatography grade silica.  
It may be hypothesised that the use of flash chromatography - in which the addition of 
pressure to the column results in a much more rapid elution of compounds than by gravity 
alone – prevents the dispersion effects that can cause closely eluting compounds to overlap.  
 
Figure 51. Comparison of particle size and distribution of standard (left) and chromatography grade 
(right) silicas. Pictures taken at 50 X magnification with a scanning electron microscope. 
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Although absolute baseline separation was not achieved, it was demonstrated clearly that a 
high yield of deoxyartemisinin-free artemisinin can be produced using simple, inexpensive 
methods. Whether this technique can be scaled to gram and kilogram levels has yet to be 
discovered.  
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8 Flavonoids as Markers of Quality 
 
Synopsis 
During an experiment to quantify levels of methoxylated flavonoids in Artemisia annua leaf, a 
correlation between flavonoid level and artemisinin levels was observed. This correlation was 
further investigated. A strong positive (>0.6) correlation between artemisinin and 
chrysosplenetin level was observed in several samples. However, in all samples assayed, a very 
strong positive correlation (>0.8) was observed between artemisinin and another flavonoid - 
hypothesised to be either eupatin or chrysosplenol-D.  
 
As the methoxylated flavonoids strongly absorb UV – unlike artemisinin - this correlation may 
be used as an indirect means of artemisinin quantification by those with access to HPLC-UV, 
but without access to HPLC-MS. 
 
This section also demonstrates that breeding new varieties of Artemisia annua for increased 
artemisinin content also results in plants with increased flavonoid content, potentially adding 
value to the crop, because of demonstrated anti-cancer activity of chrysosplenetin in in vitro 
cell viability (MTT) tests.  
 
8.1 Introduction 
The aerial parts of Artemisia annua contain, in addition to the terpenoid compounds of which 
artemisinin is one, a range of flavonoid aglycones .Typically, four different compounds are 
observed in the species, each of which is a methyl ether of quercetagetin. 
 
Figure 52 Quercetagetin 
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 Although flavonoids are commonly thought to exist within plants as glycosides (that is, as 
conjugated to a sugar molecule), within the hydrophobic enclave of the trichome these 
structures exist without the sugar component. Indeed, exudate (or surface) flavonoids, as 
these trichome-occurring compounds are known, are typically highly methoxylated structures 
that do not lend themselves to glycosidation (Taleb-Kontini et al., 2007). A high degree of 
methoxylation is observed amongst the flavonoids of A. annua, as figure 53 shows:  
 
Figure 53. Methoxylated flavonoids of Artemisia spp. 1: Eupatin. 2: Chrysosplenol-D. 3: Casticin. 4: 
Chrysosplenetin. 5: Artemetin 
 
 
The presence of trichome-stored flavonoids is widespread amongst Achillea species (Valent-
Vetschera et al., 1994), and has been reported in many other plant subfamilies, including 
Artemisia (Baraldi et al., 2008). It has been proposed that the biosynthesis of flavonoids – 
highly UV-absorbent compounds that they are – is upregulated by increased intensity of UV-B 
radiation, and that the compounds act to form a sunscreen (Jaakola et al., 2004). As with many 
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other secondary metabolites, it has also been speculated that the exudate flavonoids are a 
form of defence against insecticidal or microbial attack (Tomas-Barberan et al, 1988). 
 
Whatever the function of flavonoids in vivo, the flavonoid profile of Artemisia annua is of 
interest. The anti-cancer potential of casticin has been explored by several research groups 
who have noted its ability to halt cancerous cell growth at the G2/M stage, whilst having no 
effect on the growth of normal cells (Haidara et al, 2006, Kobayakawa et al, 2004).  
 
It has also been demonstrated that the methoxylated flavonoids casticin and artemetin were 
able to potentiate the antiparasitic action of artemisinin against Plasmodium falciparum 
cultures (Elford et al., 1987). Therefore, the usefulness of these compounds, and their 
potential to add value to an Artemisia annua crop, renders their quantification in the plant an 
important piece of research. 
 
It was during such quantification of A. annua flavonoids that the author noticed a strong 
positive correlation between artemisinin levels, and the levels of two flavonoids, in extracts of 
the plant. Since a major difficulty in the quantification of artemisinin in A. annua herbal 
material is artemisinin’s lack of a chromophore (not a problem experienced by the flavonoid 
researcher), it was hypothesised that this artemisinin: flavonoid correlation, if it could be 
demonstrated to be valid, would represent a simple way to use UV-based detection to quantify 
artemisinin in herbal material, suitable for those laboratories that do not have access to the 
expensive detectors (such as mass spectrometers) that are needed to reliably quantify 
artemisinin.  
 
How likely is a quantitative link between these two very different classes of compound? A 
shared biosynthetic pathway, at least at the latter stages of synthesis, is unlikely. But, as 
Wollenweber has observed, there is a correlation in most cases between levels of flavonoid 
aglycones and other lipophilic plant products, and the presence of secretory structures such as 
trichomes (Wollenweber et al., 1981). From this, we can speculate that a quantitative link may 
well be present simply because plants possessing more trichomes will (in theory) – possess 
more of the compounds stored or synthesized in trichomes – more of all the compounds. 
Indirectly, this brings us to a related question: does the level of artemisinin within a plant 
correlate to the trichome density? It would be logical, given that artemisinin is sequestered 
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within the glandular secretory trichomes (GSTs) of the leaf, to suppose that it does: particularly 
since the enzyme CYP7AV1, capable of catalysing multiple reactions in the biosynthetic 
pathway to artemisinin, has been localised to the GSTs of A. annua (Teoh et al., 2006). 
 
Few reports exist of the methoxyflavonoid content of Artemisia annua. Bilia (Bilia et al., 2006a) 
reported a total methoxylated flavonoid content of 2% w/w (dry leaf), with an artemisinin level 
of 0.4% w/w. Bilia also reports that of the total methoxylated flavonoid content, extracted 
using hexane, eupatin represented 19.1%, an inseparable mixture of casticin and 
chrysosplenetin made up 34.3%, and artemetin a further 9.4%.   
 
It is probable that flavonoid chemovars exist: material of differing geographical origin, or 
differing germplasm, may well produce qualitative and quantitative differences in flavonoid 
profile. It may also be that even with genetically identical plants, the profile changes with age 
and exposure to biotic and abiotic insults.  Ideally, these putative changes in profile would be 
shown to be quantitatively linked to changes in artemisinin level.  
 
So, the questions to be addressed are: 
 
1. Is there a clear quantitative link between flavonoid level and artemisinin level? 
2. If so, is this link stable even in the presence of environmental changes (the application 
of herbicides, for example, or differences in geographical location)? 
 
8.2 Materials and Methods 
8.2.1 Reagents 
Chrysosplenetin was supplied by Colin Hill of Botanical Developments Ltd as an 
artemisinin/chrysosplenetin mixture. Chrysosplenetin was separated by column 
chromatography (diethyl ether: hexane at 7:3 over a silica phase) and identity was confirmed 
by LCMS and 1H NMR.  Artemisinin was purified by Les Brown of AECS QuickPrep Ltd, using 
counter current chromatography, from an extract of A. annua supplied by Ian Flockhart of 
Botanical Developments Ltd; again, identity was confirmed by LCMS and 1H NMR. Santonin 
was purchased from Sigma-Aldrich.  Electrospray tuning mix was purchased from Agilent 
Technologies Ltd. HPLC solvents (acetonitrile, HPLC gradient grade and water, mass 
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spectrometry grade) were purchased from Fisher, as was silica (70 – 200 mesh) for column 
chromatography. Solvents for column chromatography (diethyl ether and hexane) and solvents 
for sample extraction (dichloromethane, diethyl ether and hexane) were purchased from De 
Montfort University Chemical Stores. 
 
8.2.2 Choice of extraction solvent 
Four solvents – acetonitrile, dichloromethane, hexane, and methanol – were compared for 
flavonoid aglycone extraction efficiency. Dried and powdered leaf matter was macerated 
under dark conditions, with gentle shaking, for 24 hours at a 1/10 weight-to-volume ratio. 
Following this, the samples were filtered using ashless filter paper to remove leaf material, and 
liquid was dried under nitrogen. Dried extracts were re-dissolved in HPLC mobile phase (66% 
acetonitrile, 34% methanol) and assayed by HPLC-DAD, with detection at 350 nm. 
 
8.2.3 Extraction of plant material 
Following the comparative solvent assay described in Section 8.2.2.., acetonitrile was chosen 
as the optimal solvent for the extraction of flavonoids from dried herbal material. The herbal 
matter was powdered using a pestle and mortar, and macerated under dark conditions, with 
gentle shaking, for 24 hours at a 1/10 weight-to-volume ratio. After this time, samples were 
filtered using ashless filter paper, and analysed by HPLC-DAD and HPLC-MS. 
 
8.2.4 HPLC-DAD for the quantification of flavonoids 
8.2.4.1 Reference standard 
Chrysosplenetin, obtained as an impure by-product of artemisinin purification from herbal 
material, was provided by Colin Hill of Botanical Developments Ltd. The compound was 
purified over a column consisting of 20 g silica (standard grade, 70 – 200 mesh), with a mobile 
phase of diethyl ether: hexane (7:3). Chrysosplenetin was re-crystallised to a constant melting 
range of 177 – 178 °C. Structure was confirmed by 1H nuclear magnetic resonance on a Bruker 
Ultrashield 400 MHz machine. 
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8.2.4.2 HPLC Conditions 
Separation of flavonoids was achieved using an Agilent 1100 Series HPLC system coupled to a 
diode array detector. A Grace Alltech column (150 x 2.1 mm, pore size 3 µm) was used with a 
gradient system utilising two solvent mixtures. Solvent A was prepared using HPLC mass 
spectrometry grade water with 0.1% orthophosphoric acid. Solvent B was a mixture of 
acetonitrile and methanol (both HPLC gradient grade) at a ratio of 66: 34.  
 
Separation required the following gradient (designated “Methoxyflavones”), at a constant flow 
rate of 0.3 ml/minute: 
 
Time (m) Solvent A % Solvent B % 
0 70 30 
15 50 50 
20 50 50 
25 40 60 
30 30 70 
40 20 80 
45 70 30 
48 70 30 
Post run 10 minutes 
 
Absorption of ultraviolet light by flavonoids was recorded at 350 nm. 
8.2.4.2.1 Generation of calibration curve 
A series of samples were prepared in which chrysosplenetin level ranged from 5 mg/ml to 
0.125 mg/ml. Samples were prepared in triplicate, and each sample was run three times for 
reproducibility assessment. The resulting curve was linear with a regression index of 0.9987. 
 
8.2.5 HPLC-MS for the identification of flavonoids 
A crude, resinous toluene extract of a Madagascan-grown Artemisia annua variety (a gift from 
Dr Colin Hill at Botanical Developments Ltd) was weighed out to 100 mg and mixed with 
methanol and water (in a 1:1 ratio). This was followed by partial purification, performed by  
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shaking the solution into dichloromethane. The dichloromethane fraction was dried with 
anhydrous sodium sulfate, evaporated under nitrogen, and re-dissolved in 250 µl acetonitrile.  
 
25 µl of this preparation were injected onto a Grace Alltech RP18 (octadecylsilane) column, 
with an internal diameter of 2.1 mm and a length of 150 mm. The column packing had a 
particle size of 3µm.  The mobile phase used was acetonitrile: water (6:4), at 0.2 ml/minute. A 
multimode spray chamber was used in electrospray ionisation mode, with the following mass 
spectrometer parameters:  
nitrogen flow at 8 L3/minute; drying gas temperature 350°C; capillary voltage 2800 V in 
positive mode, 3500 V in negative mode; nebulizer pressure 40 psig, and a fragmentor voltage 
of 70 V. This fragment voltage was gradually ramped in increments of 25, and mass fragments 
of the individual peaks observed at each increased voltage.  
 
Detection was in total ion chromatogram mode, with a mass range of 10 to 500 Daltons.  
 
8.2.6 HPLC-MS for the quantification of artemisinin 
8.2.6.1 Reference standards 
Reference artemisinin was provided by AECS, and found to have a melting range of 154 – 156 
°C, and a purity of > 98%. Identity of artemisinin was confirmed by electrospray 
mass spectrometry and 1H nuclear magnetic resonance on a Bruker 400-MHz Ultrashield 
machine. 
8.2.6.2 HPLC-MS Conditions  
Artemisinin was quantified using an Agilent Technologies 1100 Series high-performance liquid 
chromatography system, with a GraceSmart RP18-HPLC column (150 mm x 2.1 mm; 
pore size of 3 mm), coupled to an Agilent Technologies G1946 single quadruple mass 
spectrometer with electrospray ionization (EI), used in positive ion mode, with single ion 
monitoring (SIM). HPLC separation was achieved with an isocratic mobile phase of 60% 
acetonitrile and 40% HPLC-grade water at a flow rate of 0.2ml/minute, with a run time of 8 
minutes. The column oven was set at 25°C. 
 
The EI spray chamber and mass spectrometer parameters were as follows: nitrogen flow at 8 
L3/minute; drying gas temperature 350°C; capillary voltage 2800 V in positive mode, 3500 V in 
Section 8: Flavonoids as Markers of Quality 
 
152 
 
negative mode; nebulizer pressure 40 psig; and a fragmentor voltage of 70 V. The mass 
spectrometer was calibrated and, if necessary, tuned daily, using Agilent’s Electrospray Tuning 
Mix, to ensure peak performance.  
 
Generation of calibration curve. Santonin was used as an internal standard, with ions 
monitored at 173.3 and 247.3. The monitored artemisinin ions were 283.3 and 209.3. 
 
8.2.6.2.1 Generation of calibration curve 
A calibration curve was generated, in which artemisinin concentration ranged from 2 to 16 
µg/ml, and in which santonin, as an internal standard, was kept constant at 10 µg/ml. All 
calibration levels were prepared in triplicate and analysed three times per sample. The ratio of 
artemisinin to santonin was calculated for each analysis; linear regression of the resulting 
scatter plot was used to establish the calibration curve. The upper limit of quantification was 
given as the highest level of the calibration curve: beyond this, saturation of response 
rendered quantification less reliable. The lower detection limit was taken as five times the 
standard deviation of the measured response to the lowest calibration level, and was 
calculated to be 0.8 ng. 
8.2.7 MTT Assay for Toxicity of Chrysosplenetin to Breast Cancer Cells 
Anti-cancer (MTT) screening assays of chrysosplenetin were carried out by Dr Somchaiya 
Surichan and Dr Dyan Ankrett, of the DMU Cancer Drug Discovery Group. The protocol is given 
in Appendix 1. 
8.3 Results 
8.3.1 Number of flavonoid aglycone compounds present 
Four major peaks, with UV spectra characteristic to flavonoids, were observed in all samples 
(Figure 54).  
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Figure 54. HPLC-DAD chromatogram of extract of Artemisia annua L, separated by "Methoxyflavones" 
method and detected at 350 nm. Peak 1: unknown; hypothesised to be eupatin or chrysosplenol-D. 
Peak 2: Casticin or chrysosplenetin. Peak 3: Unknown. Peak 4: unknown. 
8.3.2 Choice of extraction solvent 
Of the four solvents tested, hexane was the least efficient overall in terms of total flavonoids 
extraction. Notably, hexane failed to extract any eupatin from samples.  Acetonitrile and 
methanol were the most efficient extraction solvents, extracting total flavonoid aglycones of 
0.27 and 0.22 % w/w respectively (Table 14).  Further tests showed that greater than 90% of 
the flavonoid content of the leaf material was extracted by this 24-hour maceration with either 
acetonitrile or methanol. Additionally, acetonitrile-extracted samples contained less green 
pigment (potentially destructive to HPLC-columns) compared to methanol extracted-samples. 
As a consequence, acetonitrile was chosen as the extraction solvent, due to its efficiency and 
similarity to the HPLC mobile phase.  
 
Table 14. Extraction of methoxylated flavonoids from dried Artemisia annua leaf matter, expressed as 
% w/w, using four different solvents. Figures in italics represent standard deviation 
Solvent Peak 1 % 
w/w 
Chrysosplenetin 
% w/w 
Peak 3 % 
w/w 
Peak 4 % 
w/w 
Total 
Flavonoids 
% w/w 
Acetonitrile 
0.05 (0.02) 0.17 (0.007) 0.02 (0.001) 
0.03 
(0.0004) 
0.27 (0.02) 
Methanol 70% 0.04 
(0.005) 0.14 (0.0009) 0.02 (0.003) 
0.02 
(0.0004) 
0.22 
(0.009) 
Dichloromethane 0.02 
(0.004) 0.12 (0.02) 0.01 (0.003) 0.02 (0.003) 
0.17 (0.03) 
Hexane 
0  0.02 (0.0013) 
0.003 
(0.0002) 
0.007 
(0.0002) 
0.03 
(0.002) 
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It was noted that the hexane extract, in addition to being low in total flavonoid content, did 
not contain the first of the four peaks (either eupatin or chrysosplenol-D); probably because 
this compound, eluting before the others, is likely to be the most polar of the four and hence 
unlikely to be extracted by such a non-polar solvent. 
 
Extraction of the same material in an aqueous methanolic solution, with added β-glucosidase, 
did not result in any increase in flavonoid content. This adds weight to the assertion by Taleb-
Kontini that surface methoxyflavones tend to exist in the free aglycone form.  
 
8.3.3 HPLC-MS for identification of flavonoids 
Electrospray ionisation is a soft ionisation technique, and unlike some other ionisation 
techniques (such as electron impact ionisation), does not generate a large number of fragment 
ions in the mass spectrum - often, at the default fragmentor voltage of 70 V, only the 
molecular ion (M + 1) is observed. Such is the case with the methoxylated flavonoids 
(artemisinin, on the other hand, exhibits significant fragmentation at this voltage).  
 
By using HPLC coupled to both DAD and electrospray ionisation MS, the mass fragments of two 
early-eluting peaks with flavonoid-type UV spectra could be studied (although four peaks with 
flavonoid spectra were observed, the two later eluting peaks were not present at sufficiently 
high levels to allow mass spectral studies). The earliest eluting peak, at 3.3 minutes, had a base 
peak of 361, and the peak eluting second, at 4.5 minutes, had a base peak of 375. The former 
figure corresponds to the protonated value expected for either eupatin or chrysosplenol-D, 
and the latter to that expected for either casticin or chrysosplenetin. 
 
The B-ring of the eupatin molecule differs from the B-ring of chrysosplenol-D, in that the 
former contains both and O-methyl and a hydroxyl moiety – the ring, if isolated from the rest 
of the molecule, would have a mass of 123. The B-ring of chrysosplenol-D, on the other hand, 
contains two hydroxyl moieties, and would have an isolated mass of 109. To identify which of 
the two compounds was present, the fragmentor voltage of the MS was increased from 70 V 
to 350 V, and the resulting fragmentation patters of this peak observed. At voltages of 250 and 
higher, a small fragment of m/z 109.3 appeared in the mass spectrum. The base peak 
remained the 361, M + 1 fragment. This evidence suggests that the first flavonoid eluting by 
HPLC is, in fact, chrysosplenol-D (Figure 55). 
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This increased fragmentation technique would not be applicable to the discernment of casticin 
from chrysosplenetin (Figure 56), as in this case the B-ring of both molecules contains one 
hydroxyl and one O-methyl moiety. Other chemical techniques, described below, were used to 
deduce which compound was present in the extract.     
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Figure 55. Mass fragments of chrysosplenol-D 
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Figure 56. Mass fragments of chrysosplenetin 
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8.3.4 NMR identification of chrysosplenetin 
It is known that both flavonoids - casticin and chrysosplenetin - occur in A. annua; Bilia has 
described the two compounds as inseparable. As both compounds have the same mass (374), 
and differ only in the position of the B-ring O-methyl group, the two cannot be differentiated 
by LCMS. The ppm shifts obtained by 1H NMR (Figure 57) of the Artemisia annua L. flavonoid 
were as follows: 3.86 (s, 3'-OCH3), 3.92 (s, 7-OCH3), 3.96 (s, 3-OCH3), 3.98 (s, 6-OCH3), 6.11 (s, 
4’-OH), 6.49 (s, H8), 7.04 (d, J = 8.4, H5’,H6’)), 7.65 (dd, J =2.0 [H2’,H6’], J = 8.4 [H6’,H5’]), 7.70 
(d, J = 1.97, H2’,H6’) and 12.60 (s, 5-OH). 
 
Homonuclear 2-D COSY 1H NMR (Figure 58) confirmed J-coupling between the 
7.04 ppm (C5’) and 7.7 ppm (C2’) peaks, but such coupling would be present in 
both casticin and chrysosplenetin.   However, homonuclear 2-D NOESY 1H NMR 
(Figure 59) demonstrated spatial proximity between H2’ and 3’-OCH3, H8 and 7-
OCH3 and H5’ and H6’. The NOESY-interation between H2’ and 3’-OCH3 indicates 
that these two groups are adjancent in space – providing strong evidence that the 
compound is in fact chrysosplenetin, not casticin. 
 
Furthermore, the melting range of the material – 177 - 178°C – points toward the 
material being pure chrysosplenetin. Literature values for the melting range of 
chrysosplenetin are 177 – 178 °C (Fukui et al., 1969), and that for casticin is given 
as 188 - 189°C (Azizuddin et al., 2009).   
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Figure 57. 1H NMR of chrysosplenetin 
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Figure 58. 2-D homonuclear (1H) COSY NMR of chrysosplenetin 
Section 8: Flavonoids as Markers of Quality 
 
161 
 
 
Figure 59. 2-D (1H) NOESY NMR of chrysosplenetin 
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8.3.4.1 Eupatin or Chrysosplenol-D? 
Insufficient sample of chrysosplenol-D was available to perform NMR analysis of this 
compound, and hence confirm compound identity. However, for the remainder of this section, 
the compound shall be identified as chrysosplenol-D, based on the preliminary LCMS data. 
8.3.5 Artemisinin and flavonoid content in Cambridge, UK, in 2007 
Table 15 shows artemisinin, chrysosplenol-D and chrysosplenetin content in Artemisia annua 
plants samples grown in Cambridge, UK, and harvested in 2007: 
 
Table 15. Levels of, and correlation between, artemisinin and two methoxylated flavonoids in three 
new varieties of Artemisia annua across a full harvest season in Cambridge, UK, in 2007. CH-D: 
chrysosplenol-D. Chryso: chrysosplenetin 
 
Variety Harvest 
Date 
ART % 
w/w 
CH-D % 
w/w 
CHRYSO % 
w/w 
Ratio CH-
D/Art 
Ratio 
Chryso/Art 
1015 25/07/2007 0.7 0.08 0.09 0.11 0.13 
01/08/2007 0.7 0.07 0.09 0.10 0.13 
30/08/2007 1.4 0.11 0.11 0.08 0.08 
06/09/2007 1.2 0.10 0.10 0.08 0.09 
06/09/2007 1 0.1 0.11 0.10 0.11 
13/09/2007 1.1 0.10 0.10 0.09 0.09 
13/09/2007 1.2 0.09 0.09 0.08 0.07 
27/09/2007 1.1 0.10 0.10 0.09 0.09 
27/09/2007 0.9 0.08 0.10 0.09 0.11 
11/10/2007 1.1 0.11 0.11 0.10 0.10 
11/10/2007 1.3 0.12 0.13 0.09 0.10 
1046-7 01/08/2007 1 0.07 0.11 0.07 0.11 
01/08/2007 0.9 0.05 0.10 0.06 0.11 
20/08/2007 1.2 0.08 0.13 0.07 0.11 
20/08/2007 1.2 0.09 0.14 0.08 0.12 
30/08/2007 1 0.08 0.12 0.08 0.12 
30/08/2007 1.1 0.09 0.13 0.08 0.12 
06/09/2007 1.2 0.09 0.15 0.08 0.12 
06/09/2007 1.1 0.08 0.12 0.07 0.11 
13/09/2007 1.4 0.12 0.17 0.09 0.12 
13/09/2007 1.3 0.13 0.17 0.10 0.13 
27/09/2007 1.5 0.13 0.18 0.09 0.12 
27/09/2007 1.5 0.11 0.15 0.07 0.10 
11/10/2007 1.2 0.09 0.14 0.08 0.11 
11/10/2007 1.3 0.11 0.16 0.08 0.13 
1012-12 30/08/2007 0.4 0.00 0.04 0 0.10 
06/09/2007 0.04 0.00 0.01  0.23 
06/09/2007 0.3 0.01 0.04 0.03 0.14 
Section 8: Flavonoids as Markers of Quality 
 
163 
 
13/09/2007 0.4 0.01 0.06 0.03 0.14 
13/09/2007 0.4 0.01 0.05 0.03 0.12 
27/09/2007 0.9 0.03 0.07 0.03 0.08 
27/09/2007 0.5 0.01 0.04 0.02 0.09 
11/10/2007 0.5 0.02 0.05 0.04 0.10 
11/10/2007 0.6 0.01 0.05 0.02 0.08 
Correlation Coefficient 
between Artemisinin and 
Flavonoid Level 
Chrysosplenol-D Chrysosplenetin 
1015 0.9 0.7 
1046-7 0.9 0.9 
1012-12 0.8 0.9 
 
8.3.5.1 Correlation between artemisinin and flavonoid content in 2007 
In all three varieties, a strong positive correlation exists between the level of artemisinin and 
the level of chrysosplenol-D. In two of the three varieties (1046-7 and 1012-12), a strong 
correlation exists between the level of artemisinin and the level of chrysosplenetin. These two 
varieties differ from 1015 in being consortium-bred. 
 
8.3.5.2 Overall flavonoid profile in 2007 
In 1015, levels of chrysosplenol-D and chrysosplenetin are nearly equal, with an mean 
chrysosplenol-D to chrysosplenetin ratio of 0.9 (+-0.08, ranging from 0.80 to 1.0). In 1046-7, 
chrysosplenol-D levels are a little lower than chrysosplenetin, with a mean ratio of 0.8, (+- 
0.01, ranging from 0.06 to 0.1). In 1012-12, chrysosplenol-D levels are much lower than 
chrysosplenetin, with a mean ratio of 0.21 (+- 0.14, ranging from 0 to 0.07). 
In two of the three cases (1046-7 and 1012-12) flavonoid levels begin to drop towards the end 
of the harvest season. 
 
8.3.5.3 The chrysosplenetin: artemisinin ratio 
The ratio of chrysosplenetin to artemisinin, when all lines are considered together, ranges 
from 0.07 to 0.23, with a mean value of 0.11 (+-0.03) –a figure which also represents the most 
commonly occurring value.  
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8.3.6 Artemisinin and flavonoid content in Cambridge-grown material in 2008 
To verify that this chrysosplenetin to artemisinin ratio of 0.1 is a real and consistent 
phenomenon, the analysis was expanded in 2008 to include eleven varieties of A. annua - both 
before and after glyphosate treatment. The results are presented in Table 16, after which 
follows a summary. Table 16shows levels of chrysosplenol-D, chrysosplenetin, and artemisinin 
in eleven varieties of A. annua grown in Cambridge in 2008. Each variety was sampled three 
times: on 31st July, 22nd September, and 22nd September following previous treatment with 
Glyphosate (GLY).  
 
Table 16. Artemisinin and flavonoid content of 2008 Cambridge-grown material, some of which 
(designated GLY) had been exposed to Glyphosate.  
 
Variety Details ART % 
w/w 
CH-D % 
w/w 
CHRYSO % 
w/w 
Ratio CH-D 
/ART 
Ratio 
CHRYSO/ART 
1015 31/7/2008 0.8 0.04 0.11 0.05 0.14 
22/9/2008 1 0.04 0.11 0.04 0.11 
22/9/2008 
GLY 
1.2 0.04 0.11 0.03 0.09 
1046-7 31/7/2008 1 0.1 0.15 0.10 0.15 
22/9/2008 1.1 0.1 0.16 0.09 0.15 
22/9/2008 
GLY 
1.3 0.12 0.19 0.09 0.15 
1012-
12 
31/7/2008 0.6 0.03 0.11 0.05 0.18 
22/9/2008 0.7 0.01 0.09 0.01 0.13 
22/9/2008 
GLY 
0.8 0.04 0.12 0.05 0.15 
1001-3 31/7/2008 0.7 0.01 0.11 0.01 0.16 
22/9/2008 0.9 0.02 0.13 0.02 0.14 
22/9/2008 
GLY 
1 0.02 0.14 0.02 0.14 
1038-1 31/7/2008 1 0.05 0.12 0.05 0.12 
22/9/2008 0.9 0.03 0.1 0.03 0.11 
22/9/2008 
GLY 
1.3 0.11 0.12 0.08 0.09 
1045-3 31/7/2009 0.8 0.07 0.18 0.09 0.23 
22/9/2008 0.9 0.06 0.15 0.07 0.17 
22/9/2008 
GLY 
1.2 0.08 0.16 0.07 0.13 
1062-1 31/7/2008 1.2 0.08 0.16 0.07 0.13 
22/9/2008 1.4 0.1 0.18 0.07 0.13 
22/9/2008 
GLY 
1.7 0.11 0.22 0.06 0.13 
1062-4 31/7/2008 1 0.08 0.11 0.08 0.11 
22/9/2008 1.2 0.15 0.16 0.13 0.13 
22/9/2008 
GLY 
1.5 0.14 0.15 0.09 0.1 
1053-1 31/7/2008 1.4 0.08 0.18 0.06 0.13 
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22/9/2008 0.8 0.05 0.14 0.06 0.18 
22/9/2008 
GLY 
1.3 0.07 0.16 0.05 0.12 
1053-2 31/7/2008 0.9 0.05 0.13 0.06 0.14 
 22/9/2008 0.9 0.04 0.13 0.04 0.14 
 22/9/2008 
GLY 
1.3 0.06 0.16 0.05 0.12 
1053-4 31/7/2008 0.8 0.07 0.08 0.09 0.1 
 22/9/2008 1.2 0.08 0.11 0.07 0.09 
 22/9/2008 
GLY 
1.1 0.11 0.11 0.10 0.1 
Correlation Coefficient between Artemisinin and Flavonoid 
Level 
Chrysosplenol-D Chrysosplenetin 
Harvest: 31/7/2008 0.8 0.6 
Harvest: 22/9/2008 0.8 0.5 
Harvest: 22/9/2008, treated with Glyphosate 0.7 0.6 
 
8.3.6.1 Correlation between artemisinin and flavonoid content 
The table above shows that, when eleven varieties are considered, a strong positive 
correlation exists between levels of chrysosplenol-D and levels of artemisinin – although this 
correlation is somewhat reduced upon application of glyphosate.  
 
The correlation between chrysosplenetin and artemisinin, however, was less pronounced, both 
with and without glyphosate treatment. This is explained by the fact that the ratios of 
chrysosplenetin to artemisinin, when all lines and treatments (i.e. with or without glyphosate) 
are considered together, varies widely from 0.09 to 0.23, although the mean (and median) 
value is 0.13 – close to that observed in the 2007 material.  As methoxylation of the flavonoid 
skeleton continues, the quantitative link with artemisinin appears to break down.  
 
8.3.6.2 Use of Glyphosate 
 
In four of the eleven varieties assayed, glyphosate treatment did not affect the chrysosplenetin 
to artemisinin ratio. In three of these cases (1046-7, 1001-3 and 1062-1), a correlated increase 
in both chrysosplenetin and artemisinin was observed. In the fourth case (1053-4), artemisinin 
level actually dropped, whilst that of chrysosplenetin increased slightly.  
 
However, in the other seven lines, the ratio of the two compoundswas affected by glyphosate 
application. In four of these (1012-12, 1045-3, 1053-1 and 1053-2), a small increase in 
chrysosplenetin was observed, but to a lesser magnitude than the increase in artemisinin. In 
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two cases (1015, 1038-1), artemisinin increased whilst chrysosplenetin level did not change. In 
the final line, 1062-4, artemisinin increased whilst chrysosplenetin level dropped. 
8.3.6.3 Comparison with 2007 material 
Samples of Artemisia annua line 1015 showed a different flavonoid profile in 2008 as 
compared to 2007. In 2008, the levels of chrysosplenol-D were much lower than the levels of 
chrysosplenetin, whereas in 2007 the levels had been nearly equal. 1012-12 and 1046-7, 
however, appeared very similar in flavonoid profile in 2008 compared to 2007. 
 
In both 2007and 2008, 1015 produced a maximum chrysosplenetin content of 0.11% w/w.  
In 2008, 1046-7 contained slightly more chrysosplenetin compared to 2007 (0.19 % w/w and 
0.18% w/w respectively). 1012-12, though, showed quite a large increase in chrysosplenetin in 
2008 compared to 2007 (0.12% w/w and 0.07 % w/w respectively). This increase was not 
reflected in the artemisinin levels, which were slightly lower in all three varieties in 2008 
compared to 2007.  
 
Such year-to-year variations - small as they are - in the chrysosplenol-D: artemisinin and 
chrysosplenetin: artemisinin ratios, within the same germplasm, show that environmental 
conditions are able to override genetic similarity, and reduce the reliability of this indirect 
means of artemisinin quality assessment. 
8.3.6.4 Consortium and non-consortium material 
To further explore the effect of environmental variation on the flavonoid profiles of Artemisia 
annua, Consortium-developed material grown in areas other than Cambridge (Surrey, Lincoln 
and Morocco) were assayed.   Table 17 shows the results. Samples 8Z – 8P were grown in 
Lincoln. 1046-7 and 1001-9 were grown in Surrey. Moroccan 1 and 2 – a Consortium bred line 
made by crossing 1053 with 1015 - were grown in Morocco. 
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Table 17. Artemisinin and flavonoid levels in Consortium material grown outside of Cambridge. Veg: 
vegetative plant. Flower: flowering plant. 
 
Sample Details Art 
% 
w/w 
CH-D % w/w Chryso % 
w/w 
Ratio 
CH-D: 
Art 
Ratio 
Chryso: Art 
8Z Harvested 
mid-
September 
2007 
0.3  0.004 0.08 0.01 0.27 
8Y 0.3 0.004 0.08 
0.01 
0.27 
8X Harvested late 
September 
2007 
0.6 0.012 0.06 0.02 0.1 
8V 0.5 0.006 0.03 
0.01 
0.06 
8P Harvested late 
October 2007 
0.4 0.003 0.03 
0.01 
0.075 
1046-7 Veg 
 
1.8 0.1 0.14 0.06 0.08 
1046-7 Flower 
 
1 0.06 0.08 0.06 0.08 
1001-9 Veg 
 
1.8 0.03 0.09 0.02 0.05 
1001-9 Flower 
 
1.4 0.1 0.06 0.07 0.04 
Moroccan 1 
 
0.5 0.012 0.058 0.02 0.12 (0.06) 
Moroccan A 
 
0.4 0.017 0.074 0.04 0.19 (0.008) 
Correlation Coefficient Chrysosplenol-D: Artemisinin 0.8 
Correlation Coefficient Chrysosplenetin: Artemisinin  0.6 
 
 
8.3.6.5 Correlation between flavonoid and artemisinin level 
When all the samples in Table 17 are considered together, a strong positive correlation (0.8) 
between artemisinin and chrysosplenol-D levels is observed. The correlation between 
artemisinin and chrysosplenetin is a little lower, standing at 0.6.   
 
8.3.6.6 Chrysosplenetin: artemisinin ratio – non-Cambridge material 
The above table (Table 17) shows that across a growth season outside of Cambridge, a wide 
range of chrysosplenetin: artemisinin ratios are seen, from 0.06 to 0.27. The case of 1046-7 is 
revealing: when grown in Cambridge, the ratio of chrysosplenetin to artemisinin in this variety 
ranged from 0.1 to 0.15 in 2007 and 2008 respectively – but in Surrey, in 2008, the ratio 
dropped to 0.08. The difference can be explained b the fact that in both locations, the 
chrysosplenetin levels were similar, but artemisinin levels in the Surrey-grown material were 
higher. 
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Additionally, the Consortium-developed but Moroccan grown material showed a 
chrysosplenetin: artemisinin ratio that differed according to drying methods. Both Moroccan 
samples were of a variety developed by crossing 1053 with 1015, but the sun-dried sample 
(Moroccan I) showed both a decrease in artemisinin and an increase in chrysosplenetin, 
compared to the “fast-dried” dried sample (Moroccan A). Both cases, though, showed much 
less artemisinin compared to Cambridge-grown material, and also much less chrysosplenetin.  
 
Finally, having examined the effects of different location on Consortium-material, the ratio of 
flavonoid to artemisinin in non-Consortium material was investigated. Table 18 shows the 
results of four non-Consortium samples.  
 
Table 18. Artemisinin and flavonoid levels in non-Consortium material. CH-D: chrysosplenol-D. Chryso: 
chrysosplenetin 
 
Sample ART % 
w/w 
Chrysosplenol-D  Chrysosplenetin Correlation 
coefficient, 
CH-D art 
Correlation 
coefficient, 
chryso: art 
% w/w Ratio 
FLAV: 
ART 
% w/w Ratio 
FLAV: 
ART 
Rutland, 
UK 
0.5 
(0.001)  
0.01 
(0)  0.02 (0) 
0.059 
(0.002) 
0.12 
(0.004)  
0.81 0.25 
Anamed 
(Swiss) 
0.8 
(0.014) 
0.04 
(0) 
0.05 
(0.0007)  
0.057 
(0.0007) 
0.07 
(0)  
Kenyan 0.9 
(0.07) 
0.06 
(0.006) 0.07 
0.1 
(0.06) 0.11 
Ghana 0.5 
(0.001) 
0.037 
(0) 
0.07 
(0.004)  
0.091 
(0.0007) 
0.19 
(0.002) 
 
The table above shows that in non-Consortium material, chrysosplenetin: artemisinin ratios 
range from 0.07 to 0.19, with the lowest ratio seen in the Anamed sample, and the highest in 
the Ghanaian. Striking, though, is the high degree of positive correlation between 
chrysosplenol-D and artemisinin level – a correlation that is not observed between artemisinin 
and chrysosplenetin. 
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8.3.7 Anti-tumour action of chrysosplenetin from Artemisia annua L. 
 
Figure 60. IC50 of chrysosplenetin against human breast cancer and normal human breast cells 
 
 
Chrysosplenetin – labelled on Figure 60 as “casticin” – showed selective toxicity to breast 
cancer cells as compared to non-cancerous breast cells. The IC50 of chrysosplenetin against 
cancerous cells (MDA-MB-468, shown in red diamonds) was 0.4 µM, whereas in non-cancerous 
cells (MCF10A, shown in blue triangles), the IC50 was much higher, at 20 µM. As the 
concentration needed to destroy 50% of normal cells was 50 times higher than that required 
to destroy 50% of cancer cells, the tumour selectivity of chrysosplenetin is said to be 50. 
 
8.4 Discussion 
8.4.1 Why quantify flavonoids of Artemisia annua? 
 
This exploration of flavonoid profiles in Artemisia annua began in 2007. Previous research had 
demonstrated the anti-cancer potential of methoxylated flavonoids (Kobayakawa et al., 2004), 
and it was thought that the presence of chrysosplenetin could add value to A. annua as a 
commercial crop – hence the interest in quantifying this compound in Consortium-grown 
material. It was during this quantification that the correlation of flavonoid levels with those of 
artemisinin were noticed.  
 
HPLC-DAD separation of extracts of A. annua showed a consistent pattern of four flavonoid-
type compounds (Figure 54), of which the peak eluting at 14.7 minutes was demonstrated, by 
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HPLC-MS and NMR comparison with a reference standard, to be chrysosplenetin. An earlier 
eluting peak chrysosplenol-D, based on LCMS analysis, but insufficient sample was available to 
allow for NMR analysis of this compound.    
 
8.4.2 Cambridge-grown material 
 
Initially, chrysosplenol-D and chrysosplenetin levels were quantified in three varieties of A. 
annua across a full harvest season (from late July or early August, to 11th October, 2007). The 
varieties were 1015 (a variety bred by the Swiss organisation Mediplant), 1046-7 (a high 
artemisinin variety bred within the consortium) and 1012-12 (a low artemisinin variety bred 
within the consortium). 
 
Chrysosplenol-D levels ranged from 0 in variety 1012-12, to 0.13% w/w in variety 1046-7.  
Chrysosplenetin levels ranged from 0.01% w/w, in variety 1012-12, to 0.18% w/w in variety 
1046-7.  
 
It was noticed in 2007 that chrysosplenol-D levels correlated positively (0.8 - 0.9) with 
artemisinin levels, and chrysosplenetin levels correlated positively (0.7 – 0.9) to artemisinin 
levels. The mean ratio of chrysosplenol-D to artemisinin was 0.07 (+- 0.02)– i.e. for every mg 
artemisinin, there was about 0.07 mg chrysosplenol-D.  The mean ratio of chrysosplenetin to 
artemisinin was 0.11 (+-0.02). This led to the question of whether chrysosplenetin level could 
be used as an indirect indicator of artemisinin level: a salient point when it is considered that 
artemisinin is difficult to quantify by UV-based detection methods, such as HPLC-DAD, and 
must instead be assayed by such means as LCMS. For those laboratories, particularly in the 
developing world, that do not have access to these more expensive means of detection, a 
reliable UV-based method would provide a suitable compromise.  
 
The following year (2008), eleven varieties of A. annua were assayed for chrysosplenol-D , 
chrysosplenetin and artemisinin content. Included in these eleven were the three varieties that 
had originally been assayed in 2007. Rather than assaying over the entire harvest season – an 
unfeasible amount of work for eleven varieties – samples were assayed from three 
environmental conditions: 
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1. Early in the harvest season (31st July 2008) 
2. Late in the harvest season (22nd September 2008 
3. Late in the harvest season following exposure to Glyphosate (crops 
sprayed with Glyphosate on 8th September 2008, and harvested on 
22nd September 2008) 
 
Again, a positive correlation between artemisinin and flavonoid content was seen – and the 
correlation was greatest (0.7 – 0.8) between artemisinin and chrysosplenol-D. The correlation 
was less strong (0.5 – 0.6) between artemisinin and chrysosplenetin. The mean ratio of 
chrysosplenol-D to artemisinin was 0.06 (+- 0.02), and the mean ratio of chrysosplenetin to 
artemisinin was 0.13 (+- 0.03). Both figures are similar to those observed in 2007. 
 
The effect of glyphosate on flavonoid content and hence flavonoid: artemisinin ratios was 
highly variable between different varieties of Artemisia annua – something that would have to 
be accounted for if flavonoid profiling were to be used to indirectly quantify artemisinin levels. 
  
8.4.3 Other material – Consortium material grown outside of Cambridge, and non-
Consortium material 
 
Upon examination of the chrysosplenol-D: artemisinin ratio in both consortium material grown 
outside of Cambridge, and in non-Consortium material, it became apparent that the 
chrysosplenetin: artemisinin ratio, whilst averaging at 0.04, shows too much temporal, 
geographical and genetic variation to provide a consistent, universal means of indirect 
artemisinin  assessment. Certainly, chrysosplenol-D levels could not be used to identify 
artemisinin levels in an unknown sample. 
 
A similar situation is observed with the chrysosplenetin: artemisinin ratio, which averaged at 
about 0.12.  
 
However, the results do show that flavonoid: artemisinin ratios are constant within batches 
(e.g., in material grown in one location during one summer, where material is harvested and 
dried in the same manner). In this case, the grower would have to determine the ratio for that 
batch early in the season – which could then be reliably presumed to remain constant. It has 
also become clear that a strong positive correlation between artemisinin and chrysosplenol-D 
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exists – this was present in all material assayed, both consortium and non-Consortium, within 
and outside of Cambridge. Such a link may be due to the fact that both artemisinin and the 
methoxylated flavonoids are trichome-based – as trichome number increases, the levels of all 
trichome-based components may be hypothesised to increase, so it may be that by measuring 
flavonoid level, the user is indirectly performing a trichome count. 
 
 As interesting as this information is, the usefulness of flavonoid quantification a as an indirect 
means of artemisinin quantification is fairly limited because of the extra-batch ratio variation, 
and it is reasonable to suppose that the TLC densitometry system of artemisinin quantification 
(described in Section 6) is a more reliable means of quality assessment for those without 
access to LCMS. However, this experiment does show that breeding new Artemisia annua 
varieties for high artemisinin content also results in plants with a high flavonoid content – 
potentially increasing the commercial value of the crop, as (discussed below) chrysosplenetin 
demonstrates potential as an anti-cancer medication. 
 
8.4.4 Anti-cancer potential of chrysosplenetin 
 
The data obtained in this study demonstrates that chrysosplenetin could have potential in the 
treatment of cancer – the compound was able to selectively inhibit the growth of human 
breast cancer cells at 0.4 µM, whilst non-cancerous cells remained unaffected up to levels 50 
times greater than this. Previous reports exist showing that methoxylated flavonoids can 
inhibit the growth of cancerous cells – casticin, for example, was shown, at levels of 0.24 µM, 
to inhibit growth of human squamous carcinoma cells in the G2-M phase. Cleary, this class of 
compounds deserves further attention as a potential source of anti-cancer drug therapy. 
 
8.5 Acknowledgements 
The author would like to thank Somchaiya Surichan and Dyan Ankrett, of the DMU Cancer Drug 
Discovery Group, for performing the anti-cancer assays of chrysosplenetin.
Section 9: Farnesol as an Inducer of Artemisinin Biosynthesis 
 
173 
 
9 Farnesol as an Inducer of Artemisinin Biosynthesis in 
Artemisia annua Hairy Root Cultures 
Synopsis 
An attempt was made to increase artemisinin yield in Artemisia annua hairy root cultures by 
feeding with exogenous farnesol. This sesquiterpene has been demonstrated, in cell cultures 
of Nicotiana tabacum, to form part of a signalling pathway that ultimately results in the up-
regulation of the mevalonic acid (MVA) pathway. It was hypothesised that uptake of farnesol 
by Artemisia annua hairy roots would result in increased artemisinin level, as a consequence of 
this up-regulation of the MVA pathway. Farnesol was added, at 12.5 µM to light- and dark-
grown cultures. Cultures were harvested after 18 days. 
 
No increase in artemisinin content was observed after this time. However, an increase in 
another, unidentified compound was observed, with mass fragments – by LCMS (ESI) – of 
203.2 and 267.2. These mass fragments match those of deoxyartemisinin, but the retention 
time of the unknown suggested it was another, as yet unidentified, compound. 
 
9.1 Introduction 
Any means by which overall artemisinin yields can be increased are worthy of investigation. 
This objective has typically been pursued pre-harvest by the spraying of crops with plant 
hormones, such as the gibberellins (Zhang et al., 2005), or with modification of nutritional 
regimes (Davies et al., 2009).  
 
Post-harvest, appropriate drying regimes can increase artemisinin yields by optimising the 
post-harvest conversion of precursors to artemisinin (Ferreira et al., 2010).   
 
For rapid testing of the effects of pre- and post-harvest treatments on artemisinin yield, a 
model system for the field crop is necessary. Greenhouse grown plants can take several 
months to reach maturity, and space considerations render use of such plants unwieldy. 
Axenic shoot cultures of the plant – developed in-house and shown to produce artemisinin at 
yields of around 10% that of field-grown plants (a figure also reported by other researchers 
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(van Geldre et al., 1997)) – would be the ideal model system, but they are difficult to maintain 
and hence the production of the volume of shoot material needed for assay is unlikely. 
 
Hairy root cultures, however, are easy to maintain and fast-growing: large volumes of material 
can be produced within weeks.  The major difficulty in the use of Artemisia annua hairy roots 
(AAHR) as a model system for the whole plant is the low level of artemisinin produced by such 
cultures. When grown under dark conditions – as is typical for root cultures – artemisinin is 
typically absent, or present only at trace levels. Reports exist demonstrating that artemisinin 
content in hairy roots can be increased to 1.8 % w/w (dry weight) when roots are grown under 
16 hours of 3000 Lux white light (Liu et al., 2002), and to 3.1% w/w (dry weight) by the 
utilization of red light (Wang et al., 2001). The former level is comparable to the leaf matter of 
a high-yielding Artemisia annua whole plant, and the latter exceeds any reported value for A. 
annua leaf artemisinin content.  
 
Such reports clearly show that under optimal environmental conditions, biosynthesis of 
artemisinin can be induced in root cultures of Artemisia annua – demonstrating the validity of 
cultures as a model system for the assay of means of increasing artemisinin production.  
 
In this study, AAHR were cultivated in the presence offarnesol (as a mixture of isomers). The 
reasoning behind the feeding of farnesol brings us to a brief discussion of the biosynthesis of 
artemisinin. 
 
9.1.1 Biosynthesis 
Farnesyl diphosphate (FPP) – a key intermediate at the point where the mevalonate pathway 
branches into sterols and sesquiterpenes - can be synthesised, in vivo, by two mechanisms - 
either via farnesol phosphokinase-mediated phosphorylation of farnesol, or by farnesyl 
diphosphate synthase -mediated condensation of IPP with DMAPP or GPP. The former was 
first demonstrated in 1995, when 100,000 g pellets from the micro-alga Botryococcus braunii 
were found to be able to selectively convert farnesol to both the mono- and diphosphorylated 
forms, in the presence of the cofactor cytidine triphosphate (Inoue et al., 1995), but this 
mechanism has not yet been demonstrated in Artemisia annua. 
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 The latter forms part of the later stages of the mevalonate biosynthetic pathway (MVA 
pathway) in Artemisia annua L, discussed in detail in Section 1.3. In this pathway, FPP – formed 
from the farnesyl diphosphate synthase-mediated condensation of isopentenyl diphosphate 
(IPP) with dimethylallyl diphosphate (DMAPP) or geranyl diphosphate (GPP) - is the precursor 
to both the plant sterols and to the sesquiterpenes; the former, via the enzyme squalene 
synthase, and the latter, via amorpha-4,11-diene synthase  (Bouwmeester et al., 1999).  
 
Figure 61. The two pathways involved in artemisinin biosynthesis. From Towler and Weathers (2007) 
 
 
9.1.2 Farnesol as an inducer of the mevalonate pathway 
 It had previously been demonstrated that feeding of 1-3H labelled E-E-farnesol to cell cultures 
of Nicotiana tabacum resulted in similarly labelled free sterols - the predominant end product 
of the mevalonate pathway (Hartmann and Bach, 2001). This experiment elegantly 
demonstrated that exogenous farnesol is capable of being utilised in the biosynthesis of MVA-
derived compounds.  
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The question remains, though, of whether there is a quantitative advantage to feeding of 
exogenous farnesol – that is, are the levels of compounds downstream of FPP actually 
increased as a result of such feeding? Farnesol itself is not an elicitor (that is, it is not part of 
the plant defensive signalling pathway, unlike, for example, salicylic acid, although it is a 
signalling molecule in bacterial quorum sensing). But Hemmerlin and Bach (Hemmerlin and 
Bach, 2000), reporting that exogenous farnesol could partially reverse mevinolin5 -induced 
inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR)6 claim that that 
farnesol may have a regulatory effect on an early step of isoprenoid biosynthesis.  
 
They reached this conclusion from the surprising observation that, contrary to previous reports 
of a farnesol-mediated degradation of HMGR in mammalian cells (Correll et al., 1994), in N. 
tabacum cell cultures, exogenous farnesol (at levels below 12.5 µM) induced microsomal 
HMGR activity. Crucially, addition of farnesol at this same concentration, but to an in vitro 
preparation of the enzyme, did not induce enzyme stimulation. This observation prompted the 
study’s authors to claim that the “previously observed activation [of HMGR, by farnesol] was 
not due to a direct interaction of the compound with the protein”, but was in fact part of a cell 
signalling pathway leading to the upregulation of the enzyme. As such, it is feasible that 
addition of exogenous farnesol to Artemisia annua hairy root cultures can, by up-regulating 
this rate-controlling enzyme, result in increased levels of artemisinin in the roots. 
 
9.1.3 This study 
It was hypothesized that adding exogenous farnesol to the nutrient medium in which AAHR 
were cultivated, and thereby increasing the pool of farnesol to the cell’s machinery, would 
result in increased biosynthesis of FPP by providing a substrate for farnesol phosphokinase. 
Furthermore, as Hemmerlin and Bach report, farnesol is capable of up-regulating the activity 
of the MVA pathway in plant cells. So, it was further hypothesised that via both of these 
 
5 Mevinolin is a fungal metabolite isolated from Aspergillus terreus. It acts to inhibit the enzyme 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR; also HMC-CoA reductase [see Footnote 4]), the 
rate-controlling enzyme of the mevalonate biosynthetic pathway. Mevinolin blocks the formation of 
mevalonic acid from HMG-CoA. Because of this function, mevinolin – under the generic name of 
Lovastatin - has found applications in the pharmaceutical industry as an inhibitor of cholesterol 
biosynthesis (HR Valera 2005).  
 
6 “3-hydroxy-3-methylglutaryl-coenzyme A” and “β-hydroxy-β-methylglutaryl-CoA” are synonyms; both 
are written in shorthand as HMG-CoA. HMGR – also written as HMG-CoA reductase - refers to the 
enzyme that catalyses the reduction of this compound. 
Section 9: Farnesol as an Inducer of Artemisinin Biosynthesis 
 
177 
 
mechanisms, the artemisinin levels of AAHR would be increased following exposure to 
exogenous farnesol. 
 
As several reports exist demonstrating that hairy roots of A. annua grown under light 
conditions produce more artemisinin than those grown under dark conditions, it was decided 
to compare the effect of exogenous farnesol on both light and dark grown roots. Souret 
(Souret et al, 2003) showed that transcription of the enzyme farnesyl diphosphate synthase 
(FPPS), which catalyses the formation of FPP via the condensation of IPP and DMAPP, was 
slightly upregulated in light-grown hairy roots compared to dark-grown, and that transcription 
levels of this enzyme correlated positively with artemisinin level7. 
 
In this experiment, hairy roots of Artemisia annua were cultivated under the following 
conditions (all at 27°C):  
 
1. Under dark conditions 
2. Under dark conditions, in the presence of farnesol at a level hypothesised to induce 
HMGR   
3. Under light conditions   
4. Under light conditions, in the presence of farnesol at a level hypothesised to induce 
HMGR  
 
 
Under dark conditions, it would be expected that FPPS is transcribed only at low levels, if at all, 
and so downstream products such as artemisinin would not be predicted to be present at 
detectable levels unless another enzyme (a putative farnesol phosphokinase for example) was 
active.  Under light conditions, FPPS would be predicted to be upregulated, therefore 
producing FPP – and, downstream, artemisinin at detectable levels - even in the absence of 
farnesol phosphokinase-mediated mechanism of FPP formation.  
 
 
7 It should be pointed out that this light-induced, FPPS-catalysed formation of FPP is distinct from the 
farnesol phosphokinase- catalysed mechanism of FPP formation that is hypothesised to be affected by 
exogenous farnesol. The latter mechanism has not been shown to be affected by light.   
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In the absence of exogenous farnesol, no farnesol-induced upregulation of HMGR would be 
predicted. But if exogenous farnesol does, as Hemmerlin and Bach claim, upregulate this 
enzyme, then an increase in MVA pathway activity and hence artemisinin level may be 
observed.  
 
It was hypothesized that condition 4 – in which both farnesol-phosphokinase, FPPS and HMGR 
activity can be speculated to be present - would produce the highest levels of artemisinin in 
Artemisia annua hairy roots.  
 
9.2 Materials and Methods 
9.2.1 Production of hairy roots of A. annua 
Seeds of A. annua 1057 – a gift from Steven Bentley at the National Institute of Agricultural 
Botany - were sterilized by first swirling in 70% ethanol for 5 minutes, and then swirling in a 5% 
aqueous mixture of hypochlorite for 15 minutes. Seeds were then washed several times with 
double distilled, sterilized water and axenically placed into small jars partly filled with MS 
medium, pH adjusted with 1M sodium hydroxide to pH 5.8, and solidified with Phytagel. Jars 
were capped, and the seedlings left to geminate under a 16 hour photoperiod.  
At six weeks, seedlings were inoculated with Agrobacterium rhizogenes LB902. A. rhizogenes 
was prepared by plating out cultured bacterium onto yeast mannitol plates supplemented with 
acetosyringone. The bacterium was cultivated for 48 hours on this medium, after which it was 
used for inoculation. To inoculate the seedlings, a small wound was made in the stem of each 
seedling using a sterile scalpel. To this wound was applied a small amount of inoculum.  
After 4 weeks, some seedlings showed the appearance of hairy roots at the wound site. These 
roots were removed and placed onto Murashige and Skoog (MS) basal cell culture media, 
solidified with Phytagel and supplemented with sucrose at 3% w/v and cefotaxime at 0.1g/L. 
The roots were cultured in the dark at 27°C and transferred onto new cefotaxime-containing 
media every 3 days until axenic growth was established; thereafter roots were cultured on the 
same media without cefotaxime. 
 
 
 
Section 9: Farnesol as an Inducer of Artemisinin Biosynthesis 
 
179 
 
9.2.2 Culturing of hairy roots in the presence of exogenous farnesol 
To 250 ml Erlenmeyer flaks containing 50 ml of sterilized liquid MS media, supplemented with 
3% sucrose, 1 g of A. annua hairy roots tips were added. Tips were taken from cultures grown 
for 18 days on solidified MS and sucrose solidified media, as described above. To half of the 
liquid cultures farnesol, prepared as a solution in DMSO, was added at a final concentration of 
12. 5 µM. To control cultures, equal volumes of DMSO were added.  
 
9.2.3 LCMS for the quantification of artemisinin 
 
LCMS was performed as described in Section 3.2.2. – 3.2.3. 
 
9.2.4 Fluorescence quantification 
Fluorescence of root media was quantified with the use of a SpectraMax 96-well plate reader, 
using SoftMax Pro software.  Wells were filled with 200 µl media. Excitation was set at 350 nm, 
and emission was read at 400 nm. 
 
9.3 Results 
 
Table 19. Root growth and chemical profile of Artemisia annua hairy root cultures, with and without 
exposure to exogenous farnesol 
 
Treatment Mass of roots 
(dry weight, 
g) 
Loss on 
drying (%) 
Artemisinin as 
mg/kg dry 
weight 
Fluorescence of 
media (Fl. 
units/ml) 
Putative 
unknown 
g/kg dry 
weight 
Dark 0.2 (0.07) 
 
 
89.9 (1.2) 
 
 
1.0 (1.7) 
 
 
0.61 
(0.10) 
3.8 (0.2) 
Dark and 
Farnesol 
0.3 (0.07) 
 
90.8 (0.3) 
 
0 0.38 (0.12) 13.1 (8.1) 
Light 0.6 (0.07) 
 
93.4 (0.7) 
 
2.0 (0.6) 
 
 
 
0.23 (0.12) 
 
1.3 (0.6) 
Light and 
Farnesol 
0.5 (0.06) 
 
 
92.7 (0.6) 
 
 
1.6 (0.9) 
 
0.24 
(0.05) 
4.7 (0.3) 
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9.3.1 Growth of hairy roots 
 
As Table 19 shows, light-grown hairy roots reached a greater final mass, as compared to those 
kept under dark conditions – at the end of the growth cycle, the mass of light-grown roots 
ranged from an average of 0.6 g dry weight in control root cultures, to 0.5 g in light-grown 
roots exposed to exogenous farnesol. The mass of dark-grown root cultures ranged from 0.2 g 
to 0.3 g dry weight, with the former being control cultures and the latter exposed to 
exogenous farnesol.  
 
Farnesol could not be demonstrated to have any significant effect, positive or negative, on 
final root mass, regardless of whether roots were cultivated under light or dark conditions.  
However, growing roots under light conditions did slightly increase the water content of those 
roots, as evinced by the increased loss on drying observed in light-grown root cultures.  
 
9.3.2 Chemical content of hairy roots in farnesol-exposed and control samples 
9.3.2.1 Artemisinin 
Artemisinin content was very low in all cases, ranging from undetectable in dark-grown roots 
exposed to farnesol, to 2.0 mg/kg DW in light-grown roots without exogenous farnesol. It will 
be noted that the standard deviation for this mean artemisinin content of dark-grown roots 
without farnesol is actually higher than the mean itself, because of large difference in 
individual results within this sample set. No significant difference between the artemisinin 
content of light-grown roots, whether treated with farnesol or not, could be observed. 
Deoxyartemisinin was not detected in any cultures. 
 
9.3.2.2 Fluorescent root exudates 
 
It was observed by the author that roots of Artemisia annua L. – both in vitro and in vivo – 
exude a fluorescent compound or compounds into the aqueous surroundings – soil, in the case 
of whole plants, or liquid media in the case of hairy roots (Figures 62 – 63). The fluorescence 
displays a maximum in the region of 350 – 400 nm. 
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Figure 62. Hairy root cultures of A. annua, growing on Phytagel solidified MS media containing 3% w/v 
sucrose, exhibitng root fluorescen 
 
 
 
Figure 63. Liquid MS medium in which hairy root cultures of A. annua had grown for 21 days, 
exhibiting fluorescent exudates. 
 
Difficulties in isolation of these highly polar compounds have prevented separation and 
purification of the compound/s responsible for this rare phenomenon of root fluorescence. To 
date, all that can safely be claimed as regards the nature of the fluorescent compound/s is 
that, as a positive response to ninhydrin is observed, a nitrogenous class of compound can be 
postulated – perhaps an iminosugar, or an amino-acid derivative. 
 
The level of fluorescent root exudates, which were measured in arbitrary units of fluorescence 
and converted here to units of fluorescence/mg root (DW), appears upon first glance to be 
highest in those roots that were grown under dark conditions, without farnesol.  But it should 
be borne in mind that the actual root mass was considerably lower in these dark grown roots, 
artificially inflating the fluorescence/root mass ratio. What this may show, though, is that 
fluorescent root exudates build up to a final concentration in the earliest days after 
inoculation, and do not increase further after that point, regardless of whether root mass 
continues to increase.  
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9.3.2.3 Unknown compound 
 
Finally, an unknown compound, with a mass spectrum containing two major fragments of 
mass 203.2 and 267.2, was observed. Although these fragments match those obtained by the 
electrospray ionisation-induced fragmentation of deoxyartemisinin, the retention time of this 
unknown compound, at 6.8 minutes, differed from deoxyartemisinin (which under this 
separation system elutes at 5.2 minutes). 
 
A clear difference between levels of this compound was observed in the sample sets: notably, 
those roots treated with farnesol showed greater levels of this compound as compared to 
equivalent roots that were not exposed to farnesol. A strong inverse correlation of -0.8 was 
observed, in dark-grown roots exposed to farnesol, between artemisinin levels, and levels of 
this unknown: that is, the higher the artemisinin level, the lower the level of this unknown. The 
correlation was  -0.6 in light-grown roots with no exogenous farnesol.  No correlation was 
observed in dark-grown roots without farnesol.  
 
It should be noted that as no reference compound for this unknown was available, the levels 
of the compound were calculated using the deoxyartemisinin calibration curve, which may not 
be appropriate – hence the description of “putative” level. However, the correlation between 
artemisinin and this unknown should still hold.  
 
9.4 Discussion 
It is clear from this short experiment that the application of exogenous farnesol to hairy root 
cultures of Artemisia annua L. did not result in an increase in artemisinin levels: if anything, a 
slight decrease was observed, although this decrease was not significant. It was also notable 
that artemisinin level, even in light-grown roots, were very low: certainly not at the levels (up 
to 3.1 % w/w DW, equivalent 31 g/kg) that have occasionally been reported by other 
researchers, described more fully in Section 9.1. However, these authors did utilise light either 
quantified in Lux, or of limited wavelength (i.e. red light). In the study reported here, roots 
were grown under general plant growth room lighting.  
 
In dark-grown roots with exposure to exogenous farnesol, and in light-grown roots without 
this exposure, an inverse correlation between artemisinin level, and level of an unknown 
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compound which may have the same molecular mass as deoxyartemisinin, was observed. But 
it is difficult to explain why such correlations were not observed in dark-grown roots without 
exposure to farnesol. It may be that both light and exogenous farnesol, independently, trigger 
production of this compound, which may be a degradation product of artemisinin, as 
deoxyartemisinin, and 10-hyrdroxydeoxyartemisinin, are hypothesised to be (Creek et al., 
2005).   
 
9.4.1 Why no increase in artemisinin following farnesol exposure? 
It may be speculated that addition of exogenous farnesol, in an attempt to increase the pool of 
farnesyl diphosphate available to the mevalonate pathway, could not increase final artemisinin 
levels directly, because current research demonstrates that artemisinin has a mixed 
biosynthetic origin – that is, the component parts of the molecule are derived from both the 
mevalonate and the deoxyxylulose pathways, as discussed in Section 1.3 and illustrated in 
Figure 61.  The most that this experiment may have done is increased levels of a precursor to 
artemisinin.  
 
Additionally, it may be that sterols were increased during this experiment, instead of 
sesquiterpenes. As no sterols were quantified, this is a question that cannot be answered.  
 
It is more likely, perhaps, that – as has been reported in other papers – the presence of 
farnesol, or a product thereof actually acted to induce HMGR degradation. This is a situation 
known to occur in yeast and mammalian cells, although, as described in the introduction to 
this section, in Nicotiana tabacum cell cultures, farnesol actually upregulated HMGR. However, 
as Cronin et al. report (Cronin et al, 2000), HMGR can undergo “regulated 
degradation...including control by a signal derived from the mevalonate pathway product 
farnesyl pyrophosphate” – as part of a feedback mechanism. So, excess FPP can actually inhibit 
the MVA pathway and hence reduce levels of MVA-derived compounds. 
 
9.4.2 Summary 
It is clear from this short experiment that much more work is needed to determine the effect 
of exogenous farnesol on the biosynthesis of artemisinin - and also to determine whether the 
phosphokinase-mediated conversion of farnesol to farnesyl diphosphate even occurs in 
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Artemisia annua, or whether – as is perhaps more probable – FPP is only formed via 
condensation of IPP and DMAPP.  
 
Additionally, greatly increasing the sample size, to reduce statistical variation, and sampling 
root cultures more frequently throughout the growth cycle, would have improved the clarity of 
the data in this experiment. 
 
Other research groups have had more success with feeding of salicylic acid to Artemisia annua 
axenic plantlets. This compound has recently been shown to up-regulate expression of the 
HMGR gene in the 24 hours following administration, and it also triggered a temporary 
increase in expression of the gene for amorphadiene synthase, the first enzyme of the branch 
of the MVA pathway leading to artemisinin. However salicylic acid did not affect regulation of 
farnesyl diphosphate synthase (Pu et al., 2009). Pu et al., and Guo et al. a year later, showed 
that salicylic acid also increases artemisinin levels by inducing an oxidative burst: a shower of 
singlet oxygen, which triggers non-enzymatic conversion of dihydroartemisinic acid into 
artemisinin. But whether the application of such compounds will be feasible on an agricultural 
scale is still to be decided. 
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10 Artemisia annua as Self-Medication 
Synopsis 
Dried leaf material of Artemisia annua, known to contain artemisinin at 0.6% w/w, was used to 
prepare herbal teas. The teas were produced either by decoction or by infusion, and the 
preparations were assayed for artemisinin, deoxyartemisinin and chrysosplenetin content. 
Teas were also prepared using water containing dissolved ferrous salts, to test the effect of 
these common water contaminants on artemisinin stability in the traditional preparations.  
Over-the-counter preparations of Artemisia annua (in the form of tinctures, capsules of dried 
powdered leaf and capsules of active pharmaceutical ingredient) were similarly assayed for 
relevant phytochemicals. 
 
Artemisinin levels were higher in infusions than decoctions, but the reverse was true for 
chrysosplenetin. Preparations made using iron-contaminated water contained more 
artemisinin than those prepared using double-distilled water. Deoxyartemisinin levels did not 
increase as artemisinin levels decreased, indicating that the latter is not degraded to the 
former. 
 
Over the counter preparations were generally of poor quality, some containing no detectable 
artemisinin or chrysosplenetin. The exception was a batch of capsules advertised as containing 
100mg pure artemisinin, which contained on average 80 mg of the active pharmaceutical 
ingredient.  
 
10.1 Introduction 
Artemisinin was first isolated and identified in 1972, and the molecule was licensed in China in 
1986. In the few years that have followed the drug’s discovery, artemisinin has come to form 
the basis of front-line antimalarial therapy in much of the world, in the form of artemisinin-
combination therapy, or ACT (Schlitzer, 2008) 
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10.1.1 Non-tablet forms of Artemisia annua L. 
Despite the undisputed efficacy of ACT, the drugs do remain out of the reach of many who 
need them, whether for economical or geographical reasons (Bate and Hess, 2009). For that 
reason, there are those who propose that self-medication with preparations of Artemisia 
annua L. is a suitable alternative for ACT, under some circumstances. Amongst those making 
these case are the Research Initiative into Traditional Antimalarial Medicines (RITAM), who 
argue that the use of teas made of Artemisia annua leaf is sustainable as an emergency 
treatment for malaria for those living in remote areas (Willcox, 2004). Action for Natural 
Medicine, or Anamed, a charity based on Germany, provide Artemisia annua “starter kits”, 
consisting of seeds and instruction for growth, drying and use of the dried herb as an infusion, 
although they do recommend that the tea is used in combination with another antimalarial, 
and that only those resident in malarial-endemic regions make use of the tea – i.e. tourists 
should not use it as prophylaxis. 
 
Both RITAM and Anamed are concerned with the health of locals living in malaria-endemic 
regions, and not with those wishing only to travel on leisure or business.  However, numerous 
internet-based herbalists target Western tourists, promoting preparations of Artemisia annua 
as tinctures, capsules containing powdered leaf, and capsules containing purified artemisinin. 
A few sites carry testimonials from users of these products, like that from one user: “I am 
happy to have found a natural substance that can help protect me on my business travels to 
Asia and Africa; I have never enjoyed using the regular anti-malaria tablets”.  
 
The World Health Organisation’s stance on these alternative preparations of Artemisia annua 
L. is one of disapproval. In a statement, the WHO writes that “Since the World Health 
Organization (WHO) recommended the use of artemisinin-based combination therapies for 
malaria in 2001, a number of other forms of Artemisia annua L for use as anti-malaria 
‘remedies’ have appeared”, and that the “WHO does not recommend the oral use of any form 
of artemisinin other than capsules and tablets”. In particular, they note that it is virtually 
impossible for a tea bag to contain the amount of artemisinin required to effectively treat 
malaria (WHO, 2008).  
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10.1.2 This Study 
In this study, the chemical profiles of a range of non-tablet forms of Artemisia annua L. were 
assayed. In the first part of the study, teas were prepared from dried leaf of Artemisia annua L. 
Teas were prepared as 1g herb in 40 ml water, and were prepared as either infusions or 
decoctions. In addition, the effect of the presence of iron salts in the water used to prepare 
the tea was studied. It is known that the peroxide group in artemisinin reacts with ferrous iron 
in a Fenton-type reaction, yielding radical intermediates and deoxygenated (and therefore 
pharmaceutically inactive) end-products, such as deoxyartemisinin and 3-
hydroxydeoxoartemisinin. Whilst this reaction is essential to the anti-malarial activity of 
artemisinin in the infected red blood cell, it would be unfortunate if the reaction took place - 
and artemisinin was deoxygenated - before the medication has even entered the body.  
 
The levels of ferrous salts added to water were chosen to reflect levels typically found in 
drinking water. The highest level added (600 µg/L) was chosen as it exceeds palatable level 
(WHO, 2008).   
 
In the second part of the study, over-the-counter (OTC) preparations of Artemisia annua L. 
were purchased from online retailers. Tinctures, capsules of powdered dried leaf, and capsules 
of purified artemisinin were assayed. 
 
All samples – teas and OTC preparations – were assayed for artemisinin, deoxyartemisinin, and 
chrysosplenetin.   
 
10.2 Materials and Methods 
10.2.1 Infusions 
Extraction: distilled water. 1g of dried Artemisia annua was weighed and placed into a 100 ml 
Erlenmeyer flask. Distilled water was heated on a hot plate to a temperature of 90°C, upon 
which 40 ml was added to the dried herb. The mixture was stirred with a glass rod and set 
aside for 10 minutes, with regular stirring.  After this time, the mixture was filtered through 
muslin and the herb squeezed to remove all excess liquid. Filtrate was cooled on ice and 
extracted in 3 x 40 ml dichloromethane. Pooled dichloromethane fractions were dried on a 
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rotavapor at 50°C, and assayed by LCMS for artemisinin and deoxyartemisinin content, and 
HPLC-DAD for chrysosplenetin content.  All samples were prepared in quadruplicate. 
 
Extraction: water containing iron salts. High iron: To 1L distilled water was added 600 µg of 
either ferrous sulfate or ferrous chloride tetrahydrate. Low iron: To 1L distilled water was 
added 150 µg of either ferrous sulfate or ferrous chloride tetrahydrate.  Samples using iron-
contaminated water were prepared as above. 
 
10.2.2 Decoctions 
Extraction: distilled water. 1g of dried Artemisia annua was weighed and placed into a 100 ml 
Erlenmeyer flask. To this was added 40ml of water. The mixture was stirred with a glass rod 
and brought to the boil on a hotplate. The mixture was kept boiling, with regular stirring, for 
10 minutes. After this time, the mixture was filtered through muslin and the herb squeezed to 
remove all excess liquid. Filtrate was cooled on ice and extracted in 3 x 40 ml dichloromethane. 
Pooled dichloromethane fractions were dried on a rotavapor at 50°C, and assayed by LCMS for 
artemisinin and deoxyartemisinin content, and HPLC-DAD for chrysosplenetin content. All 
samples were prepared in quadruplicate. 
 
Extraction: water containing iron salts. High iron: To 1L distilled water was added 600 µg of 
either ferrous sulfate or ferrous chloride tetrahydrate. Low iron: To 1L distilled water was 
added 150 µg of either ferrous sulfate or ferrous chloride tetrahydrate.  Samples using iron-
contaminated water were prepared as above. 
 
10.2.3 Analytical conditions  
LCMS conditions for the assay of artemisinin are described in Section 3.2.3. LCMS conditions 
for the assay of deoxyartemisinin are identical, except that the ions quantified for 
deoxyartemisinin were 203.2 and 267.2. A separate calibration curve of deoxyartemisinin over 
santonin was prepared, using reference samples of deoxyartemisinin ranging from 2.5 to 15 
µg/ml, and santonin as internal standard at 20 µg/ml.  HPLC-DAD conditions for the assay of 
flavonoids are described in Section 8.4.3.2. 
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10.3 Results 
Table 20, below, shows the amount, in mg, of artemisinin, deoxyartemisinin and 
chrysosplenetin extracted from 1g of dried Artemisia annua by 40 ml water infusion or water 
decoction. 
 
Table 20. Artemisinin, deoxyartemisinin and chrysosplenetin levels in teas of Artemisia annua L. A 
dichloromethane  extract, prepared under the same conditions (i.e. 1g in 40 ml DCM) is shown for 
comparative purposes 
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Table 21 shows the artemisinin, deoxyartemisinin and chrysosplenetin level, as % w/w, in 
three over-the-counter capsules prepared from Artemisia annua L.  
 
Table 21. Artemisinin, deoxyartemisinin and chrysosplenetin content of capsules of prepared 
Artemisia annua L. 
 
Capsules Artemisinin % w/w Deoxyartemisinin % 
w/w 
Chrysosplenetin 
% w/w 
Manufacturer A, 
Powdered Herb 
Capsules.  
425 mg/capsule.   
0.008 (0.002) 0.007 (0.002) 0.06 (0.001) 
Manufacturer B, 
Powdered Herb 
Capsules  
750 mg 
Artemisia leaf/3 
capsules.   
0 0 0 
Manufacturer A,  
Artemisinin 
Capsules 
100 mg art per 
capsule  
37.8 (1.4) 0.2 (0.002) 0 
 
 
Table 22 shows the artemisinin, deoxyartemisinin and chrysosplenetin level, as µg/ml, in two 
over-the-counter tinctures of Artemisia annua L.  
 
Table 22. Artemisinin, deoxyartemisinin and chrysosplenetin content in tinctures of Artemisia annua 
L. 
Tinctures Artemisinin  µg/ml Deoxyartemisinin 
µg/ml 
Chrysosplenetin µg/ml 
Manufacturer C, 
1:5 Tincture, 45% 
Ethanol 
0 7.2 (2.5) 30 (0.07) 
Manufacturer D, 
1:4 tincture, 55% 
Ethanol  
20.5 (2.4) 0.9 (0.5) 200 (0.5) 
 
10.3.1 Artemisia annua tea 
10.3.1.1 Extraction efficiency 
Solvent extraction of Artemisia annua L. by dichloromethane resulted in the highest recovery 
of artemisinin – 5.8 mg from 1g of dried herb. Compared to this, the lowest extraction 
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efficiency for artemisinin – 8.6 % - was observed in decoctions prepared using distilled water. 
The highest extraction efficiency for artemisinin – 28.8 % - was observed in infusions prepared 
using low levels of ferrous sulfate.  
 
 Solvent extraction of Artemisia annua L. by dichloromethane resulted in the highest recovery 
of chrysosplenetin – 0.48 mg from 1g of dried herb. Compared to this, the lowest extraction 
efficiencies for chrysosplenetin – 6.3 % - were observed in infusions prepared using distilled 
water, and infusions prepared with low and high levels of ferrous sulfate. The highest 
extraction efficiency for chrysosplenetin – 14.6 % - was observed in decoctions prepared using 
high levels of ferrous chloride. 
 
10.3.1.2 Tea prepared from distilled water – infusions vs. decoctions 
It is clear from the results that water infusions of Artemisia annua L. contain more artemisinin 
than water decoctions – 0.84 mg on average, as compared to 0.5 mg. Whether this is because 
of higher extraction efficiency of infusions as compared to decoctions, or increased 
degradation of artemisinin in decoctions compared to infusions, is unclear. What is clear is that 
although more deoxyartemisinin is observed in the decoction – which may indicate 
degradation of artemisinin – in fact, the overall ratios of artemisinin to deoxyartemisinin do 
not change between infusions and decoctions. Both contained deoxyartemisinin at around 
14% of the artemisinin level (for comparison, deoxyartemisinin in the solvent extract was 10% 
of the artemisinin level). 
 
This evidence suggests that if artemisinin is degrading in the decoctions, it is not degrading to 
deoxyartemisinin – as if it were, then deoxyartemisinin levels would be expected to rise 
concurrently with a decrease in artemisinin levels.  Higher levels of chrysosplenetin were 
observed in decoctions compared to infusions.  
 
10.3.1.3 Effect of ferrous sulfate on artemisinin and deoxyartemisinin level 
The presence of ferrous sulfate resulted in increased levels of artemisinin and 
deoxyartemisinin in the extracts, as compared to extracts prepared using distilled water.  This 
was true for both infusions and decoctions, and for both low and high levels of ferrous sulfate.  
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At low ferrous sulfate levels, infusions contained an average of 1.67 mg artemisinin, compared 
to 1.24 mg in decoctions. At high levels of ferrous sulfate, infusions contained 1.03 mg, 
compared to 0.61 mg in decoctions. So it is apparent that a dose-dependent effect of ferrous 
sulfate on artemisinin content is seen - high levels of ferrous sulfate result in lower artemisinin 
in extracts compared to lower ferrous sulfate levels. But even extracts containing high ferrous 
sulfate levels contained more artemisinin than extracts prepared using distilled water alone.  
 
Deoxyartemisinin content did not vary between infusions and decoctions prepared in low 
levels of ferrous sulfate, being about 0.3 mg in both types of extraction. Deoxyartemisinin 
content did not significantly vary between infusions and decoctions prepared in high levels of 
ferrous sulfate, being about 0.16 in the former and 0.13 mg in the latter. This is evidence that if 
the low artemisinin level in decocted samples containing higher levels of ferrous sulfate is due 
to degradation of artemisinin, then artemisinin is not degraded to deoxyartemisinin but to 
some other compound.  
 
In decoctions, a reduced amount of chrysosplenetin was observed in samples prepared using 
low ferrous sulfate levels compared to those prepared in either water, or water containing 
high ferrous sulfate levels. The presence of ferrous sulfate, at either level, had no effect on 
chrysosplenetin level of infusions.  
 
10.3.1.4   Effect of ferrous chloride on artemisinin and deoxyartemisinin level 
The presence of ferrous chloride resulted in increased levels of artemisinin and 
deoxyartemisinin in the extracts, as compared to extracts prepared using distilled water.  This 
was true for both infusions and decoctions, and for both low and high levels of ferrous 
chloride.  
 
At low levels of ferrous chloride, a large difference between artemisinin content in decoctions 
as compared to infusions was observed – 0.82 mg in the former, 1.65mg in the latter. 
Artemisinin content did not change significantly when high levels (as compared to low levels) 
of ferrous chloride were used in decoctions – an average of 0.83 mg was observed in these 
samples – but high ferrous chloride levels in infusions resulted in a drop in artemisinin 
contents compared to low ferrous sulfate infusions (1.29 mg in the former, compared to 1.65 
mg in the latter).  
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Despite the striking difference in artemisinin content in infusions vs. decoctions prepared using 
low ferrous chloride levels (1.65 mg compared to 0.82 mg), very little difference in 
deoxyartemisinin content was observed ( 0.33 mg in infusions, 0.29 mg in decoctions). Again 
this suggests that if artemisinin is degraded in decoctions, the degradation product is not 
deoxyartemisinin.  
 
Further evidence for this is presented by the fact that a large difference in artemisinin content 
was observed between decoctions and infusions prepared using high levels of ferrous chloride 
(0.83 mg compared to 1.29 mg, respectively), but no significant change in deoxyartemisinin 
level is observed between these two types of sample. Again, it would be expected that of 
ferrous salts catalyse the conversion of artemisinin to deoxyartemisinin, that deoxyartemisinin 
levels would rise as artemisinin levels fall.  In fact, when all samples prepared in this tea study 
are taken into account, a positive correlation of 0.9 is observed between artemisinin and 
deoxyartemisinin levels – strongly suggesting that one is not converted to the other. 
 
In decoctions, an increased amount of chrysosplenetin was observed in extractions prepared 
using high levels of ferrous chloride as compared to low (0.07 mg as compared to 0.04 mg, 
respectively). No difference in chrysosplenetin content between high and low levels of ferrous 
chloride was observed in infusions.   
 
10.3.2 Summary of tea 
In summary, it was found that the presence of iron salts, at either 150µg/L or 600 µg/L, 
resulted in higher artemisinin levels in the final extract than distilled water alone. This was true 
for both infusions and decoctions, although in all cases infusions contained higher artemisinin 
levels as compared to decoctions. At the higher iron salt level, less artemisinin was seen in 
both infusions and decoctions than at the lower salt level. However, even in these cases 
artemisinin levels were still higher than that observed in pure distilled water.  
 
Deoxyartemisinin levels were independent of these sampling variations. 
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Chrysosplenetin levels were higher in decoctions as compared to infusions, where both 
distilled water and high iron salt level was used. Low iron salt level in decoctions did reduce 
chrysosplenetin levels as compared to decoctions prepared with water or high salt levels.  
 
10.3.3 Over the counter preparations of Artemisia annua L.  
10.3.3.1 Capsules 
Capsules advertised as containing powdered Artemisia annua herb were purchased from two 
manufacturers. Those purchased from Manufacturer A were sold as containing only A. annua 
leaf material. Those from manufacturer B were advertised as containing Artemisia annua leaf 
as part of a mixture of other herbs, and claimed a total content of A. annua leaf per dose (3 
capsules) of 750 mg. 
 
Capsules from Manufacturer A did contain discernible levels of artemisinin, but the level was 
low, at 0.008 % w/w. Deoxyartemisinin was present in almost equal amounts. Chrysosplenetin 
was present at 0.06 % w/w: unusually, this flavonoid was present at higher levels than 
artemisinin. All previous leaf material tested throughout this investigation contained 
flavonoids at levels lower than artemisinin: typically, at only 10% of the artemisinin level. 
 
No artemisinin, deoxyartemisinin or chrysosplenetin could be detected in capsules supplied by 
Manufacturer B. 
 
Capsules advertised as containing pure artemisinin, isolated from Artemisia annua leaf 
material, were purchased from Manufacturer A. The capsules were sold as containing 100 mg 
artemisinin per capsule, plus bulking agents. 
 
The content of the capsules were weighed and found to contain, on average, 211 mg of white 
powder. The powder contained artemisinin at 37 % w/w, which amounts to an artemisinin 
content of 80 mg per capsule. 
 
10.3.3.2 Tinctures 
Tinctures of Artemisia annua L. leaf material were purchased from Manufacturers C and D. The 
tincture purchased from Manufacturer C had a tincture strength of 1: 5 (i.e. 1 weight of herb to 
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5 volumes of liquid), and 45% alcohol was used as the solvent. That purchased from 
Manufacturer D had a tincture strength of 1:4, and 55% alcohol was used as the solvent. 
No artemisinin was detectable in the tincture purchased from Manufacturer C. 7.2 µg/ml of 
deoxyartemisinin were detected and 30 µg/ml of chrysosplenetin. 
The tincture purchased from manufacturer D contained 20.5 µg/ml artemisinin and 200 µg/ml 
chrysosplenetin. Very little deoxyartemisinin was found: only 0.9 µg/ml. It will be noted that in 
both these cases, as in the powdered herb capsules, the chrysosplenetin content was higher 
than the artemisinin content.  
 
10.4 Discussion 
Note: in the following discussion, the phrase “DMU study” is used to demote the work carried 
out by the author and reported in this Section. 
10.4.1 Artemisinin levels in Artemisia annua herbal teas 
10.4.1.1 The literature 
In 2004, Mueller et al. published details of a study in which they found that a tea prepared 
from Artemisia annua L. dried leaf material contained up to 94 mg of artemisinin, when 9g 
dried leaf was prepared as a 10-minute infusion in 1 litre of water. When 5g herb per litre of 
water was used, the extract contained 47 mg artemisinin (Mueller et al., 2004).  
 
These levels are high; considerably higher than the results reported in this thesis. The 
Artemisia annua dried leaf used by Mueller was reported as containing artemisinin at 1.4 % 
w/w, which is higher than the 0.6 % w/w reported from the Consortium-grown herb used in 
the DMU study. Additionally, in the DMU study, 1g of herb was extracted, rather than the 5g or 
9g used by Mueller. But even if 9g of Consortium-grown herb had been extracted, it can be 
extrapolated that maximum artemisinin levels would have been no higher than (1.67 mg x 9 =) 
15.03 mg. 
 
Mueller’s results were questioned by Jansen, in recent correspondence in Transactions of the 
Royal Society of Tropical Medicine and Hygiene. Jansen repeated Muller’s experiment using 
dried leaf material of similar artemisinin concentration, and found that the concentrations of 
artemisinin in the teas - 24.2 mg/l - were much lower than the 94 mg/L claimed by Mueller. 
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Jansen concludes that “...the herbal tea approach to artemisinin as a therapy for malaria is 
totally misleading and should be forgotten as soon as possible” (Jansen, 2006). 
 
 Several responses to Jansen’s letter were published in the following months, including one by 
researchers from the Research Initiative on Traditional Antimalarial Methods (RITAM) 
Artemisia annua Task Force, who argued that Jansen’s “statement is totally misleading and 
should be forgotten as soon as possible” (Willcox, 2007). Their reasons for the support of this 
use of tea include the hypothesis that artemisinin is only one of a range of antimalarial 
compounds acting in synergy, and that in reality much higher concentrations of A. annua tea 
would be prepared. Mueller et al. responded that in their trial, in 10 human volunteers, a peak 
plasma level of 240 ng artemisinin per ml was detected -  26 times higher than the minimum 
artemisinin concentration of 9 ng/ml required for growth inhibition of Plasmodium falciparum 
in vitro (Heide, 2006). In the light of this, it is difficult to explain the high recrudescence rates 
observed in Mueller’s  study.  
 
It is also worth noting that even in the original 2004 paper, Mueller notes that the daily 
recommended dose of 500 mg of artemisinin is not reached,  “the traditional Artemisia 
preparations contained at best 94 mg artemisinin/L... i.e. 19% of the usual clinical dose of pure 
artemisinin (500 mg/d), and resulted in unacceptable recrudescence rates”. For that reason, 
Mueller did not actually recommend the use of A. annua tea as a substitute for ACT (Mueller et 
al., 2004).  
 
10.4.1.1.1 Traditional preparations? 
It is worth noting that almost all studies performed on “traditional” preparations of Artemisia 
annua have assumed that traditional preparations involved dry leaf matter, prepared as either 
decoction or infusion. But a recent paper by Wright et al. (Wright et al., 2010) took a slightly 
different approach to “traditional” preparations of Artemisia annua. The authors followed the 
precise instructions given in Ge Hong’s 1st century text Zhou hou bei ji fang, which required 
that the fresh herb be soaked in water for up to 12 hours, and then wrung, or squeezed, to 
extract a concentrated juice. No heat was applied. Using this process, Wright et al. found, in 
the expressed liquid, an artemisinin content of 72.6 mg/L – which compared favourably with 
that found in an infusion of dried leaf (14.5 mg/L). However, this product, whilst suppressing 
growth of P. falciparum in vitro (a 1: 222,222 dilution of the juice, containing 0.33 ng/ml 
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artemisinin, inhibited 50% of growth), was not able to reduce parasitemia in P. berghei 
infected mice. But a more concentrated preparation, made not by wringing but by pounding 
the fresh herb in a pestle and mortar, was able to reduce parasitemia in mice by up to 96%. 
This pounded preparation contained artemisinin at 293 mg/L, and a 1: 500,000 dilution, 
containing 0.59 ng/ml artemisinin, was able to inhibit 50% of parasitic growth in vitro. For 
comparison, Wright et al. found that the IC50 of artemisinin control was 3.8 ng/ml – 
considerably higher than the artemisinin content of the effective doses of either type of juice. 
This implies synergistic action, in the extracts, of artemisinin and at least one other compound.   
 
However, as interesting as this study on the use of fresh Artemisia annua leaf is, those bodies 
that recommend the use of Artemisia annua tea do promote the infusion or decoction of dried 
leaf matter – perhaps to ensure a year-round supply of the herb. 
 
10.4.1.2 The DMU study 
The results presented in this study show that Artemisia annua tea preparations – whether 
infusions or decoctions - could not realistically reach the recommended doses of 250 - 500 mg. 
The highest artemisinin level observed in the DMU study, in an infusion prepared using water 
containing low levels of ferrous sulfate, was only 1.67 mg from 1 g of herb, or 0.04 mg/ml 
artemisinin. At such an extraction efficiency, almost 300 g of herb would be required to 
obtained 500 mg artemisinin in a preparation of tea, if dried leaf material containing 
artemisinin at 0.6 % w/w was used.  
 
10.4.1.2.1 Ferrous salts 
An unexpected outcome of the DMU study was the observation that the presence of low levels 
of ferrous salts, especially ferrous sulfate, improved the extraction efficiency for artemisinin. 
This phenomenon was observed in both infusions and decoctions. Although higher levels of 
ferrous salts somewhat reduced extraction efficiency as compared to low levels, the 
artemisinin content of all teas prepared in the presence of ferrous salts was greater than 
equivalent control (i.e. no iron salts) teas. 
 
No evidence that artemisinin was converted to deoxyartemisinin, in the presence of ferrous 
salts, was observed. It had previously been suggested that the presence of ferrous ions in an 
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artemisinin solution was likely to induce the degradation of artemisinin to deoxyartemisinin. 
This observation was made in a study of the microbial metabolism of artemisinin, in which 
artemisinin was supplied to cultures of Rhizopus chinensis and Cunninghamella elegans. 
Deoxyartemisinin was detected in experimental controls which contained no added micro-
organisms. The authors of that study hypothesized that artemisinin degradation to 
deoxyartemisinin was triggered by ferrous salts in the nutrient medium (J-X Zhan, 2002).  From 
this, the author had speculated that the presence of ferrous ions in water used to prepare 
Artemisia annua tea may also trigger this degradation. But this did not appear to be the case. 
 
Creek et al., in a 2005 study (Creek et al., 2005), found that artemisinin was indeed degraded 
by the ferrous ions, in an aqueous solution, but not to deoxyartemisinin. In fact, the major 
product formed during the reaction was 3-hydroxydeoxoartemisinin:  
 
 
Figure 64. 3-hydroxydeoxoartemisinin 
 
 
As this compound has the same mass – 282 – as artemisinin, it would have been detected by 
LCMS at the M + 1 ion: appearing as an additional peak (assuming that the retention time of 
this compound was different to that of artemisinin). But no such peak was observed in the 
chromatograms. 
 
It is more likely that the concentrations of ferrous salts used were insufficiently high to induce 
degradation of artemisinin to the inactive metabolites. In the Creek study, artemisinin was 
present at 0.03 mM and ferrous sulphate at 3mM – i.e. the ferrous sulfate was in excess, which 
was not the case in the DMU study, in which ferrous chloride tetrahydrate levels ranged from 
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0.75 to 3 µM, and ferrous sulfate heptahydrate from 0.5 to 2 µM, but artemisinin reached 237 
µM in the highest sample.  
 
10.4.1.2.2  Chrysosplenetin levels in Artemisia annua herbal tea 
The highest level of chrysosplenetin was seen in a tea prepared by decoction, in the presence 
of high levels of ferrous chloride. On average, higher levels of this flavonoid were observed in 
teas prepared by decoction rather than infusion, although some overlap between 
chrysosplenetin levels in the two types of preparation was observed when low levels of ferrous 
salts were used. In teas prepared in distilled water, the decoctions extracted twice as much 
flavonoid as the infusion. However, the levels were low compared to the solvent control.  
10.4.2 OTCs 
The over the counter preparations of Artemisia annua varied widely in quality. Using the 
capsules of pure artemisinin sold by Manufacturer A, the WHO recommended dose could be 
reached – but, as this would constitute, monotherapy, would not be recommended. Equally 
disturbing is the possibility of consumers using these capsules as a form of supplement, or 
prophylaxis – the use of artemisinin as prophylaxis being not only inefficient but also 
potentially dangerous for public health, as it increases the likelihood that resistance will 
develop. 
 
WHO recommended dosages could not be reached with either of the powdered herb capsules 
tested.  However, as those supplied by Manufacturer A did contain low levels of artemisinin, 
the danger of resistance induction as a consequence of suboptimal dosing remains. A similar 
concern can be raised by the use of tinctures, in particular that sold by Manufacturer D.   
 
10.4.3 Artemisinin monotherapies 
All of the Artemisia annua preparations discussed in this section – teas, capsules and tinctures 
– would be classed as artemisinin monotherapies. Although it has been demonstrated in vitro 
that chrysosplenetin, another constituent of Artemisia annua L., can potentiate the anti-
plasmodial activity of artemisinin (Elford et al., 1987) until the optimal dosages of 
chrysosplenetin (and the mechanism of action of this compound) have been elucidated, the 
presence of this compound in an extract is not sufficient to describe the extract as 
“combination therapy”. 
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It is also notable that, except for the capsules of pure artemisinin sold by Manufacturer A, 
none of the preparations discussed would be capable of reaching recommended dosages of 
artemisinin. Therefore, all of the preparations constitute artemisinin monotherapy, and all but 
one constitute monotherapy at a suboptimal dose – and, as Bate and Hess write, “exposure to 
artemisinin monotherapy tablets and substandard drugs has the potential to accelerate 
parasite resistance to artemisinin” (Bate and Hess, 2009)  
 
The implications of casual use of such preparations vary according to geographical location. In 
northern Europe, where unregulated use of Artemisia annua is likely to be based upon 
capsules and tinctures, the Anopheles mosquito cannot survive, and the ingestion of such 
products is unlikely to be harmful. The risk is greater when these products are used by visitors 
to malaria-endemic regions, and the health risks apply to both the visitor, and to the local 
population.  
 
 In malaria-endemic regions, though, the use of Artemisia annua tea is more probable than the 
use of OTCs.  As long as licensed artemisinin-combination therapy remains expensive and out 
of the reach of those who need it, advice such as that given by Anamed – “If you live and work 
where malaria is a daily hazard, we invite you to grow and use Artemisia annua anamed 
yourself...Harvest the leaves, dry them and store them for use whenever required” - is perhaps 
understandable. But, apart from the fact that the quality of Artemisia annua leaf material 
varies from year to year depending on environmental factors, there are also pharmacological 
problems with such usage. As Barnes et al. say, for artemisinin-derived therapies to be 
effective, “Drug concentrations must exceed minimum parasiticidal concentrations (MPCs) 
until all parasites are eliminated; this usually takes at least four 48-h asexual life cycles in P. 
falciparum” (Barnes et al., 2008). Whether any form of self-medication will achieve these 
consistently high drug concentrations has yet to be demonstrated.
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11 Discussion: The LINK Project 
11.1 Artemisia annua L. as a new crop for the UK 
11.1.1 Background 
The Defra-funded pilot project NF0613 – “Field cultivation of Artemisia annua and enhanced 
extraction of artemisinin used in novel antimalarial treatments” – ran from 2005 until 2006.  
This £140,046 project, which ran as a collaboration between the National Institute for 
Agricultural Botany (NIAB), Botanical Developments Ltd (BDL) and East Malling Research 
(EMR), examined the feasibility of establishing an artemisinin supply chain, from crop in the 
field to purified active pharmaceutical ingredient (API), based entirely within the UK.  
 
A major component of this pilot project was to “determine the quality and biodiversity of 
available Artemisia annua germplasm” (Defra, 2006).  To that end, supplies of Artemisia annua 
germplasm – in the form of seed – were obtained from as many international sources as could 
be identified, with the double aim of 
 
a) understanding the quality of material currently available, and  
b) obtaining genetically diverse material suitable for a large-scale breeding programme. 
 
A total of 32 different lines of Artemisia annua were grown in field trials during Project NF0613 
(a “line”, in this sense, indicating an inbreeding plant variety, in which all the offspring are 
almost genetically identical). The resulting plant material was scrutinised on two levels: first, 
for ability to survive and grow well in the UK climate, and second, for artemisinin content – 
expressed as weight for weight percentage artemisinin in dried plant material. Previous field 
trials in other countries indicated that artemisinin content in Artemisia annua ranged from 
0.06 – 1.38 % w/w, as Table 23 illustrates. 
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Table 23. Artemisinin content in geographically diverse Artemisia annua L. (Delabays et al, 2002) 
 
Geographical region of 
growth 
Artemisinin (% w/dry 
weight) 
USA 0.06 – 0.21 
Argentina 0.1 
Spain 0.24 
China 0.79 – 1.07 
Vietnam 0.86 
Switzerland 
(Mediplant) 
1.38 
 
Analysis of the 32 lines grown in Project NF0613 showed a maximum artemisinin level of 1.2%, 
in the Swiss Mediplant line. This line was propagated from cuttings and acted as the main 
control sample in all the analytical work. In addition, three of the 26 lines tested in 2005 had  
both high artemisinin content and good agronomic characteristics, and these lines were 
designated 1001, 1019, and 1012.  
 
NF0613 demonstrated that certain Artemisia annua lines grew very well under UK weather 
conditions (summer 2005) and a few of the better adapted lines also had high levels of 
artemisinin. The fact that some Artemisia annua lines could not only grow vigorously here in 
the UK, but also produce high artemisinin levels, was enough to persuade the members of this 
new consortium that here was a project that could be taken much further. In fact, estimates 
based on the artemisinin levels produced in these test crops demonstrated that from one 
hectare of land, 11kg of artesunate (the drug that is derived from artemisinin) could be 
produced: enough for 18,000 doses of drug. This compared very favourably to the situation in 
China, wherein one hectare could, at current productivity, contribute only 3 – 4.5 kg of 
artesunate (Grewal, 2009). 
11.1.2 Next steps – new partners  
Project NF0613 - wholly Defra-funded - led to the instigation of project LK0822, which was 
focused on “Developing an alternative UK industrial crop Artemisia annua, for the extraction of 
artemisinin to treat multi-drug resistant malaria”. This latter, £1,094,395, four-year project 
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was jointly funded by Defra, the Horticultural Development Council (HDC), and Frontier 
Agriculture Ltd.  
 
Project LK0822, in line with its greater objectives, included a larger number of partners than 
the pilot project NF0613. New to the consortium were Humber VHB, a commercial supplier of 
herbs and salad seedlings, who would evaluate seed production by the newly developed 
varieties; Frontier Agriculture Ltd, who specialise in helping farmers develop and market their 
produce, and who would, in this project, concentrate on agronomic techniques for the optimal 
growth of the crop. De Montfort University’s Natural Products Research laboratory, as new 
partners, would be required to develop improved analytical techniques for the high-
throughput analysis of plant samples, as well as devising ways to purify artemisinin from 
pharmaceutically inactive congeners.  
 
Continuing with the project were the National Institute for Agricultural Botany (NIAB), East 
Malling Research (EMR) and Botanical Developments Ltd (BDL). NIAB were to take charge of 
the breeding programme, whilst studies of the plant’s nutritional requirements were carried 
out by EMR. As before, BDL would concentrate on sample analysis and artemisinin purification, 
in collaboration with DMU.  
 
11.1.3 Next Steps - expanded objectives 
Project NF0613 had succeeded in its objective to characterise the available germplasm.  
Project LK0822, in line with the objective to establish Artemisia annua as a viable UK crop, was 
now to take this further. On the breeding side, researchers at NIAB would instigate a breeding 
programme, using the best of the germplasm identified in NF0613, to produce a brand new 
Artemisia annua line. This, ideally, would demonstrate vigorous growth combined with a 
consistently high artemisinin content. It would also produce large amounts of seed, as 
quantified by Humber VHB.  Frontier Agriculture Ltd would take the new varieties and develop 
optimal sowing and harvesting techniques, and EMR would vary the crop’s micronutrient 
regimes. Such explorations of the agronomic preferences of the new varieties would allow 
these new plants to reach their full potential in terms of artemisinin yield per hectare.  
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On the analytical side, Natural Products Research (NPR) at De Montfort University would 
quantify artemisinin levels in all of the plant material produced by NIAB, Frontier and EMR, and 
report the results to the relevant department.  
NPR would also report the levels of other potentially useful compounds, such as the 
methoxylated flavonoids, and the levels of unwanted material – deoxyartemisinin, in the main. 
Such regular feedback would ensure that the breeding programme and agronomic techniques 
were effective, and heading along the right direction. 
 
NPR would also work on improved means for the isolation of artemisinin from the plant, with a 
particular focus on the removal of deoxyartemisinin – a pharmaceutically inactive compound 
that in all previous assays had been found to co-elute and co-crystallise with artemisinin.  
 
11.1.4 Outcomes 
The large-scale cultivation of Artemisia annua is an essential step in the stabilisation of the 
global supply of artemisinin. However, the plant is, essentially, a weed – and a weed hailing 
from the mountainous regions of China, a climate quite different to that of the UK. Although 
the pilot project had shown that the growth of the plant in the UK was feasible, it was felt that 
continued improvements in artemisinin yield could be made by a combination of breeding new 
varieties and optimising agronomic practises. 
 
 Over the last four years, the combined efforts of the Consortium partners have produced, 
year-on-year, new varieties that show consistently increased artemisinin levels as a 
weight/weight percentage. A maximum level of 1.2 % w/w was measured during the 2005 - 
2006 pilot project. By the end of 2009, after the growth and analysis of around 6000 plants, a 
variety that produced artemisinin at a level of 2.2% w/w - almost a 100% increase – was 
developed, and the artemisinin content of this new line was externally validated (see Section 
3.3.4). Moreover, seed yields from the newly developed varieties – initially as low as 7g/plant – 
were now as high as 30g/plant. Agronomic techniques had also helped to improve overall yield 
per hectare, as described in the Consortium’s 2009 Annals of Botany publication. Assuming a 
constant artemisinin level of 2% w/w, one hectare of Artemisia annua could yield up to 60 kg 
of artemisinin (Colin Hill, personal communication). These figures compare well with the 2010 
industry average of 0.8 % w/w (dry weight) artemisinin in leaf material of Artemisia annua, 
from which a maximum artemisinin yield per hectare would not exceed 24 kg. 
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11.1.5 The future 
Given the success of this four-year LINK project, the Consortium is presently applying to Defra 
for extended funding, with the combined objectives of continuing to raise artemisinin yields by 
improved breeding and agronomic techniques, and the isolation  and testing of other bioactive 
compounds from Artemisia annua L. It is also to be hoped, now that the expertise is in place, 
that this “artemisinin supply chain” can act as a model for the development of other non-food 
crops for the UK agricultural market. 
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12 Summary 
12.1 The economics of artemisinin 
Artemisia annua L. is, at present and for the foreseeable future, the only source of artemisinin 
for artemisinin combination therapy (ACT). And, as ACTs are, in several regions of the world, 
the only effective antimalarial drugs left, a stable supply of this parent compound is essential.  
 
However, a stable supply of artemisinin has not yet been established. 2006 was the last year in 
which global supply of artemisinin exceeded global use of ACT treatments – since that time, 
demand for the drug has steadily increased, whilst global supply of artemisinin has decreased 
(Grewal, 2009) Part of the reason for this decrease in artemisinin production is that, initially, 
high prices for the compound resulted in global overproduction. This overproduction led to 
something of a glut in the market, and, naturally, reduced prices followed, leading many small-
scale growers of Artemisia annua L. to abandon the crop. This “boom and bust” pattern is 
predicted to continue until the global supply of the compound is stabilised, and it has been 
estimated that by 2015, a “significant increase in supply [of artemisinin will be] needed to 
meet steady state demand” (Grewal , 2009). 
 
12.2 A UK-based supply chain – issues of quality control 
The objective of the Consortium was to demonstrate that an artemisinin supply chain – from 
crop in the field to pure artemisinin – could be established by large-scale commercial growers 
within the UK – helping to ensure a guarantee artemisinin yield and hence stabilising global 
supply. But for a supply chain to succeed, rapid, reliable and economical quality assessment 
had to be put in place, for all stages of the chain – from fresh herb in the field, to dried leaf in 
the laboratory, and for partially-purified and purified artemisinin.  
 
This thesis presents methods developed for: 
 
a) Field-based quantification of artemisinin in dried leaf, based on TLC-densitometry 
b) Laboratory-based high-throughput quantification of artemisinin in dried leaf and 
partially pure and purified extracts, based on LCMS-ESI 
 
Section 12: Summary 
 
207 
 
The former technique, requiring a minimum of user training and utilising a basic desktop 
scanner, would be applicable not only to UK-based artemisinin supply chains, but also to small-
scale growers in developing countries. Whilst densitometry as a means of quality control is not 
a new technique, the work presented in this thesis represents the first time that inexpensive 
Biosoft® software – which costs less than £200 – and a basic desktop scanner have been 
utilised for this purpose.  
 
The latter, LCMS-based technique, does require training and investment on the part of the 
end-user. But this thesis demonstrates that by using narrow-bore columns and reducing run 
times, large savings can be made on solvent purchase and disposal with no reduction in 
precision and accuracy. Validation of this method by an external laboratory confirms the 
efficacy of this high-throughput technique. 
 
Furthermore, Sections 5 and 7 demonstrate that, having identified material with a high 
artemisinin content, the artemisinin can be isolated from the closely-eluting, pharmaceutically 
inactive deoxyartemisinin, using standard flash chromatography equipment.    
 
To persuade commercial growers to adopt Artemisia annua as a crop, added value – as in 
other compounds, besides artemisinin, that can be isolated and marketed form the crop – is an 
important issue. As part of the work submitted in this thesis, the levels of chrysosplenetin – a 
flavonoid found within leaf trichomes of the plant – were quantified, and chrysosplenetin itself 
was assayed against human breast cancer cells. It was shown that chrysosplenetin, which is 
found in Artemisia annua at levels of up to 0.17% w/w, was able to inhibit grown of human 
breast cancer cells at an IC50 of 0.4 µM – compared to an IC50 in control, non-cancerous cells, 
of 20 µM. 
 
Additionally, whilst carrying out the quantification of chrysosplenetin, a correlation between 
artemisinin levels, and level of another flavonoid-type compound – hypothesised to be eupatin 
– was observed. This correlation – greater than 0.8 - was present in all leaf material analysed, 
and may well provide an indirect means of artemisinin quantification. Artemisinin has no UV-
chromophore and therefore requires more complex and expensive means of analysis – 
typically MS-based.  For those without access to LCMS, flavonoid quantification may provide 
an alternate means of quality control. 
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12.3 Self-medication 
Aside from quality control techniques, a separate theme explored within this work is that of 
self-medication with Artemisia annua L. Despite the WHOs disapproval of this practise, the 
promotion of Artemisia annua tea is widespread, and it is easily to purchase preparations – 
tinctures, capsules and so on – of the plant. In Section 10, a sample set of Artemisia annua teas 
and over-the-counter products were assayed for artemisinin, deoxyartemisinin and 
chrysosplenetin content. Although literature reports exist of artemisinin in herbal teas, to the 
author’s knowledge, this thesis represents the first report of deoxyartemisinin and 
chrysosplenetin levels in tea – and also the first time that the effect of using iron-contaminated 
water to prepare tea, had been studied. 
 
Section 10 shows that, as others have found, artemisinin content in tea, whether prepared as 
an infusion or decoction, is very low – in the region of 0.02 – 0.04 mg/ml, and chrysosplenetin 
levels are even lower, at a maximum of 0.002 mg/ml. As expected, deoxyartemisinin levels 
were about 1/10th of artemisinin levels, and, perhaps surprisingly, were not increased in the 
presence of iron salts – even when salts were present at 600 µg/L – a high level for drinking 
water. This suggests that using iron-contaminated water at these fairly high levels will not be 
detrimental to the quality of the tea, but the efficacy of tea, considering the low levels of 
artemisinin, is questionable.  
 
Section  10 also showed that the quality of OTCs varies widely, from tinctures and capsules of 
dried leaf that contained no detectable artemisinin or chrysosplenetin, to capsules of pure 
artemisinin containing 80mg/capsule of the compound. But all of these preparations, even 
those high in artemisinin, containing monotherapy – a practise strongly disapproved of by the 
WHO, because of the risk of artemisinin-resistant strains of P. falciparum developing, a 
situation that has begun to become reality in Cambodia. 
 
12.4 Reflections 
 
It is clear that, given time and resources, much more work could be done on the potential of 
establishing A. annua in the UK. In particular the levels of more compounds – precursors such 
as artemisinic acid, and dihydroartemisinic acid, which can be converted to artemisinin – could 
be quantified. Lack of sufficient reference material prevented such studies being undertaken 
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for this research. It would also have been illuminating to further explore the use of exogenous 
compounds to increase levels of artemisinin within the plant. Although Section 8 describes a 
small experiment of this nature, a much larger experiments using whole plants and a wider 
range of exogenous compounds – chitosan, or methyl jasmonate, for example – would provide 
useful information as whether artemisinin levels in a crop can be economically increased. 
 
The stability of artemisinin in stored, dried Artemisia annua leaf is certainly worth exploring – 
an experiment monitoring levels of artemisinin, deoxyartemisinin and 3-hydroxyartemisinin 
(the latter two being putative microbial degradation products) would either reassure growers 
that the dried crop is indeed stable in storage, or would provide motivation to either process 
the leaf immediately upon harvest, or improve storage conditions. If funding became available, 
this assay would be a matter of priority. 
 
Finally, the anti-cancer potential of chrysosplenetin could also be explored further – perhaps 
taking into account potential synergistic actions of chrysosplenetin with artemisinin.  
 
Future research, focussing on one or all of these issues, would be most valuable in confirming 
the feasibility of Artemisia annua L. as a new non-food crop for the UK. In the meantime, it is 
hoped that the work presented in this thesis goes a small way toward this ultimate goal.
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Appendix 1. Anti-Cancer Assay of Chrysosplenetin against 
Human Breast Cancer Cells 
 
MCF7 cells were grown in RPMI 1640 with phenol red and MDA468 cells were grown in RPMI 
1640 without phenol red supplemented with L-glutamine (2mM).  MCF10A cells were grown in 
DMEM: Ham’s F-12 supplemented with human insulin (10µg/mL-1), human epidermal growth 
factor (20ng/mL-1) and hydrocortisone (500ng/mL-1).  All media were supplemented with 10% 
(v/v) heat inactivated foetal calf serum (56°C for 45 minutes to inactivate complement 
components).  Cells were maintained at 37°C, 5% CO2 in air with 100% humidity.  Cells at 
subconfluence were harvested for experimental use as indicated in section 3.2.4. 
Cytotoxicity screen 
To harvest adhered cells, medium was aspirated and 1mL of a 1% trypsin-EDTA solution was 
added to the cells and gently agitated for 30 seconds. The trypsin-EDTA solution was 
subsequently removed and immediately replaced by a further 1mL and the cells incubated at 
37°C for approximately 5 minutes or until cells were visibly non-adherent.  The resultant cell 
suspension was placed in a sterile container with 5mL of fresh medium.  To determine the 
density of the cell suspension, an aliquot (100µL) was added to 100µL of a trypan-blue solution 
(0.4%) and the number of viable cells determined using a Neubauer haemocytometer (depth 
0.1mm, 1/400mm2).  The cell suspension was diluted with medium to give a cell count of 
2x103cells.mL-1 and aliquots (100µL) were dispensed into sterile, 96-well microtitre plates.  
With the exception of MCF7 cells, all cells were incubated for 24 hours prior to the addition of 
the compounds of interest.   
 
For MCF7 cells, after allowing approximately 4 hours for cells to adhere, 100L of medium 
containing 10μM TCDD (from 100mM stock in DMSO, giving a final concentration of 10nM) or 
medium with 0.2% (v/v) DMSO only as a control was added to each well containing cells to give 
a final concentration of 10nM TCDD and 0.1% (v/v) DMSO, for 24 hours to induce CYP 
expression. The medium was then aspirated and 100L fresh medium added.  
 
Chrysosplenetin added to the cells was ten-fold serially diluted in warm medium (37°C), under 
subdued light, from an appropriate stock (in DMSO) to give final concentrations of 100, 30, 10, 
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3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 and 0.0003μM (in quadruplicate). The final concentration 
of DMSO did not exceed 0.1% (v/v).  Cells were then allowed to grow in the presence of either 
chrysosplenetin or 0.1% DMSO (controls) for 96 hours to attain 80-90% confluence in the 
control wells.  
 
After 96 hours 50L of 2mg/mL-1 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromide in sterile phosphate buffer) was added to each well and incubated at 37°C for 2 hours.  
All medium was then aspirated and the product (reduction of the yellow tetrazolium salt by 
mitochondrial dehydrogenase of viable cells, forming an insoluble intracellular purple 
formazan) was solubilised with 150L DMSO.  Plates were vortexed and the absorbance at 
540nm determined using a Molecular Devices SpectraMax M5 plate reader with SoftMax® Pro 
software, version 4.8. 
Relative toxicities of chrysosplenetin within each cell line were evaluated by determining 50% 
of growth inhibition (IC50).  The absorbance at 540nm was plotted using non-linear regression 
curve fit of the percentage of the control value versus the negative logarithm of the molar drug 
concentration range using GraphPad Prism version 3.00 for Windows. 
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Appendix 2. Reuters News Article on LINK 0822 
 
 
INTERVIEW-Crop scientists treble yield of anti-malaria drug 
 
Wed Dec 2, 2009 10:14am GMT 
 
 
* Experiments show artemisinin yield of 2.2 percent 
 
* UK crop scientists say want to talk to drug companies 
 
* Artemisinin combination therapy drugs best malaria weapon 
 
 
 
By Kate Kelland 
 
CAMBRIDGE, England, Dec 2 (Reuters) - British crop scientists say they have trebled 
the yield of a key malaria drug ingredient and want to talk to drug companies about 
how their work could help in the fight against the killer disease. 
 
Steven Bentley, a researcher at Britain's National Institute of Agricultural Botany 
(NIAB), says four years of experiments in cross breeding wormwood plants has greatly 
increased the yield of artemisinin, a natural anti-malaria drug. 
 
"Results from this year's harvested trials indicate that we've increased the 
concentration of artemisinin to in excess of 2.2 percent -- almost three times the 
industry average of 0.8 percent," he told Reuters in an interview. 
 
"We've made progress year on year, we know where we're going and we seem to able 
to notch it up with some consistency." 
 
Artemisinin, derived from the sweet wormwood plant, is the best drug available against 
malaria, especially when used in artemisinin combination therapy (ACT) medicines 
made by companies such as Swiss drugmaker Novartis AG (NOVN.VX) and France's 
Sanofi-Aventis SA (SASY.PA). 
 
But low artemisinin yields in the usual growing areas in Africa and Asia have made 
prices stubbornly high and contributed to a slow roll-out of the treatments across the 
world. 
 
Around 40 percent of the world's population is at risk of malaria, a potentially deadly 
disease transmitted via mosquito bites. It kills more than 1 million worldwide each year 
and children account for about 90 percent of the deaths in the worst affected areas of 
sub-Saharan Africa and parts of Asia. 
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A report last month said millions were dying from malaria because they can't afford life-
saving ACT medicines. [ID:nL187891] 
 
Bentley, whose work on artemisinin is funded through a British government-backed 
research project, said he and his colleagues at the NIAB now want a closer relationship 
with drug companies who use the ingredient. 
 
"We've got great plants, we can do seed production, and we want to work with them," 
he said. 
 
 
ESTIMATED NEED 
 
Experts say around 6,500 hectares of land -- most of it in China, Vietnam, Africa and 
India -- was devoted to wormwood crops in 2009, producing 30 tonnes of artemisinin a 
year -- enough for 60 million treatments. 
 
The need in 2010 is estimated at 260 million treatments, requiring 130 tonnes of 
artemisinin or 28,000 hectares of the crop. 
 
Novartis, which Bentley says is already in contact and has been supportive of the 
NIAB's work, says it is keen to improve access to ACTs and has the capacity to provide 
100 million treatments of its Coartem drug a year if orders come in on time. 
 
Bentley said scientists had in the past been dubious about whether good quality 
artemisinin could be produced in Britain. But with the results he has achieved so far, 
and trials of NIAB's seed taking place in countries such as Morocco, Canada and 
Mozambique among others, he says such doubts should fade. 
 
"Many people were understandably sceptical about the ability of anybody in the UK to 
make a serious contribution, but now we have been able to prove our credentials," he 
said. 
 
NIAB's yield results have been independently confirmed and Bentley is sure there is 
more to come. 
 
"We are confident that in our plant breeding material we have better lines coming along 
that could yield 2.5 percent." 
 
He says there is no great secret to their success other than rigorous scientific 
methodology and ensuring each cross breed is made using parents with the best 
genetic potential. 
 
"You've got to have the right genes, just like with humans," he said. "You've got to have 
the right potential in the plants and then give them the conditions to express that 
potential." 
 
Weather conditions in Cambridge in eastern England where Bentley works are typical 
of England -- not too hot, not too cold and with variable rainfall. 
 
Bentley has brought what he calls his "elite parents" into a normal glass greenhouse for 
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the winter and will plant out new cross-breeds in June for harvest in September. 
 
Once the plants are established, their needs are simple and variations in rainfall don't 
appear to affect them too much. 
 
"Basically, it really is a very good weed," he said. "It is very vigorous and we don't have 
many problems with them at all ... The only thing we really need is a scarecrow, 
because the rooks sometimes come and dig them up." (Editing by David Holmes) 
((kate.kelland@thomsonreuters.com; +44 (0)7990 567 059)) 
 
From http://uk.reuters.com/article/idUKGEE5B01SB. Article accessed on 1st March 
2010.  
Appendices 
 
215 
 
Appendix 3. Davies et el (2009).  Enhancement of 
artemisinin concentration and yield in response to 
optimization of nitrogen and potassium supply to 
Artemisia annua. Annals of Botany 104 (2) pp 315-323
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